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CHAPTER 1 
INTRODUCTION AND LITERATURE 
REVIEW 
 
1.1 Introduction 
Cardiovascular mortality is one of the leading causes of death in the 
industrialized world. Sudden cardiac death (SCD) occurs mainly following 
acute myocardial infarction (MI) [1]. Ventricular tachyarrhythmias, namely 
ventricular tachycardia (VT) and ventricular fibrillation (VF), are the cause 
of cardiac arrests in the majority of cases. The incidence of spontaneous 
ventricular tachyarrhythmia and SCD increases with worsening left 
ventricular ejection fraction.  Implantable defibrillators and 
pharmacotherapy have been the mainstay treatment of such 
tachyarrhythmia but never the less mortality remains high. Yamada et al. 
and other authors have reported that intercellular electrical uncoupling 
mediated by decreased conductance of gap junctions is associated with 
ventricular tachyarrhythmia in the diseased heart [2-4]. Gap junctions form 
channels between adjacent cells. The core proteins of these channels are 
the connexins. Connexins43, 40 and 45 are all found in the mammalian 
heart. Connexin43 (Cx43) is the most prevalent with alterations in 
expression associated with both ventricular and atrial arrhythmias. 
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Connexin40 (Cx40) is predominantly expressed within the atria and has 
been associated with atrial arrhythmias. Connexin45 (Cx45), the least 
prevalent and hence the least studied of the three connexins isotypes, has 
been increasingly associated with  fatal ventricular tachyarrhythmias [3]. 
 
In this review, I will discuss the mechanism of ventricular tachyarrhythmia 
and review the data supporting gap junction remodelling, with a focus on 
Cx45 and Cx43 having an important pathogenic role in such arrhythmias. 
In addition I will briefly discuss gene therapy vectors and methods of in 
vivo delivery to the heart.  
 
1.2 Sudden Cardiac Death 
Cardiovascular disease remains the single most common cause of natural 
death in developed countries [5]. Sudden cardiac death (defined as “death 
outside hospital”, “dead on arrival” or “dead in emergency”) from cardiac 
causes has been estimated to account for approximately 50 percent of all 
deaths from cardiovascular causes [5, 6]. Acute ventricular 
tachyarrhythmias account for the majority of SCD [6]. These are often 
triggered by acute coronary events, occurring in persons with or without 
3 
 
known cardiac disease or in association with structural heart abnormalities 
[6, 7].   
 
Zipes, Camm et al. have reported an overall incidence of sudden cardiac 
death of 0.1 to 0.2% per annum in the general population [8]. This number 
increases dramatically to 10% per annum in Australian patients with 
reduced left ventricular function following MI and inducible VT at 
electrophysiological study (EPS) [9]. The cumulative risk of SCD however 
remains high after MI, accounting for ~ 50% of overall mortality [9]. 
 
1.2.1 Mechanism of Sudden Cardiac Death from Arrhythmia 
The most common pathophysiological cascade involved in fatal 
arrhythmias in patients suffering from coronary artery disease or structural 
cardiac abnormality is VT degenerating into VF then into asystole [10]. The 
other reported cascade is of bradyarrhythmia or pulseless electrical 
activity secondary to electromechanical dissociation occurring in patients 
with advanced heart disease [11]. Patients with various genetic or 
acquired cardiac repolarisation abnormalities such as ion-channel 
abnormalities, acquired long-QT syndrome, or left ventricular hypertrophy 
(LVH); polymorphic VT or torsades de Point are the usual initiating 
arrhythmias in SCD [7]. Lastly, atrial fibrillation which leads to especially 
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high ventricular rates could result in SCD in patients suffering from Wolf-
Parkinson-White syndrome [7]. 
 
Two common patterns have been described in the initiation of fatal 
arrhythmia in patients with ischemic heart disease [7]. One, where 
myocardial ischemia is precipitated when the energy demands exceed 
supply to cardiac muscle. This usually occurs following occlusion of a 
coronary artery by thrombus and is what leads to life threatening 
ventricular tachyarrhythmias by alteration of the electrophysiology of the 
myocardium. Another mechanism by which coronary artery disease may 
cause sudden death is post infarction, the myocardial scar can provide the 
substrate for re-entrant ventricular tachyarrhythmias. The latter 
mechanism occurs independent of the presence of myocardial ischemia. 
In addition, several other triggering mechanisms have been recognised; 
including systemic metabolic, neurochemical, neurophysiological factors, 
and exogenous toxic or pharmacological effects [5, 6, 12]. Table 1.1 
summarises the causes of sudden cardiac death in the adult population. 
Note that coronary artery disease and dilated cardiomyopathy make up 
the majority cases. Figure 1.1 demonstrates causes and incidence of SCD 
in adult human.  
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Table 1.1 Causes of Sudden Cardiac Death in the Adult Population 
[13] 
 
As seen in the table coronary artery disease and coronary artery disease 
account for the majority of sudden cardiac death in the adult population.  
 
 
Causes Men Women 
CAD 80% 42% 
DCM 10% 18% 
VHD 5% 18% 
Normal 3% 9% 
Other 2% 13% 
 
CAD, coronary artery disease; DCM, dilated cardiomyopathy; VHD, 
valvular heart disease. 
 
 
 
 
 
 
 
 
 
 
 
6 
 
1.2.2 Physiology of Ventricular Tachyarrhythmia 
Re-entry is the underlying electrophysiological mechanism of VF and VT. 
Mines et al. in 1914 was the first to define re-entry as a persisting electrical 
impulse that reactivates an area of previously activated myocardial tissue 
that is no longer refractory; thereby resulting in a circle movement of 
activation [14]. The length of such a circle depends on its wavelength. This 
is defined by the mathematical product of the refractory period and the 
conduction velocity. The termination of the re-entry by interruption of the 
circle is proof of this concept.  Essentially, a suitable substrate and a 
trigger are required to initiate an arrhythmia. Myocardial infarction 
generates arrhythmogenic substrate and triggers through changes in 
tissue architecture and ion channel expression/function respectively 
thereby resulting in such a re-entry circuit and ventricular tachyarrhythmias 
[4].  This has been described with gap junctional uncoupling resulting in 
conduction slowing and arrhythmia in regions of ischemic myocardium [4]. 
Similarly, in patients with a remote MI, the scar provides the substrate and 
ventricular ectopic beats act as the trigger [4].  
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Figure 1.1: Pathophysiology and Epidemiology of Sudden Cardiac 
Death [15] 
Figure below demonstrates causes and incidence of SCD in adult human. 
 
 
 
 
8 
 
1.2.3 Evaluation of Patients at Risk of Ventricular 
Tachyarrhythmia 
Clinical evaluation of survivors as well as those at risk of SCD is important 
to identify and initiate preventative management or reduce risk of further 
SCD. It is therefore necessary to take a detailed history as the initial step. 
Risk factors for coronary artery disease such as diabetes, hypertension, 
smoking, family history and hyperlipidaemia are not of much help in 
predicting patients at risk of tachyarrhythmias or SCD [16]. Those whom 
however suffer from heart failure; defined as impairment of left ventricular 
ejection fraction are at higher risk especially with an ejection fraction of 
less than 35% [8, 13, 17]. Electrocardiography can help diagnose 
disorders associated with SCD but has a low predictive value. Variables 
such as width of QRS, voltage length and QT length help in diagnosing 
QT syndromes and LVH and implicate a higher risk ECG. 
Electrophysiological (EP) studies can identify patients at risk of SCD; 
specifically in those in the high risk group (ejection fraction <40%) [18]. 
The accepted end point is inducible sustained VT, while non-sustained VT, 
polymorphic VT or VF maybe non-specific findings [18]. 
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1.3 Management of Ventricular Tachyarrhythmia 
Contemporary clinical management of VT and VF consists of 
pharmacological agents and device-based electrical therapy for the 
prevention and treatment, respectively, of VT/VF and its catastrophic 
sequelae. Drugs are of moderate efficacy and do not, in most patients, 
obviate the need for a prophylactic implantable cardio-defibrillator (ICD). 
In addition to this, many drugs used to prevent VT/VF have serious side-
effects including pro-arrhythmia. Implantable cardio-defibrillators are 
highly effective in detecting and treating VT/VF by either anti-tachycardia 
pacing or defibrillation. In achieving this ICDs have the capacity to prevent 
SCD and save lives. The limitations of ICDs are however; the morbidity 
associated with implantation and maintenance of the hardware, the pain 
of receiving direct current (DC) shocks while conscious, the anticipatory 
anxiety of future shocks, the cost in a prohibitive economic environment 
and the inability of this therapy to directly target the underlying 
pathophysiology. A subset of patients, who do not achieve satisfactory 
symptom control with ICD or drug therapy, are eligible for catheter based 
ablation intervention. These patients typically have an ICD and experience 
multiple shocks for VT/VF that are not controlled by pharmacotherapy. It 
can be gleaned that management of patients with VT/VF and at risk of 
SCD is complex and associated with a significant health and financial 
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burden [13]. Consequently, an imperative exists to better understand the 
underlying pathophysiological mechanisms accounting for ischemia 
induced electrical instability; in the hope of finding specific therapeutic 
targets. 
 
1.4 Gap Junctions 
Most normal myocardial tissue volume is made up of cardiomyocytes; 
between those cells there are fibroblasts. Fibroblasts are cardiac non-
myocytes that are arranged in sheets and strands that run in parallel to 
the prevailing direction of muscle fibres [19]. Isolated cardiomyocytes and 
fibroblasts form functional gap junctional channels [20]. 
 
Gap junctions mediate the electrical transmission that underlies the hearts 
coordinated mechanical activity. They play an essential role for normal 
cardiac function. They are intercellular channels that serve as pathways 
for the direct cell-to-cell transfer of ions and small molecules in all 
multicellular systems. In mammalian tissues these channels are 
ubiquitously expressed and also serve biological functions such as tissue 
homeostasis, development and differentiation [21, 22]. 
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There has been extensive study in the past of active membrane properties 
and repolarization; however, cell to cell electrical coupling and its role in 
conduction slowing in myocardial disease has been the subject of 
increased scientific attention [23, 24].  
 
Gap Junction Channels 
Gap junctions are located at the cell poles in clusters within intercalated 
discs. A variety of large and small intercalated discs are found parallel to 
the long axis of the cell, in comparison to the small intercalated discs 
which are only found in regions at right angles to the long axis [25].  
 
As shown in Figure 1.2 A, gap junctions are formed by the union of two 
hemi-channels (connexons) each contributed to by two adjacent cells. 
Biochemically, each hemi-channel contains six connexin proteins 
surrounding an aqueous pore that can be homomeric (similar connexins 
in a connexon) or heteromeric (mixed connexins in a connexon) [21, 25-
28]. Even within one hemi-channel, different connexins can be integrated 
which can result in either homotypic (containing the same connexins) or 
heterotypic (containing different connexins) channel formation as shown 
in Figure 1.2 B.  
12 
 
Connexins form a multi-gene family of closely related proteins but not 
identical trans-membrane proteins [29]. Each connexon has its specific 
biophysical characteristics and forms channels that have unique 
properties of conductance and permeability. The electrical and 
biochemical characteristics of each gap junction are dependent on its 
constituent connexins. Various other mechanisms such as intracellular 
hydrogen and free calcium concentration, extracellular fatty acid 
composition and (de)phosphorylation of the individual connexin proteins 
can modulate the properties of the gap junction [30, 31]. 
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Figure 1.2 Gap Junction Structure 
A) A connexon consists of 6 transmembrane connexin. Two cell 
membranes connected by docked connexons with a central aqueous 
pore. B) Connexons can vary in the proportion and distribution of their 
constituent connexin isotypes (green and pink).  
A) 
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B) 
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Gap Junction Conductance 
Action potential propagation from cell to cell is mediated by current flow 
through gap junctions. The action potential propagation in cardiomyocytes 
is dependent on extracellular and intracellular transfer of ions across an 
action potential wavefront between depolarised and polarised zones as 
shown in Figure 1.3.  
 
Gap junction conductance is regulated by enhancing factors (such as 
PKCα or PKA) or reducing factors (such as hydrogen, calcium, sodium, 
loss of ATP) [32]. The number of gap junctions can be regulated in the 
long term by factors affecting the expression or degradation of connexins 
[33]. The propagation of action potential is determined by sodium channel 
availability, tissue architecture (including cell morphology and interstitial 
collagen strands) and gap junctions [32].  
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Figure 1.3 Action Potential Propagation 
Figure below demonstrates depolarisation of wavefront across coupled 
myocytes from depolarised (blue) to polarised (red). Gap junction in green 
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Role of Gap Junctions in Arrhythmia 
Within the heart, gap junctions are responsible for the coordinated 
propagation of electrical activity that triggers the sequential contraction of 
the cardiac chambers. The current flow through the gap junctions is 
primarily through the intercalated discs at the end-to-end intercellular 
connections. Gap junctions affect the cell to cell electrical coupling in the 
heart. The magnitude of cell to cell electrical coupling is modulated by the 
type of connexon expressed; their distribution and density as well as by 
their rates of expression and degradation [34].  
 
Propagation in cardiac muscle has been noted to be faster in the 
longitudinal than in the transverse axis of the cells [35]. Experiments using 
the gap junction uncouplers such as heptanol or palmitoleic acid have 
been carried out and revealed that transverse propagation is more 
sensitive to electrical uncoupling, block occurred more promptly for 
transverse than for longitudinal propagation. The decrease in conduction 
velocity following the uncoupling supports an increased risk of 
arrhythmogenesis following uncoupling [35, 36].  
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Arguments against a role of gap junctions in electrical coupling were also 
implicated as experiments by Jongsma and Wilders et al. reported that a 
90% decrease in the number of gap junctions was required to reduce 
conduction velocity by only 25% [37]. This was under normal/standard 
conditions. In addition, in simulated ischemia in cell pairs, gap junction 
coupling remained large enough to balance action potential duration 
between the coupled cells until in-excitability occurred [38].  
 
Studies that support the role of gap junction in arrhythmia included 
experiments with heterozygous Cx43 knockout mice revealing 25% 
reduction in conduction – a modest effect never the less [39-41].  On the 
other hand, Lerner et al. reported increased pacing induced ventricular 
tachycardia in Cx43+/− mice than in Cx43+/+ [40]. Moreover, numerous 
studies had shown an antiarrhythmic effect of peptides like AAP10, 
AAPnat or rotigaptide enhancing gap junction conductance [42-46].  
 
Ventricular Tachyarrhythmia and Gap Junctions 
There are two main patterns in the initiation of fatal arrhythmia post 
myocardial infarction. In the event of acute ischemia, gap junctions can 
be rendered non-functional by pH-dependent post-translational 
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modifications resulting in a substrate for functional re-entry. Gap junction 
uncoupling occurs after 20–30 minutes of ischemia. Ischemia results in 
the depletion of ATP and the accumulation of H+ and Ca2+ in the cytoplasm 
of ischaemic cells, which has shown to decrease gap junction 
conductance in isolated paired cardiomyocytes [47, 48]. Intracellular rise 
of long chain acylcarnitines has also been reported to cause gap junction 
uncoupling [42].  
 
Of note, it has also been reported that structural uncoupling by interstitial 
collagen deposition can contribute to VF [32]. 
 
In the chronic post-infarction heart, the role of gap junctions is less clear. 
Explanted hearts of patients undergoing cardiac transplantation for 
advanced ischemic heart disease were studied by Smith et al [24]. In 
normal myocardium (free from histologically detectable structural 
damage), there was no difference in the size of distribution of labelled 
gap junctions, or in their number per intercalated disk, between left 
ventricular tissue (in which functional impairment was severe) and 
right ventricular tissue (in which functional impairment was minimal). 
Gap junctions in cardiac myocytes that were however at the border of 
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healed infarct zones showed widespread generalised derangement. 
Instead of being aggregated into discrete intercalated disks, gap 
junctions were spread extensively over myocyte surfaces. This 
disorderly organisation may contribute to alterations in conduction 
that are capable of precipitating re-entry arrhythmias. They also 
reported that some infarct areas were bridged by continuous strands 
of myocytes, coupled to one another by gap junctions, hence linking 
healthy myocardium on either side. These bridges were reported in 
some instances to be no wider than a single attenuated myocyte. 
They hypothesized that avoidance of arrhythmia may therefore 
depend on the continued survival of this single cell. 
 
As described in the previous section ventricular tachyarrhythmia occur as 
a result of focal conduction slowing at the infarct border-zone. This has 
been studied by and is understood to be contributed to by down-regulation 
of Cx43 and inhomogeneity in the peri-infarction area [49]. This region of 
slow conduction forms an essential part of the fixed re-entry substrate [23, 
50]. Moreover, there might be structural uncoupling by interstitial collagen 
deposition. This in addition to either down-regulation of Cx43 or the up 
regulation of Cx45. The latter has been purported to be associated with 
ventricular tachyarrhythmia. 
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Atrial Fibrillation and Gap Junctions 
Similarly in the atrium, gap junctional remodelling is also believed to 
provide a pro-arrhythmic substrate by altering action potential conduction. 
Slowing action potential propagation can promote arrhythmia according to 
the classical re-entry model or due to fibrillatory conduction. In atrial 
fibrillation, inhomogenic expression of connexins has been found with 
areas of almost normal expression and areas with nearly no expression 
[51]. Other authors observed a lateralisation of gap junctions [52, 53].  
 
1.5 Connexins 
Connexins are a family of proteins that constitute the building blocks of 
gap junctions (Figure 1.4).  Each connexin has its own capacity to 
influence the biophysiological properties such as: voltage dependence, 
channel conductance and permeability of the resulting gap junction. 
Connexin proteins are made up of four transmembrane alpha helices and 
two extracellular loops [54]. Each connexin has three highly conserved 
cysteine residues, which make disulphide bonds between the loops and 
are essential for the formation of a functional gap junction channel. There 
have been 21 connexins protein isoforms found to date in the human 
proteome with different physiological and regulation processes [34, 55].  
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Figure 1.4 Connexin Structure 
A connexin (pink) consists of 4 trans-membrane α helices (M1, M2, M3, 
M4) linked together by 2 extracellular loops (EL1, EL2) and 1 cytoplasmic 
loop (CL). Both the N-terminus and C-terminus have an intracellular 
location. 
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1.5.1 Connexin Distribution in the Myocardium 
In the heart, the most prominent connexins associated with electrically 
active tissue are Cx43, Cx40, and Cx45. Connexin isotype expression 
varies between different chambers and structures of the heart. The 
dominant ventricular connexin is Cx43 [22, 56, 57].  This connexin is 
expressed in nearly all myocytes of the working atrial and ventricular 
mammalian myocardium regardless of the stage of development. 
However, it is not found in the nodal cells of the sino-atrial (SA) and 
in small amounts in the atrio-ventricular (AV) node [58-60]. Davis et 
al. demonstrated in human cells that bundle branch cells (the fastest 
conducting cells in the heart) contained the largest gap junctions with 
extensive levels of Cx43, 40 and 45. Nodal cells, on the other hand, 
have slower conduction and thereby had the smallest gap junctions 
with small levels of Cx45 and Cx40 expressed. Atrial myocytes 
express moderate amounts of Cx40, 43 and 45, while ventricular 
myocytes expressed only Cx43 and 45 [60].  
 
Expression of connexins may differ between mammalian species. In 
rodents, Cx43 is not found in the His-Bundle and the proximal parts 
of both bundle branches but is present in the distal parts [61]. In large 
animals, it is found in all parts of the ventricular conduction system. 
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Connexin45, in rodents, is present in the AV node and the ventricular 
conduction system and only in very low levels of the surrounding atrial 
and ventricular myocardium [62]. It is not found in the SA node of 
rodents but has been noted in the SA node of rabbits. Connexin40 is 
found in low levels of the SA node of rabbits, dogs and cows [61]. It 
is found mainly in the ventricular conduction system where it co-
localizes with Cx45 [31]. It is known to be strongly co-expressed with 
Cx43 in the atrial myocardium except in rat atrial myocardium. Of 
note, Cx40 is also present in ventricular myocardium during foetal and 
neonatal development but this does decline substantially until it is 
virtually absent in the adult stages [31].  
 
1.5.2 Connexin43 
Connexin43 gap junctions are permeable to organic ions and 
molecules of less than 1K Da [63]. Three different conductance’s 
have been described, 20-30pS, 40-60pS and 70-100 pS depending 
on phosphorylation as well as open or closed state of the hemi-
channels [63]. The molecular weight of Cx43 is between 41 to 46 kDa 
depending on its phosphorylated state. The conductance and 
permeability of gap junctions composed of Cx43 can be modulated by 
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intracellular pH, intracellular calcium or ATP concentration. In 
summary, cGMP-dependent protein kinases, protein kinase C, 
protein tyrosine kinase, casein kinase reduce the cell to cell 
conductance and permeability; while mitogen activated protein 
kinases (in cardiomyocytes) and PKA do the opposite by increasing 
the cell to cell permeability and conductance[63].   
 
1.5.3 Connexin43 and Ventricular Arrhythmia 
Connexin43 has been implicated in several studies as one of the main 
connexins associated with ventricular tachyarrhythmia [24, 64-66].   
 
Connexin43 and Acute Myocardial Infarction 
Connexin43 is found in its phosphorylated state in normal perfused 
hearts. With ischemia Cx43 becomes dephosphorylated due to an 
activation of mitochondrial KATP and reduced energy available for 
protein kinases [67]. This then leads to cellular uncoupling and as a 
result of the hemichannels remaining open, cell death and eventual 
irreversible tissue injury.  
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Connexin43 Distribution in Chronic Myocardial Infarction Model 
Following myocardial infarction, Ursel et al. have reported in their 
longitudinal study (canine model) that as the infarcts healed, resting 
potential, action potential amplitude, and upstroke velocity returned to 
normal by 2 weeks, while action potential duration took two months to 
return to normal [68]. Never-the-less because of diminished 
connections between cells and slow conduction persisted in healed 
infarcts contributing to the occurrence of chronic arrhythmias [68].  
 
Peters et al. studied Cx43 content in gap junctions in ischemic hearts 
and in hypertrophied human hearts [69]. They carried out quantitative 
immunohistochemistry studies on surgically obtained myocardial 
samples. They reported a significant reduction in gap junction surface 
area in those with ischemic myocardium (0.0027 µm2/µm3), in 
hypertrophied hearts (0.0031 µm2/µm3) when compared to normal 
myocardium (0.0051 µm2/µm3) [69]. They also noted a reduction in 
content of Cx43 in the diseased myocardial gap junctions as 
compared to the normal myocardium. This study showed that the 
reduction in surface area of gap junction may lead to reduction in 
conduction velocity and thereby increased ventricular 
tachyarrhythmia. 
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Transgenic studies 
Several studies of transgenic mice with either knockout or 
heterozygous knockout Cx43 have been studied [39, 70-72]. Those 
with Cx43 deletion (-/-) died shortly after birth and therefore 
investigators were unable to record any electrical activity. On the 
other hand, in one study, heterozygous (Cx43 +/-) neonatal mice had 
a 30% slower conduction in paced hearts compared to wild type 
(Cx43 +/+) [70]. In this same study, conduction velocity worsened in 
adult mice with a 44% reduction in heterozygous compared to wild 
type mice. These studies in Cx43 gene altered mice were, however, 
not always consistent as Morley and his associates had noted no 
change in conduction velocity between heterozygous Cx43 deficient 
and wild type mice [72]. Morley used optical voltage mapping, a 
different and more accurate method to measure conduction velocity 
in these mice.  A further study by Stephan et al. used a murine model 
genetically engineered to express decreasing levels of Cx43 [73]. 
They reported that a heterogeneous reduction of Cx43 of 18% leads 
to conduction slowing compared to wild type mice and more 
importantly leads to an 80% increase in lethal tachyarrhythmias.  
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Somatic studies: 
Xun Ai and associates have studied the effects of Cx43 in rabbit 
myocardium [74]. They had initially noted that rabbits with heart 
failure had a reduction in expression of Cx43 as well de-
phosphorylation of Cx43. This likely contributed to reduced cell 
coupling and therefore an increase in SCD from arrhythmia. This led 
to them to both knockdown and over-express Cx43 using adenovirus 
vector transmission in rabbit myocardium. Knockdown of Cx43 led to 
decreased intercellular coupling (assessed by Lucifer Yellow (LY) dye 
transfer); while overexpression of Cx43 in their heart failure rabbit 
model improved dye coupling compared to controls. They noted that 
the overexpressed Cx43 protein was located throughout the myocytes 
membrane (similar pattern to their control group) and the 
phosphorylation status was also comparable to those of the heart 
failure controls.  
 
Roell et al. undertook an interesting study where they were able to show 
that that transplantation of embryonic cardiomyocytes in mice with 
myocardial infarcts protects against the induction of ventricular 
tachycardia [75]. Engraftment of skeletal myoblasts, bone marrow cells or 
cardiac myofibroblasts, did not offer the same protection against VT 
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induced by pacing. They reported that engraftment of embryonic 
cardiomyocytes resulted in improved electrical coupling between the 
surrounding myocardium and the infarct region as well as increased 
conduction velocity, and decreased the incidence of conduction block 
within the infarct. They then genetically engineered skeletal myoblasts to 
express Cx43 and engrafted them into infarcted hearts revealing a similar 
protection against VT to that achieved by engrafting embryonic 
cardiomyocytes. Hence they deduced that engraftment of Cx43-
expressing myocytes has the potential to reduce ventricular arrhythmias 
in the post-infarct model through the augmentation of intercellular coupling 
[75].  
 
Greener et al. also studied the effects of Cx43 over expression in a 
post-infarct VT pig model [64]. Following infarction by transient left 
anterior descending (LAD) coronary artery occlusion, pigs with inducible 
VT were treated with adenoviral Cx43, or βgal, or no gene transfer. They 
reported a 60% reduction in VT inducibility following Cx43 gene therapy 
compared to controls. The Cx43 protein levels were two fold higher in the 
infarct border of those treated with Cx43 compared to controls suggesting 
a mechanistic effect of Cx43 in slowing conduction and inducing 
arrhythmia in the healed scar border. 
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Human Studies of Connexin43 
There have been several human studies showing an association 
between expression levels of Cx43 and heart diseases with increased 
susceptibility to ventricular tachyarrhythmias [69, 76, 77].  
 
Peters et al. studied Cx43 content in gap junctions in ischemic hearts 
and in hypertrophied human hearts reporting reduced expression of 
Cx43 [69]. Other studies have also confirmed that there was a 
reduction in Cx43 expression in other forms of heart disease, 
including ischemic cardiomyopathy, dilated cardiomyopathy and 
inflammatory cardiomyopathies [76, 77]. These conditions are all 
associated with an increased risk of SCD due to ventricular 
tachyarrhythmias. This supports the hypothesis that altered 
expression of Cx43 leads to abnormal coupling between 
cardiomyocytes which in turn leads to conduction slowing and thereby 
the propensity to SCD through ventricular tachyarrhythmias [23]. 
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1.5.4 Connexin45  
Channel Properties: 
Most investigations into the function of gap junctions composed of 
Cx45 have been done on immortalised, gap-junction deficient cells 
such as SkHep1 or Hela cells[31, 78-80]. It has been cloned in 
mouse, human and rat DNA. Its coding region consists of 396 amino 
acids in the human and rat genome, and 395 amino acids in the 
mouse genome [81]. Gap junctions composed of Cx45 are selective 
for cations [61, 81]. Veen et al. have reported them to be voltage 
dependant with half maximal activation at +/- 20mV. Connexin45 has 
also been noted to be more sensitive to intracellular pH than Cx43, 
with complete block occurring at a pH of 6.3 [82]. Multiple studies 
have assessed its permeability properties and noted that it was 
moderately permeable to fluorescent dyes LY, dichlorofluorescein 
(DCF) but not 6-carboxyﬂuorescein (6CF) [31, 79]. There are 15 
possible phosphorylation sites for PKC in human Cx45 and 17 in 
rodents and mice, mainly on the serine but also on the tyrosine 
residues [31]. With regards to its size as its name suggest its size is 
45kD – 48kD (depending on phosphorylated state). Valiunas et al. 
reported that Cx45 gap junctions have relatively small unitary 
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conductance for (~26pS) but were still able to pass some fluorescent 
dyes [83]. 
 
Connexin45 and Myocardial Development 
Connexin45 is the first connexin to be expressed in the heart and is 
therefore essential for foetal myocardial development [84, 85]. Sebastien 
et al. have shown that Cx45 protein expression can be detected in the 
mouse heart at day 8.5 to 9.5 post conception but the beyond day 10.5 
post conception the protein could no longer be detected with 
immunofluorescence microscopy [59]. Immunoblotting technique, 
however; continued to detect the protein in the neonatal heart implying it 
was still being synthesized. In the major part of the adult mouse heart 
Cx45 was undetectable except in the anterior regions of the 
interventricular septum and in trace amounts in the ventricular free wall; 
supporting its presence in the myocardial conduction system.  
 
Connexin45 and Arrhythmia 
In the adult heart under pathological conditions, such as heart failure, 
increased expression of Cx45 can occur [86]. Pathological conditions can 
also affect other connexins, for example, Cx43 has been shown to be 
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reduced in failing hearts [77, 87]. Reduced Cx43 expression may result 
in diminished coupling and thereby contribute to re-entrant 
tachyarrhythmia. However there has been data from Cx43 knockout mice 
showing that there needs to be a 70-90% reduced expression to manifest 
into a significant conduction delay or arrhythmia [88, 89]. It seems that 
the more modest reductions observed in heart disease are unlikely to be 
the cause of abnormal rhythm generation. Therefore it is conceivable that 
the up-regulation of Cx45 may have an effect of electrical conduction. 
One possible mechanism for this is that ventricular gap junctions in 
diseased hearts are made up of Cx43, Cx45 or oligomerize with each 
other to form mixed Cx43/Cx45 channels.  From a biophysical perspective 
Cx45 gap junctions display a much lower unitary conductance than Cx43 
channels, a property that underpins their prevalence in the AV and atrial 
nodes. These sites physiologically demand slow but safe electrical 
conduction. The functional effects of heteromeric Cx43/Cx45 channel 
formation on gap junctional intercellular coupling have been assessed in 
heterologous expression systems and in primary myocytes [80, 81, 90]. 
The resulting heteromeric gap junctions yielded disparate functions to 
their homomeric counterparts raising the possibility that heteromeric 
channel formation may be one mechanism by which intercellular 
communication can be altered.   
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Transgenic Models 
In a transgenic, cardiac-restricted, Cx45 over-expressing mouse model 
there was an increased incidence of spontaneous and inducible 
ventricular tachyarrhythmia [90]. Moreover there have been studies using 
a knockout mouse model, which died from heart failure in utero at 
embryonic day 10. The embryonic hearts were found to be dilated due to 
defective vascular development. However even with the absence of 
Cx45, heart contractions were initiated but there was conduction block 
though the atrioventricular canal and the contractions in the outflow tract 
were not co-ordinated with those in the ventricle. This does support the 
previously mentioned studies of Cx45 being present in the ventricular 
conduction system.  Cecilia lo et al. also reported that knockout embryos 
exhibited an endocardial cushion defect due to failure of cells in the 
myocardium to requisite epithelial-mesenchymal transformation [62]. This 
suggested that Cx45 has a role to play in the development of the 
endocardial cushion.   
 
This is in contrast to a recent study by Yamada el al. where they created 
lines of mice that were either Cx45 deficient or Cx45 overexpressed 
hearts [91]. The Cx45 deficient hearts that survived did not have any 
electrophysiological differences to those of the wild type mice. More-over, 
in contrast to their previous study, this study of Cx45 overexpressed mice 
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did not show any in vitro differences in electrophysiological properties [3]. 
Of note the overexpressed mice had a two-fold increase in Cx45 and the 
studies were in vitro whole heart preparations. This may be the reason 
for the difference in observed results.  
 
While some of the studies in genetically altered mice support our 
hypothesis that up-regulation of Cx45 contributes to conduction slowing 
and arrhythmia formation the strength of the findings is limited by the 
models employed. The use of transgenic mice to study connexin biology 
and arrhythmia is limited by changes in the expression of unintended 
molecules and the high-level of structural abnormalities encountered [62]. 
The latter could explain the genesis of any arrhythmia independent of the 
molecular alteration. While it is agreed that use of conditional transgenics 
may overcome these limitations, the somatic gene transfer approach 
would be superior in this context for the following the reasons.  Firstly, 
acute genetic changes will be induced in the adult heart essentially 
mimicking those likely to occur in the context of acute myocardial disease. 
Secondly, heterogeneity of gene transfer also mimics the heterogeneous 
pattern of connexin expression in the diseased heart and is likely to result 
in higher levels of arrhythmia burden than the low levels seen by 
Betsuyaku et al. [90]. Employing systemic transfer method of gene it is 
likely that transmural heterogeneity will also be achieved.  
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1.6 Viral Vectors  
The predominant use of viral vector systems in the preclinical models of 
gene therapy is a reflection of the increased gene transfer efficiencies 
achievable with these systems. For gene therapy to be successful, an 
appropriate amount of the therapeutic gene must be delivered into the 
target tissue without substantial toxicity.  
 
Gene delivery systems can be broadly classified into either non-viral 
physico-chemical systems and recombinant viral systems [92, 93]. I will 
concentrate on the latter in this section of the review. The three most 
commonly used viral vector systems are shown in Table 1.2. 
 
Adenoviral and Lentiviral Vector Systems 
Historically, recombinant human adenoviral vectors have been the most 
commonly used vectors in pre-clinical gene therapy models and in clinical 
cardiovascular gene therapy [94]. This vector system has been widely 
used given the high functional vector titres achievable, ease of production 
and broad target cell tropism, particularly within the cardiovascular 
system [95]. All major cardiac cell types can be efficiently transduced by 
adenoviral vectors both in vivo and in vitro. The pattern of in vivo 
transduction in mammalian species is dependent on the method of 
delivery. Guzman et al. showed a direct myocardial injection results in 
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intense transduction at the site of injection, while Barr and his associates 
used an intra-coronary delivery system resulting in a more widespread 
transduction in the distribution of injected coronary vessel [96, 97].  
Disadvantages of using the adenoviral vector system include its capacity 
for evoking an intense immune and inflammatory reaction, the pre-
existence of neutralising antibodies to commonly used vectors, the de 
novo development of these antibodies (therefore inability to re-administer 
same vector serotype), and the lack of vector integration [95].  
 
Lentiviral vectors transduce target cells by genomic integration [95]. The 
first developed lentiviral vector system was based on the human 
immunodeficiency virus (HIV) type 1 [98]. The advantages of this system 
is the ability to confer long-term stable gene expression, the capability of 
transducing mitotically quiescent cells, relative ease of production and an 
increased packaging capacity when compared to recombinant adeno-
associated viral (rAAV) vectors [95].  The major disadvantages are the 
pathogenicity of the parental virus and development of an immune 
response following cardiac delivery [95].  
 
Recombinant Adeno-Associated Virus Gene Transfer Vectors 
Recombinant adeno-associated virus  vectors are derived from the 
dependant parvovirus rAAV type 2 [99].  This vector system has a number 
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of advantageous attributes such as a lack of parental agent pathogenicity 
and vector-related cytotoxicity, minimal immunogenecity, and the 
capacity for stable long-term transgene expression through genomic 
integration [100]. These vectors also possess natural tropism for striated 
muscle and can confer stable long-term transgene expression in cardiac 
muscle in immunocompetent hosts [101]. They are therefore a favourable 
vector system in clinical studies. 
 
The major limitations of rAAV vector systems include the d i f f i c u l t y  
i n  production of high-titre vector stocks of consistent purity and 
bioactivity, a limited packaging capacity of 4.8 kb and the possibility for 
the formation of pre-existent neutralising antibodies in human population.   
 
A number of additional rAAV serotypes have been described.  Pseudo 
typing rAAV-2 genomes modifies vector tropism and has been found to 
markedly enhance cardiac muscle transduction when capsid serotypes 
six, eight and nine are used [102]. 
 
Recombinant Adeno-Associated Virus Vector 2-9 
Recombinant adeno-associated virus vector 2 serotype 9 has been 
extensively studied in recent years. It is a human isolate and the terminal 
galactose is the primary cell surface receptor for the rAAV9 [103]. Co-
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receptors however remain unknown [104]. Studies in rodent and mice 
hearts have revealed higher transduction with rAAV9 than rAAV1, 
rAAV5, rAAV7, or rAAV8 following direct intramyocardial administration 
[105, 106].  However, other studies have reported less efficient transfer 
of rAAV9 compared to rAAV6 or rAAV8 when transendocardial 
administration was used [107, 108]. Despite this, Fish et al. as well as 
Pleger et al. have successfully used rAAV9 vectors via intracoronary 
administration in gene therapy trials involving porcine heart failure 
models [109, 110]. Importantly, rAAV9 is more effective in cardiac gene 
transfer via the intravenous route when compared to rAAV1 or rAAV6 
[104]. A further point to comment on is that rAAV9 has been observed to 
display broad bio-distribution in off-target organs after administration 
than rAAV6 [104]. Never-the-less pre-existing humoral immunity to 
rAAV9 is lower than rAAV1 or rAAV6 in humans [111]. 
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Table 1.2 Comparisons of Major Viral Vector Systems 
Vectors Adenovirus rAAV Lentivirus 
Functional Titre 
(per mL) 
Up to 1012 Up to 1010 Up to 109 
Genome dsDNA ssDNA ssRNA 
Insert Capacity 7 to 30 kb 4.8 kb 10 kb 
Integration No Yes (randoma) Yes (random) 
Pattern of 
transgene 
expression 
Transient Long-term Long-term 
Cell-cycle 
dependent 
transduction 
No Nob No 
Host/Vector 
interactions 
Cytotoxic and 
immunogenic 
Minimally 
immunogenic 
Minimally 
immunogenic 
 
a rep positive vectors are capable of site-specific integration 
b Transduction efficiency may be influenced by target cell mitotic activity 
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1.7 Myocardial Vector Delivery Methods 
Catheter-based Myocardial Delivery 
Several methods could be used to allow catheter delivery of genes to 
the myocardium including, intracoronary route, endocardial delivery or 
by retro-infusion of the coronary veins. 
 
Intracoronary delivery has been reported to result in variable 
transduction efficiencies. This may be due to biocompatibility of 
catheters and vectors, differences between animal species or vector 
related variability such as titre. Gene transfer efficiency has also been 
reported to be limited with only 50% transduction efficiency [112].  
 
Percutaneous endocardial delivery is limited to focal gene transfer to the 
myocardium thereby it is best applied to therapeutic angiogenesis or to 
focal arrhythmia therapy [113, 114]. Steerable needle-tip catheters 
through which vector can be injected into specified regions of 
endocardium have been developed and evaluated in both animal models 
and in human trials [115-117]. 
 
Retro-infusion of the coronary veins is the most recent described method 
out of the three. It involves infusion of a vector retrograde via the 
coronary veins and has been reported to result in gene transfer 
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efficiencies comparable to intracoronary injection with its use been 
validated in animal models [118-120].  
 
Direct Myocardial Delivery 
Some investigators believe that there is an advantage of direct myocardial 
injection of angiogenic growth factors or genes over the intracoronary 
delivery method.  This may be achieved via the transthoracic or sub-
ziphisternal approach. The direct approach is the desired method for 
regional myocardial ischemia and focal arrhythmia therapy. Use of this 
model in the literature has been mainly in animal models. It has been used 
both in small and large animal models. It has been described in a rat MI 
model where injection of human vascular endothelial growth factor 
(VEGF) 165 cDNA in the MI border zone induced angiogenesis [121]. 
Similarly in an ovine study, sheep which received intramyocardial 
injections of a plasmid encoding VEGF165 in the border zone had shown 
fractional shortening and wall thickening improvement in this area as 
compared with controls [122]. Other animal studies have successfully 
used this method of gene transfer and validated its efficiency in gene 
transfer [123, 124]. This direct-injection method offers a readily applicable 
delivery route to produce a highly localized expression of transgenes; 
however, transduction is restricted to the area surrounding the site of 
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injection. Another significant limitation is that acute inflammatory 
responses due to injury tend to develop at the injection sites and hence 
may limit the therapy and enable an adaptive immune response against 
the vector.  
 
Pericardial Delivery 
Myocardial gene delivery has been described via the pericardial space. 
The rationale for utilizing this approach is its anatomical proximity to the 
myocardium and the accessibility of the pericardial sac for percutaneous 
vector delivery. This method has been utilized in animal models including 
a rabbit model of chronic myocardial ischemia where basic fibroblast 
growth factor (bFGF) delivered via the pericardial space demonstrated 
enhanced new epicardial small vessel growth [125]. However in a dog MI 
model, administration of Ad/VEGF165 did not demonstrate increase in 
serum VEGF levels or improved collateral perfusion [126]. On the other 
hand, pericardial expression of the gene was noted 2 weeks following 
delivery of the gene. The benefit of this mode of delivery is prolonged 
exposure of the administered gene across a wider area of targeted 
surface. Animal models have supported the feasibility and safety of this 
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delivery mode but the suitability in patients with pericardial adhesions 
following multiple procedures is not feasible [127, 128].  
 
Surgical Delivery 
Surgical gene delivery is the most invasive approach and would be 
associated with significant morbidity associated with accessing the 
myocardium. This said it can potentially be performed while the patient is 
undergoing coronary artery bypass grafting or thorascopically.  
 
Gene delivery via multiple direct injections into the myocardium in open-
chested small animal models is well established [129]. This however 
results in only limited transgene expression to the targeted area. Hajjar 
et al. have described an improved method of delivery into the aortic root 
via a catheter introduced into the left ventricular cavity while the 
ascending aorta and pulmonary artery are transiently occluded [130]. 
Modifications to this method have also been described [131, 132]. The 
major limitation to this method is its invasive nature and this would limit 
its use in human trials; except in the setting of cardiac surgery. 
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Systemic Delivery with Myocardial Transduction 
Systemic delivery has been getting wider interest especially with the 
development of vectors that specifically target the myocardium such as 
the rAAV6 and rAAV9. The benefit being its ease of use and widespread 
exposure of the gene throughout the myocardium. The major 
disadvantage is ﬁrst-pass uptake by low-afﬁnity receptors in the lungs or 
metabolism in the liver resulting in decreased bioavailability for 
myocardial uptake as a result of the intravenous infusion [133]. A study 
by Bostick et al. demonstrated efficient transduction with facial vein 
injection in mice throughout the entire heart with rAAV9 microdystrophin 
gene therapy. This further translated into phenotypic changes with 
amelioration of electrocardiographic abnormalities in dystrophin-
deficient mouse (DMD) model [134]. It is expected that utilising other 
peripheral veins and the same vector would result in similar results. On 
the other hand,  intravenous bolus injection of bFGF has been ineffective 
in inducing an angiogenic response in a canine model of myocardial 
ischemia felt to be as a result of uptake by low affinity receptors in lung 
system [128]. Thereby the correct vector system needs to be chosen 
carefully to prevent first pass metabolism or uptake by low affinity 
receptors. I proposed the use of rAAV9 vector via the peripheral rat vein 
for transduction of myocardium in our experiments. 
 
46 
 
1.8 Summary 
In summary, cardiovascular mortality remains the leading cause of death 
in the industrialised world. Ventricular tachyarrhythmias are the major 
cause of cardiac arrest in the majority of cases. Anti-arrhythmic drugs 
have failed to reduce incidence of cardiac death. While ICDs are effective 
against ventricular tachyarrhythmia, their use is associated with a 
significant morbidity. Therefore our understanding of post-MI induced 
arrhythmia is important and appears to be incomplete.  
 
Re-entry arrhythmias are a prominent feature of ischemic heart disease. 
In experimentally induced MI, EP studies have identified the border zone 
of myocardial infarcts as sites in which slow conduction, responsible for 
sustained re-entry, arises. Slow conduction, attributable to intercellular 
uncoupling, and areas of complete conduction block, persist at the sites 
of experimentally induced infarction after healing, thereby contributing to 
chronic arrhythmogenesis. In human ischemic cardiac disease, a 
reduction in the size and density of gap junctions in these cells has been 
reported [24]. 
 
It is well understood that the low resistance pathways that allow the 
electrical impulse to flow rapidly and repeatedly between cardiac muscle 
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cells, ensuring that their mechanical responses are orderly and 
synchronous in the healthy heart, are formed by gap junctions. It is 
thereby clear that gap junctions have a significant role in modulating tissue 
conduction velocity, and through aberrant expression lowers the threshold 
for arrhythmia.  
 
Gap junctions are formed of various connexins. Pathophysiological 
changes are reflected by the chamber specific expression and function of 
connexin isoforms. Connexin expression itself is clearly dynamic in 
expression and affected by many intracellular and extracellular factors. 
Influential factors that affect conductance include the degree of connexin 
phosphorylation, connexin location, and total junctional connexin content. 
To add to the complexity, changes such as transgenic alterations, somatic 
gene transfer, or arrhythmia induction may alter connexin physiology.  
 
Abnormal Cx43 and Cx45 in the ventricle are associated with ventricular 
arrhythmias, while abnormal Cx40 in the atria is associated with atrial 
fibrillation. Connexin43 has been well studied in the MI model. In the acute 
MI, Cx43 has been described to be reduced and lateralised in the infarct 
zone, and this has also been extended to the chronic MI model [64-66, 
135]. These alterations correlated with heterogenous conduction by in 
vivo measures and slowed conduction velocity during ex vivo testing [64]. 
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Greener et al. have showed that gene transfer–mediated overexpression 
of Cx43 increased the absolute amount of phosphorylated and 
intercalated disk-localized Cx43, improved conduction velocity, and 
reduced VT inducibility [64]. Hence it may be extrapolated that Cx43 
expression and function is important for ventricular conduction velocity 
and arrhythmia mechanism.  
 
Connexin45 on the other hand remains not well investigated. There are 
studies supporting its overexpression in human heart failure and it 
association with increased arrhythmogenesis. Moreover transgenic mice 
models have been created that do support the hypothesis of Cx45’s 
involvement with conduction slowing and increased arrhythmogenesis 
[90]. This area remains under evaluated and hence the aim of this PhD. 
 
The success in gene therapy in the clinical era is dependent on several 
key factors: appropriate vector platforms, efficient delivery methods, 
documentation of clinical feasibility and consistent safety and efficacy. 
Choosing the appropriate vector and method of delivery is therefore 
paramount.  
 
 
The most difficult issue with human and animal studies is to use models 
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that mimic disease state controls. Clearly patients with myocardial 
ischemia are not adequate controls for valvular, dilated or inflammatory 
cardiomyopathies. Transgenic models while widely used have several 
disadvantages and do not mimic the human diseased heart. Somatic gene 
transfer presents itself as the most appropriate technique to assess true 
functional significance of relative connexin isotype expression. With the 
appropriate control vector and delivery method, the confounding factors 
identified may be avoided. 
 
Based on the above literature review, Cx45 pathophysiology will be 
studied using a rAAV9 vector system and somatic gene transfer. 
Once establishing that Cx45 expression may contribute to ventricular 
arrhythmia, it is important to study it in a disease model. The rat 
infarct model is used given its ease of production and both Cx43 and 
Cx45 expression will be modulated to further understand arrhythmia 
in the MI model. 
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CHAPTER 2 
MATERIALS AND GENERAL METHODS 
 
 
 
In this chapter methods are described. These have been employed across 
most of the research project. Specialized methods or variations of these 
general methods are described in their respective results chapters 
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2.1 Molecular Biology 
2.1.1 Chemicals, Reagents, and Plastic/Glassware 
Analytical grade chemicals and reagents were used and the suppliers of 
these are indicated throughout the text. Also, only reagent grade water 
(MQH20) was used when solution production required water.  
 
All plastic and glassware were washed, rinsed with MQH20, and autoclave 
sterilized prior to use. 
 
2.1.2 Bacterial Strains and Plasmids 
Sure 2 super-competent cells were used (genotype: e14-(McrA-) 
Δ(mcrCB-hsdSMR-mrr)171 endA1 gyrA96 thi-1 supE44 relA1 lac recB 
recJ sbcC umuC::Tn5 (Kanr) uvrC [F´ proAB lacIqZΔM15 Tn10 (Tetr) Amy 
Camr source: Stratagene]. Tables 2.1 and 2.3 below described the 
plasmids used in this research project. All plasmids used had an ampicillin 
resistance gene. 
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Table 2.1: DNA Plasmids used within this Research Project 
Plasmid Description Source 
Adeno-
associated viral 
vector 9 
Viral vector rAAV subtype 2/9 
known to be specific for 
cardiomyocytes 
Dr Jim Wilson, The 
University of Pennsylvania, 
USA  
pXX6 plasmid Helper plasmid Children Medical Research 
Institute, Sydney, Australia 
rAAV9 Capsid 
plasmid 
rAAV Capsid plasmid 
pPPT.CX45 LV plasmid encoding cDNA for rat 
Cx45 
Vector plasmids produced 
by Eddy Kizana prior to 
research program based on 
pRRLsin18.cPPT.CMV.eGF
P.WPRE 
Sydney, Australia 
pPPT.Cx43 LV plasmid encoding cDNA for rat 
Cx43 
pPPT.NS11 Plasmid encoding a non-silencing 
gene 
pPPT.shRNA LV plasmid encoding a shRNA to 
silence Cx45 
pPPT.GFP LV plasmid encoding enhanced 
Green fluorescence protein 
pPPT.CX43 LV plasmid encoding cDNA for rat 
connexin43  
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pUC18 Transformation control plasmid Thermo Scientific, United 
States 
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2.1.3 Bacterial Growth Media 
Escherichia coli were grown in Luria-Betani (LB) broth, NZY+ broth or on 
solid LB-agar. Fresh broth was prepared when required using 0.5% (w/v) 
yeast extract (Sigma-Aldrich), 1% (w/v) tryptone (Sigma-Aldrich), and 1% 
(w/v) sodium chloride (Sigma-Aldrich) dissolved in MQH20.  
Bacteriological agar 1.5% (w/v) was added to fresh broth when LB-agar 
was required. Media was autoclave sterilized at 121°C for 20 minutes. 
Ampicillin at a concentration of 100µg/mL was added after the media was 
cooled to approximately 55°C, and poured into 10cm petri dishes and then 
left in a reverse cycle hood to cool down and solidify.  
 
Fresh NZY+ broth was prepared using 1% (w/v) NZ amine (Sigma-
Aldrich), 0.5% (w/v) yeast extract, and 0.5% (w/v) sodium chloride 
dissolved in MQH2O. The pH was adjusted to 7.5 by using sodium 
hydroxide (Sigma-Aldrich) then autoclave sterilized. Prior to use 12.5mL 
of 1M MgCl2, 12.5mL of 1M MgSO4, 20mL of 20% (w/v) and ampicillin 
100µg/mL was added per litre of media. 
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2.1.4 Propagation of Plasmids 
2.1.4.1 Cloning DNA using SURE 2 Super Competent Cells 
SURE2 (Stop Unwanted Rearrangement Events) cells obtained from 
STRATAGENE were thawed on ice, and 100µL of cells were aliquoted 
into pre-chilled 14-mL BD Falcon polypropylene round–bottom tubes on 
ice. Two µL of the Beta-ME provided by STRATAGENE was added to the 
cells and incubated on ice for 10 minutes with gentle swirling every 2 
minutes. Fifty ng of the DNA was added to the cells and incubated on ice 
for 30 minutes. After the tubes were heat-pulsed in a 42oC water bath for 
30 seconds, they were further incubated on ice for 2 minutes.  Nine 
hundred µL of preheated (42oC) NZY broth was added and incubated at 
37oC for 1 hour with shaking at 250rpm. A hundred µL of the mixture was 
then plated on LB agar plates. Plates were incubated at 37oC overnight. 
Approximately 50 colonies are expected. The efficiency of those cells ≥1.0 
10X9 cfu/µg of required DNA. 
 
2.1.4.2 Making a Glycerol Stock 
A starter culture was produced by inoculating 5mL LB broth with a single 
fresh colony of transformed cells in a 14mL polypropylene tube and then 
incubated for 6-8 hours on an orbital shaker at 37oC. The starter culture 
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was added to 200mL of LB broth and incubated on an orbital shaker at 
240rpm at 37oC overnight. Spectrophotometry would be used to assess 
that cultures reached mid-log phase growth (absorbance of 0.4 at 600nm). 
The next morning, a glycerol stock was made by mixing 850µL of the 
bacterial suspension with 150µL of glycerol stock (Sigma-Aldrich) and 
subsequently stored in a -80oC freezer. For long term storage after 
24hours the stock was then transferred to liquid nitrogen storage until 
further use. 
 
2.1.4.3 Small Scale Production of Plasmid DNA 
Small scale preparation were firstly carried out to confirm the plasmid DNA 
according to the alkaline lysis method using commercially available 
buffers provided by Qiagen mini prep kit. Five mL LB medium was 
inoculated with a single colony from a freshly streaked selective plate or 
from our glycerol stock. This was incubated for 16 hours at 37oC on an 
orbital shaker and pelleted at 6000 x g for 3 minutes at room temperature. 
The bacterial pellet was then resuspended in 250µL of Buffer P1 
containing RNASE A. The mixture was transferred to a micro-centrifuge 
tube. Cells were lysed with a 250µL of buffer P2 and mixed thoroughly by 
inverting the tube 4-6 times; then incubated for 5 minutes at room 
temperature. Genomic DNA, protein, and cell debris were precipitated 
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with the addition of 350µL of buffer N3 and mixed thoroughly at room 
temperature. This was then centrifuged for 10 minutes at 13,000 rpm 
(Sorvall RC 6+ centrifuge). The supernatant was applied to a QIAprep 
spin column by pipetting and centrifuged for 60 seconds at 13,000 rpm. 
The flow-through was discarded and the spin column was washed by 
adding 0.5mL Buffer PB and centrifuged at 13,0000rpm for 1 minute. The 
flow-through once again then centrifuged for a further minute. The 
QIAprep column was placed in a clean 1.5mL microcentrifuge tube. To 
elute the DNA, 50 µL buffer EB (10mM tris-HCl, pH 8.5) was applied to 
the centre of the QIAprep spin column, let it stand for 1 minute then 
centrifuged for 1 minute at 13,000rpm. Spectrophotometry was then used 
to assess DNA concentration and purity. A Nanodrop was then used to 
assess DNA concentration and purity. DNA was also subjected to 
restriction endonuclease digestion followed by agarose gel 
electrophoresis and UV imaging to confirm the DNA characteristics. 
 
 2.1.4.4 Maxiprep Plasmid DNA Extraction 
A starter culture was made by inoculating 5mL of LB broth from a glycerol 
stock of the required plasmid DNA in a 14mL polypropylene tube and 
incubated for 6 hours on an orbital shaker at 37oC.  One mL of the starter 
culture was then added to a 200mL of LB broth in a 1L conical flask on an 
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orbital shaker at 240rpm at 37oC overnight. The following morning, the 
culture was pelleted at 6,000g for 15 minutes at 4oC. The supernatant was 
discarded and the bacterial pellet was processed by the alkaline lysis 
method using a commercially available Qiagen HiSpeed Plasmid Maxi kit 
according to the manufacturer’s protocol. The cell pellet was resuspended 
in 10mL of buffer P1 containing RNase A. Followed by lysis with the 
addition of 10mL of buffer P2 and incubated for 5 minutes at room 
temperature. Genomic DNA, protein, and cell debris were precipitated 
with the addition of 10mL of chilled buffer P3 and incubated for 10 minutes 
at room temperature. A HiSpeed Maxi Tip was equilibrated with 10mL 
buffer QBT during the incubation period. The lysate was then filtered with 
a QIAfilter cartridge onto the HiSpeed Maxi Tip and allowed to pass 
through the resin by gravity flow. Following 60mL of buffer QC was used 
to wash the HiSpeed Maxi Tip and the DNA eluted using 15mL of buffer 
QF into a 50mL polypropylene tube. DNA was precipitated with 10.5mL of 
100% (v/v) isopropanol (Sigma-Aldrich) for 5 minutes. The 
elute/isopropanol mixture was filtered through a QIAprecipitator. Five mL 
of 70% (v/v) ethanol (Fronine) was then used to wash the QIA precipitator 
and air dried. DNA was subsequently eluted with 1mL of Tris buffer. 
Nanodrop was then used to assess DNA concentration and purity prior to 
storage in a -80°C freezer. The yield of plasmid DNA achieved varied 
between 0.2mg to 1.5mg. 
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2.1.4.5 Gigaprep (Large scale) Production of Plasmid DNA 
To extract large amounts of plasmid specifically plasmid pXX6, the Qiagen 
High Speed Maxi Prep was used according to the manufacturer’s protocol. 
The cell pellet was resuspended in 125mL of buffer P1 containing RNase 
A. Lysis was enacted with the addition of 125mL of buffer P2 and 
subsequent incubation for 5 minutes at room temperature. Genomic DNA, 
protein, and cell debris were precipitated with the addition of 10mL of 
chilled buffer P3 and subsequent incubation for 125 minutes at room 
temperature. During the incubation period, a HiSpeed Giga Tip was 
equilibrated with 75mL buffer QBT. The lysate was filtered with a QIAfilter 
cartridge onto the HiSpeed Giga Tip and allowed to pass through the resin 
by gravity flow. The HiSpeed Maxi Tip was washed with 600mL of buffer 
QC and the DNA eluted using 100mL of buffer QF into two 50mL 
polypropylene tube. DNA was precipitated by mixing with 70mL of 100% 
(v/v) isopropanol (Sigma-Aldrich) and centrifuged at 15000g for 30mins at 
4°C and the supernatant removed. The pellet was washed with 10mL of 
70% (v/v) ethanol (Fronine) and centrifuged at 15000g for 10mins at 4°C. 
The supernatant was then removed carefully and the pellet air dried. The 
pellet was dissolved in 1mL of Tris buffer. DNA concentration and purity 
of the new plasmid stock was assessed with Nanodrop prior to storage in 
a -80°C freezer. The yield of plasmid DNA varied between 1mg to 4mg. 
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2.1.4.6 Estimation of Plasmid DNA Concentration and 
Purity 
The concentration and purity of DNA was determined by 
spectrophotometry measuring absorbance at wavelengths of 260nm and 
280nm. This method assumes that 50µg of DNA to have an absorbance 
of 1.0 at 260nm and pure DNA has a 260/280 absorbance ratio of 1.8 
(Sambrook et al.) [136]. 
 
DNA samples were routinely subjected to spectrophotometry and 
measurements were made at one or two dilutions.  
 
2.1.4.7 Agarose-gel Electrophoresis 
Horizontal agarose-gel electrophoresis was used to analyse plasmid DNA 
following restriction enzyme digest. Preparation of the agarose gel was at 
0.8% (w/v) agarose (Amresco) in TAE (40 mM Tris-acetate and 1 mM 
EDTA) heated at low power microwave oven until the agarose was 
molten. Following ethidium bromide (Sigma-Aldrich) was added at 1 
µg/mL once the agarose was cooled to about 55oC. When it had set, 1 to 
3 µL of 6 x 6 gel loading buffer (30% (v/v) glycerol, 0.25% (w/v) 
bromophenol and 0.25% (w/v xylene-cyanol FF in MQH2O) was added to 
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5 to 15 µL of DNA sample and loaded onto the gel. Molecular weight 
marker I (Bioline - Roche Colecular Products), was used to estimate the 
size of DNA fragments. The gel was run in 1 X TAE buffer at a constant 
voltage of 100 Volts until the dye front had moved a suitable distance. A 
UV trans-illuminator was used to examine the gels and then photographed 
using a Gel Doc 100 (Bio-Rad) Camera. 
 
 
2.1.4.8 Restriction Endonuclease Digestion of Plasmid DNA 
Restriction endonuclease digestion of DNA was performed according to 
the manufacturer’s specifications. Diagnostic restriction endonucleases 
were performed on 500-1000 ng of plasmid DNA using 5 – 10 units of 
enzyme. The digests were performed in 1.5mL polypropylene 
microcentrifuge tubes in the presence of the appropriate buffer in a total 
volume of 20 µL of MQH2O. The digests were incubated at the requisite 
temperature for 1 hour then were analysed by agarose-gel electrophoresis 
for DNA characterisation. 
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2.2 Cell Culture 
2.2.1 Cell Lines, Reagents, and Plastic/Glassware 
Table 2.2 lists the cell lines and respective culture conditions used during 
this project. 
 
Cell culture media was freshly supplemented with the cell culture grade 
reagents specified in Table 2.2 prior to the commencement of individual 
experimental protocols.  
 
For subculture and other manipulations, human embryonic kidney 
(HEK293) cells were washed with Dulbecco’s Phosphate Buffered Saline 
(DPBS) (lacking calcium and magnesium) (Lonza) and detached and 
aggregated using 0.05% Trypsin/0.5mM EDTA solution (Sigma-Aldrich).  
 
Sterile filtered foetal bovine serum (FBS; SAFC Biosciences), was stored 
at -20ºC. When required it was heat inactivated by warming to 37ºC for 30 
minutes. Ten mL of Dulbecco’s Modified Eagles Medium (DMEM) with 
FBS was added to the detached aggregate to inactivate the trypsin. 
 
63 
 
Cell culture plastic ware including culture flasks and serological pipettes 
were obtained from Falcon and Corning and were only used once. All 
glassware was washed, rinsed with MQH2O and autoclave sterilized prior 
to use. 
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Table 2.2: Cell Types used in Cell Culture Experiments 
Cell Type Description Source Medium 
HEK293 Human embryonic 
kidney cells 
Children’s Medical 
research Institute, 
Westmead Children’s 
hospital  
1,2 
NRVM Primary Day 2-3, 
neonatal rat ventricular 
myocytes 
Adult Sprague 
Dawley rats, Animal 
Resourced Centre, 
Western Australia 
3,4,5,6 
1. Dulbecco’s Modified Eagles Medium (DMEM; Invitrogen) 
supplemented with 10% (v/v) FBS (SAFC Biosciences)  
2. Iscove's Modified Dulbecco's Medium (IMDM; Invitrogen) 
supplemented with 10% (v/v) FBS (SAFC Biosciences). 
3. Hank’s Balanced Salt Solution (HBSS; Invitrogen)  
4. HBSS with 1mg/mL Ultrapure Trypsin (Trypsin 4.066 USP u/mg, 
Chymotrypsin 12.13 USP u/mg; USB Corporation) 
5. HBSS with 1mg/mL Collagenase Type 2 (245u/mg; Worthington) 
6. Medium 199 (Invitrogen) supplemented with 1% HEPES Buffer 
Solution (Invitrogen), 1% MEM Non-Essential Amino Acids 
(Invitrogen), 1.75g Glucose (Sigma-Aldrich), 2mM L-Glutamine 
(Invitrogen), 1.5μm/L Vitamin B12, 20U/mL Penicillin solution 
(Sigma), and 2% or 10% (v/v) FBS (SAFC Biosciences). 
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2.2.2 General Cell Culture Methods 
Cell culture methods employed in this research project are detailed by 
Sambrook et al. [136]. Cells were grown in disposable polystyrene 
flasks/dishes (Falcon, Greiner and Corning) or sterile glassware 
containing their respective media as detailed in the above Section 2.2.1. 
All cultures were incubated in a 5% CO2 environment at 37ºC. 
 
2.2.2.1 Cell Counting using a Haemocytometer 
Adherent cells were counted following trypsinisation into a single cell 
suspension at a concentration of 105 to 106 cells per mL. A 10uL aliquot 
was applied beneath each side of a cover slipped haemocytometer 
(Neubauer). A 10X objective of an inverted microscope (Olympus CK2) 
was used to count live cells. The number of cells in the 4 major outer 
corners of each of the 2 chambers (8 squares in total) was averaged, 
corrected for dilution, and multiplied by 104 to give the number of cells per 
mL. 
 
2.2.2.2 Subculture of Adherent HEK293 Cells 
When cultures became approximately 70% confluent or were required for 
experimentation, cells were subcultured by enzymatic detachment and 
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replating. Culture media was firstly aspirated from the flask and the cells 
were washed once with 5mL PBS. Two mL of 0.05% Trypsin/EDTA 
solution was added to the culture and placed at 37ºC humidified chamber 
for 2 minutes to further cell detachment. Trypsin was then subsequently 
inactivated by the addition of 10mL of culture media. To further dis-
aggregate the cells the media was pipetted up and down approximately 5 
times. An aliquot of the cell suspension was seeded into a new culture 
flask with fresh culture media according to the dilution required. Cells were 
split one to three times per week depending on their growth kinetics. 
 
2.2.2.3 Short and Long term Storage of HEK293 cells 
To allow short term and long term storage, cells required were detached 
by trypsinisation during exponential growth and pelleted by centrifugation 
(1500rpm, 5 minutes). Media was aspirated and the cells resuspended at 
2 X 106 per mL in storage media consisting of culture media with 20-50% 
FBS and 10% (v/v) DMSO (Sigma-Aldrich). Cell suspension aliquots of 
1mL were placed in sterile cryovials (Nunc) and stored at -80ºC for short 
term storage. Twenty four hours later, those needed for long term storage 
were then moved to liquid nitrogen. 
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To recover cells from short and long term storage, cells were rapidly 
thawed in a 37ºC water bath. The contents of the cryovial was mixed with 
9mL of warmed (37ºC) culture media to remove the DMSO, pelleted at 
1500 rpm for 5 minutes, and resuspended in fresh culture media following 
aspiration of the supernatant. 
 
2.2.3 Primary Cell Culture 
2.2.3.1 Plating Surface Preparation  
 
 
Surfaces of 8 well plates intended for cardiomyocytes culturing were 
sterilized with ultraviolet light for 1 hour on the day of ventricular 
harvesting from rat pups. Surfaces were then coated at room temperature 
using a fresh 25mg/mL solution of fibronectin powder (BD Biosciences) 
dissolved in MQH20 that had been previously filter sterilized with a 0.45μm 
PVDF syringe driven filter. 
 
2.2.3.2 Isolation of Neonatal Rat Ventricular 
Cardiomyocytes  
These cultures were established by Dr Ajita Kanthan in Westmead 
Millennium Institute. Neonatal RVMs suspended in culture media were 
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supplied for experimental use in this project. The experiments for 
procuring NRVMs were approved by the Westmead Hospital Animal 
Ethics Committee.  
 
Two litters of rat pups (1 -3 days old Sprague-Dawley) were used for each 
dissection. Pups were sprayed with 70% ethanol, decapitated with a large 
pair of straight surgical scissors (Roboz Surgical Instrument Co), and their 
chests opened with angled delicate scissors (Roboz Surgical Instrument 
Co). Ventricles were excised and minced in ice cold Hank’s balanced salt 
solution (HBSS) without calcium and magnesium (Sigma-Aldrich). 
Following 2 rinses with ice cold HBSS, ventricular tissue was transferred 
to a glass jar containing 40mL of trypsin/HBSS solution, and agitated on 
an orbital shaker at 75rpm at 4ºC for 16 hours. The media was then 
aspirated and discarded. Warm 10% serum culture media was added and 
gently agitated in a 37ºC water bath for 4 minutes. The media once again 
was aspirated and discarded. Fresh collagenase/HBSS (8mL) was added 
to the tissue and gently agitated in a 37ºC water bath for 1 minute. The 
collagenase/HBSS solution was aspirated and discarded. Eight mL of 
fresh collagenase/HBBS solution was added to the tissue and gently 
agitated in a 37ºC water bath for 1 minute. To assist with myocytes 
dissociation, the tissue and media was pipetted up and down once with a 
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10mL serological pipette. The media was aspirated and added to ice cold 
HBSS and kept on ice. Again 8mL of collagenase/HBSS was added to the 
tissue and the process repeated 3 times. The 4 aliquots of HBSS solution 
containing dissociated cells were pelleted at 50 x g at 4ºC for 8 minutes. 
The supernatant was aspirated and the pellets resuspended in 8mL of ice 
cold HBSS. The cell suspension was then filtered with a 40μm cell strainer 
(BD Biosciences). The filtrate was centrifuged at 50 x g at 4ºC for 6 
minutes and the supernatant was aspirated and discarded. The pellet was 
resuspended in warm 10% serum culture media, pre-plated into a 150cm2 
tissue culture flask, and incubated at 37ºC at 5% CO2 for 2 hours. This 
pre-plating step allowed for the removal of fibroblasts.  
 
Media containing non-attached cardiomyocytes was then aspirated and 
placed into a 50mL polypropylene tube. The tissue culture flask was 
rinsed carefully with 10% serum culture media and the rinse also added 
to the 50mL polypropylene tube. The media was gently mixed by pipetting 
up and down once. Cells were then counted as described in Section 
2.2.2.1. A further 10% serum culture media was added to the cell 
suspension to achieve a final density of 7x105 cardiomyocytes/mL. A 
confluent monolayer was achieved at 24 hours post plating at this density. 
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2.2.3.3 Post Plating Care of Cardiomyocyte Cultures  
 
Twenty four hours after plating cardiomyocytes, media was aspirated and 
the myocytes washed once with pre-warmed 37°C PBS. Pre-warmed to 
37°C fresh 10% serum culture media was added to the myocytes and the 
cells returned to the humidified incubator. To prevent the growth of 
fibroblasts, media was replaced with fresh pre-warmed to 37°C 2% serum 
culture media at 48 hours and 90 hours post plating. 
 
2.3 Production and Application of Recombinant Adeno-
Associated Viral Vectors 2/9 
2.3.1 Recombinant Adeno-associated Viral Vector Plasmids 
Recombinant adeno-associated virus serotype 2/9 vector was used 
throughout this research project.  The plasmids used for vector production 
were cloned by Dr Renuka Rao in the lab and sequencing was carried out 
to determine a forward orientation relative to Chicken Beta Actin (CBA) 
promoter. The vectors also contained the Woodchuck hepatitis virus post-
transcription (WPRE) regulatory element. The Cx45, Cx43 and GFP were 
sub-cloned from the respective Lentivirus vectors (Table 2.4) (from Dr 
Eddy Kizana) into the Multiple Cloning Site (MCS) of the rAAV vector 
back-bone (Figure 2.1). For the silencing vector, RNA polymerase III 
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promoter (H1) together with a short hairpin RNA (shRNA) for Cx45 or a 
scrambled Non-Silencing sequence was sub-cloned upstream to the CBA 
promoter into the KpnI site. For controls GFP reporter in the rAAV vector 
and the empty vector were used. For a list of plasmids generated for this 
project see Table 2.3 
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Figure 2.1 Vector Map 
Vector map for rAAV-9. Transgenes GFP, Cx43 or Cx45 were inserted 
in the same site downstream of the CBA (chicken beta actin) promoter. 
WPRE = woodchuck hepatitis virus post-transcriptional regulatory 
element **** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
5’ - ITR CBA promoter 
Transgene 
(GFP, Cx43, Cx45) 3’ - ITR 
ECOR1 splice site 
 
WPRE 
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Table 2.3 Plasmids 
Plasmid Description Source 
pXX6 plasmid Helper plasmid Children Medical 
Research Institute, 
Sydney, Australia 
rAAV9 Caspid 
plasmid 
AAV Caspid plasmid 
rAAV.Cx45 Vector 
AAV.Cx45.WPRE 
Dr Renuka Rao 
Westmead Millennium 
Institute, Sydney, 
Australia  
rAAV.GFP Vector 
AAV.GFP.WPRE 
rAAV.Cx43 Vector 
AAV.Cx43.WPRE 
rAAV.sh45 Silencing vector 
H1868 
AAV.Sh.Cx45.WPRE 
rAAV.shNS Non-Silencing vector 
H1NS 
AAV.NS.WPRE 
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Table 2.4 Lentiviral Vectors 
Vector Description Source 
pRRLsin18.cPPT.CMV.GFP.WPRE Lentiviral GFP Dr Eddy Kizana 
Westmead 
Millennium 
Institute, 
Sydney, 
Australia  
pRRLsin18.cPPT.CMV.Cx43.WPRE Lentiviral Cx43 
pRRLsin18.cPPT.CMV.Cx45.WPRE Lentiviral Cx45 
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2.3.2 Vector Production 
Recombinant AAV vectors were produced using a helper-virus free 
system by calcium-phosphate co-precipitation transfection of the three 
vector plasmids into HEK293 cells. The method well described by Xinping 
Huang and Steven Gray was used and runs over several days [137-139]. 
All Solutions used are listed in Table 2.5. 
 
The cells were cultured as mentioned previously and then using trypsin 
were split with a 1/5 or 1/10 ratio depending on need.  
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Table 2.5 Reagents used for Vector Production 
Reagent Description 
TE(10%) Tris   0.061g 1mM final 
EDTA   0.019g  0.1mM final 
Made to 500mL with MQH20 after adjusting 
to pH 8 and autoclaved 
2M CaCl2 (147.02 MW) 29.404g of CaCl2.2H2O in 100mL MQH20. 
Autoclaved 
2XHepes-buffered saline 
(HBS) 
NaCl 8.182g 280mM final 
HEPES 5.959  50mM final 
Make up to 500mL with MQH20 after 
adjusting to pH 7.0 and autoclaved 
0.15M Na2HPO4 10.647g in 500mL MQH20. Adjusted to pH 
7.1 and autoclaved 
Resuspension Buffer NaCl (58.44 MW)  2.922g  100mM final 
MgCl2.6H2O (203.3MW)   0.2033g 2mM 
final 
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1M tris (121.14MW)   5mL   10mM final 
Made up to 500mL MQH20. Adjusted to pH 
8.0 and autoclaved 
Citric Saline 10X KCl (74.5513 MW)   50.3g    1.35M final 
Sodium Citrate (294.1 MW)   22.05g   0.15M 
final 
Dissolved in MQH20 and adjusted to 
500mL. Autoclaved. Diluted 1:10 with 
sterile MQH20to prepare a 1X solution 
(50mL of 10X citric saline plus 450mL 
water) 
Growth Medium  DMEM 
10% FBS 
Transfection Medium IMDM 
10% FBS 
Maintenance Medium DMEM 
2% FBS 
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2.3.2.1 Preparing HEK293 cells for Transfection 
HEK293 cells were seeded onto one hundred and twenty 10cm tissue 
culture dishes at 3.5x10x6 cells/dish with 8mL of growth medium. The cells 
were 50-70% confluent at time of transfection. The following morning the 
growth medium was replaced with Transfection Medium three hours 
before transfection. The dishes were changed 4 at a time carefully while 
leaving 2mL of old medium on the cells so they do not dry out. Removing 
and replacing 6mL of medium gently with a 25mL disposable pipette. 
 
2.3.2.2 Transfection Solution 
The triple plasmid transfection was done with the following plasmids using 
the Calcium Phosphate method 
15µg DNA/Dish: 
  3µg Vector DNA 
  3µg Packaging/Capsid Plasmid 
  9µg Helper plasmid 
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Solution A  
 
 Volume 120 dishes 
(mL) 
 
3 x Plasmid DNA X 2mg 
100% TE Y  
2M CaCl2 7.5 0.5M 
Total 60  
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Solution B  
 Volume 120 dishes 
(mL) 
2 x HBS 59.4 
0.15M Na2HPO4 0.6 
Total 60 
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Four mL of Solution A was aliquoted into 15 polypropylene (opaque) 15mL 
round-bottom tubes. Four mL of Solution B was aliquoted to 15 
polystyrene (clear) 15mL round–bottom tubes. Solution A was slowly 
added drop wise using a P200 pipette, while mixing to Solution B to 
precipitate the DNA. Solution mix was then incubated for 20 minutes at 
room temperature before adding precipitate to cells, 1mL per dish. Cells 
were incubated overnight at 37oC. Sixteen hours Later the medium was 
changed to Maintenance Medium. Sixty hours after transfection, the cells 
were harvested from the transfected dishes by scraping cells into the 
medium. They were pipetted 5 times using a 10mL pipette to help take off 
as much of the cells from the dishes and collected into 50mL tubes. The 
cells were pelleted by centrifugation at 1500rpm for 5 minutes. The 
supernatant was discarded. The pellets were then resuspended by using 
15mL of Resuspension Buffer starting from tube one and then transferred 
to tube two and so on. This step was repeated a further five times to a 
cumulative total of 90mL of Resuspension Buffer from the 120 dishes. 
 
 
 
 
82 
 
2.3.2.4 Vector Purification and Concentration  
The reagents are listed in Table 2.6 
The cell suspension was frozen and thawed 3 times in a dry ice/100% 
ethanol bath (approximately 20 minutes for each freeze and thaw cycle), 
then centrifuged at 4000rpm for 15 minutes. The supernatant was 
collected and the pellet discarded. Benzonase (Sigma) was added to the 
supernatant at 50units/mL and incubated at 37oC for 30 minutes. The 
mixture was centrifuged at 4000rpm for 10 minutes and the supernatant 
collected. Ice cold saturated (NH4)2SO4 was added to the supernatant at 
1/3 of the original volume and incubated on ice for 10 minutes. After 
centrifugation at 4000rpm for 15 minutes, the supernatant was collected 
and this time 2/3 of original volume ice cold saturated (NH2)2SO4 was 
added to the supernatant and incubated on ice for 20 minutes. Following 
centrifugation at 12,000g for 15 minutes the supernatant was discarded. 
The pellet was then resuspended in at total of 60mL of 1.37g/mL CsCl 
solution and transferred into 6X10mL SW41 Centrifugation tubes 
(Beckman, UltraClear, 14x89mm). One mL of 1.5g/mL CsCl was added to 
the bottom of each tube using a Pasteur pipette as a cushion. The tubes 
were balanced and then ultra-centrifuged in a SW41 rotor (Sorvall RC 6+) 
at 16oC for 40 hours at 36000rpm. After 40 hours the tubes were taken 
out of the rotor; 2mL was removed from the top of each tube. Using a 21 
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gauge needle the bottom of the tubes was pierced and solution collected 
in 1mL fractions into 14mL polypropylene round-bottom tubes. The 
fractions were analysed by qPCR to determine which fractions had the 
highest concentration of virus. The fractions with the highest yield (usually 
2-3 fractions) were pooled together and dialysed twice with PBS (with 
calcium and magnesium) using a Slide-A-Lyzer Dialysis Cassette (10,000 
MWCO, 3mL - 9mL Pierce Cat 66810). The second dialysis was kept on 
overnight in the cold room (4oC) while being stirred slowly. Next morning 
the dialysis fluid was replaced with fresh PBS, this time with 5% Glycerol 
added and dialysed for an additional 4 hours. The virus was then 
concentrated with Vivaspin 20 (100,000 MWCO) at 3000g at 4oC to get a 
total of 1mL final concentration. This was then divided equally into 10 
tubes each containing 100µL of concentrated virus. Two µL was frozen 
separately for PCR the next morning following a single freeze and thaw 
as would be the case with virus used for animal experiments. The sample 
left for qPCR was then thawed on ice and diluted into 1:103, 1:104, 1:105 
and 1:106 and was used to ascertain the amount of viral vector by qPCR. 
The yield was usually 1.0 – 1.5x1013/mL. 
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Table 2.6 Reagents for Vector Purification and Concentration 
Reagent Description 
Saturated 
ammonium sulphate 
solution 
530g of (NH4)2SO4 dissolved in 1L of water and 
pH adjusted to 7.0 while warming to help it 
dissolve. Solution was filter sterilized using a 
0.45mcm cellulose filter (Nalgene) pre-wet with a 
few drops of water. Stored at 4oC. 
Cesium chloride 
solution 1.5g/mL in 
PBS 
33.75g of CsCl was dissolved in PBS (with 
Calcium and Magnesium) adjusted to a final 
volume of 50mL. 1mL of the solution was 
weighed to check the density of the solution to 
get 1.5g/mL -> if it weighed less, then more CsCl 
was added to the solution. Solution was then 
filter sterilized through a 0.2µm filter pre-wet with 
a few drops of water. Then stored at room 
temperature 
Cesium Chloride 
solution 1.37g/mL in 
PBS 
50g of CsCl was dissolved in PBS (with Calcium 
and Magnesium) adjusted to a final volume of 
100mL. 1mL of the solution was weighed to 
check the density of the solution to get 1.5g/mL -
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> if it weighed less, then more CsCl was added 
to the solution. Solution was then filter sterilized 
through a 0.2µm filter pre-wet with a few drops of 
water. Then stored at room temperature 
Dialysis Solution 4L 
made 
PBS (with Calcium and Magnesium) 
CaCl2 anhydrous   0.1g/L 
MgCl2.6H2O      0.1g/L 
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2.3.4 Assigning Titre to Vectors 
Recombinant AAV2/9 titre was assigned by qPCR as described by Huang 
et al.[137] 
 
2.3.4.3 Real Time Quantitative PCR of Genomic DNA 
Sequences for the rAAV forward primer AAV1277F (5’-
CCGTTGTCAGGCAACGTG), reverse primer AAV1361R 
(AGCTGACAGGTGGTGGCAAT), and probe (5’ – 
[6FAM]TGCTGACGCAACCCCCACTGGT[TAM]) were used as 
described by Huang el al. and manufactured by Sigma Aldrich [137, 140].  
A master mix was made up with 1µL of probe, 0.8µL of each forward and 
reverse primers, 4.9µL of DNASEfree RNA (Sigmal Aldrich) and a master 
mix 12.5µL (Bioline), and 5µL of DNA per PCR reaction. As a negative 
template control, 5µL of H20 was used.  
 
All reactions were carried out in triplicate and ampliﬁcations were 
performed with 1 cycle of 95°C for 10 minute, 35 cycles of 95°C for 15 
seconds, and 60°C for 2 minutes using a Rotor-Gene 6000 PCR cycler 
(Corbett) or Rotor-Gene 3000 PCR cycler (Corbett). Concurrent standard 
curves were generated using 7 serial 10 fold dilutions from 
87 
 
108molecules/µL of the plasmid AAV-CBA-WPRE digested iECOR1. The 
number of vector DNA molecules in each sample reaction was calculated 
by comparing threshold cycle values of samples to the standard curve. To 
determine the ﬁnal viral vector titre, the number of vector DNA molecules 
of each sample reaction was corrected for dilution and then averaged.  
 
2.4 Immunohistochemistry – Staining for Connexins 
2.4.1 Antibodies for Immunohistochemistry 
Primary and secondary antibodies used during experiments are listed in 
Table 2.7. Antibodies that required storage at -20°C were divided into 
10µL aliquots using microcentrifuge tubes to minimise freeze-thaw cycles. 
 
Antibody Validation 
Specificity of antibodies to Cx43, Cx45 and GFP were validated using 
non-transduced HEK293 cells that are known to be devoid of connexins 
and GFP. Specific antibody reactivity was established in cells transfected 
plasmids expressing each of these transgenes. 
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Table 2.7: Immunohistochemistry Antibodies 
Primary Ab Specificity Host Species Source Dilution 
Connexin45 Mouse, 
monoclonal 
Millipore 1 in 200 
Connexin43 Rabbit,  
monoclonal 
Millipore 1 in 800 
Connexin43 Mouse,  
Monoclonal 
Millipore 1 in 250 
Connexin43 Rabbit, 
Polyclonal 
Chemicon 1 in 250 
Connexin45 Rabbit  
Polyclonal 
Gift from Dr 
M. Koval, 
Department 
of Medicine, 
Washington 
University 
School of 
Medicine, St. 
Louis, 
Missouri 
USA 
1 in 200 
Secondary 
Ab Specificity 
Fluorophore    
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Mouse Fc Alexa Fluor 488 Goat, F(ab’)2 
fragment 
Invitrogen 1 in 1000 
Rabbit Fc Alexa Fluor 594 Goat, F(ab’)2 
fragment 
Invitrogen 1 in 2000 
Mouse Fc Alexa Fluor 594 Goat, F(ab’)2 
fragment 
Invitrogen 1 in 2000 
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2.4.2 Ventricular Tissue Sectioning 
All Cryo-sectioning was performed with a Microm HM 505E microtome 
cryostat. The temperature of the cooling chamber was set at -20°C prior 
to the commencement of tissue handling and cutting. Frozen ventricular 
tissue embedded in OCT compound were mounted on a cryostat chuck 
pre-cooled with dry ice, and placed on the cryostat arm. A microtome knife 
was used to initially trim the specimen, and then cut 5µm-7µm sections of 
ventricle that were transferred to glass slides (Superfrost Ultra Plus; 
Thermo Scientific) and kept on in the chamber until transfer to -20oC 
freezer until required for use.  
 
2.4.3 Fixation, Permeabilisation and Immunostaining 
Ventricular tissue sections and cell cultures were fixed, permeabilised and 
immunostained using the same method. Samples were fixed with 4% 
(w/v) paraformaldehyde for 15 minutes at room temperature. 
Paraformaldehyde was freshly prepared by dissolving 3.2g in 80mL of 
PBS containing calcium and magnesium at 56oC. The pH was adjusted to 
7.4 with 5M NaOH. Slides were then washed 3 times with PBS for 5 
minutes each time. As the primary antibody epitopes are intracellular 
antigens, samples were subject to permeabilisation with 0.1% (v/v) Triton 
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X-100 (Sigma-Aldrich) in PBS for 15 minutes. This was followed by 3 
gentle washes with 0.05% (v/v) Tween 20 (Sigma-Aldrich) in PBS (PBST) 
for 5 minutes each on an orbital shaker. Following the wash and 
permeabilisation non-specific sites were blocked with a blocking solution 
from Dako (Protein Block, serum-Free) for 1 hour. The blocking solution 
was then removed and samples were then incubated with primary 
antibody diluted in blocking solution overnight at 4°C.  
 
The following morning, samples were washed 3 times with PBST for 5 
minutes each on an orbital shaker. Secondary antibody, diluted with 0.1% 
(v/v) cold fish skin gelatine in PBST, was added to samples for 1 hour at 
room temperature in the dark. This was followed by 3 gentle washes with 
PBST for 5 minutes each on an orbital shaker in the dark. Samples were 
then dried for half an hour before being cover slipped (Deckgläser; 
Menzel-Gläser) mounted with Prolong Gold anti-fade reagent with DAPI 
(Life Technologies). This was then allowed to set in the dark, overnight 
and 4°C. 
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2.4.4 Co-immunostaining 
Co-immunostaining was carried out using a protocol similar to the above 
method with some modification. Ventricular tissue sections and cell 
cultures were fixed, permeabilised and immunostained using the same 
method. Samples were fixed with 4% (w/v) Paraformaldehyde for 15 
minutes at room temperature. Paraformaldehyde was freshly prepared by 
dissolving 3.2g in 80mL of PBS containing calcium and magnesium at 
56oC. The pH was adjusted to 7.4 with 5M NaOH. Slides were washed 3 
times with PBS for 5 minutes each time. Samples were subject to 
permeabilisation with 0.1% (v/v) Triton X-100 (Sigma-Aldrich) in PBS for 
15 minutes. This was followed by 3 gentle washes with 0.05% (v/v) Tween 
20 (Sigma-Aldrich) in PBS (PBST) for 5 minutes each on an orbital shaker. 
Following the wash and permeabilisation non-specific sites were blocked 
with a blocking solution from Dako (Protein Block, serum-Free) for 1 hour. 
The blocking solution was then removed and samples were then 
incubated with primary antibody diluted in blocking solution overnight at 
4°C. Given this was for co-immunostaining, two primary antibodies were 
mixed and used (both had different host species to allow different 
secondaries to be used). 
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The following morning, samples were washed 3 times with PBST for 5 
minutes each on an orbital shaker. Secondary antibody, diluted with 0.1% 
(v/v) cold fish skin gelatine in PBST, was added to samples for 1 hour at 
room temperature in the dark. Again given this was for co-localisation 
studies, 2 different secondaries corresponding to the primary antibody 
species were mixed together as per the above Table 2.7 (2 different 
fluorescent markers were used for detection). This was followed by 3 
gentle washes with PBST for 5 minutes each on an orbital shaker in the 
dark. Samples were then dried for half an hour before being cover slipped 
(Deckgläser; Menzel-Gläser) mounted with Prolong Gold anti-fade 
reagent with DAPI (Life Technologies). This was then allowed to set in the 
dark, overnight and 4°C. 
 
2.4.5 Fluorescent Image Acquisition and Processing 
Imaging was performed under oil immersion using either an inverted wide 
field fluorescent microscope (Leica DMIL and Nuance FX system Camera 
(420-720nm, 20-40nm bandwidth, Cooled Sony ICX285) with a 40X – 
100X objective (Leica 40X/0.50 Ph2 /1.1 506273 HI plan 1) or a confocal 
laser scanning microscope (Olympus FV 1000) using a 40X – 60X 
objective (Olympus 40X/1.30/0.20 (WD) Oil UPLFLN). Digital images from 
the Leica microscope were acquired into PC based software (Nuance 
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imaging software version 3.1) using a digital camera (Nuance FX) fitted to 
the microscope. Digital images from the confocal microscope were directly 
acquired into PC based software (Olympus FV10-ASW Version 1.7). 
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Table 2.8: Filter Sets for Leica DMIL Microscope 
Filter Sets Exciter (nm) Emitter (nm) 
DAPI 315 – 420 385 - 515 
GFP 430 – 510 475 - 575 
DsRed 480 – 570 565 ALP 
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Table 2.9: Excitation Wavelengths and Emission Filter Sets for the 
Olympus Confocal Microscope 
Filter Sets Excitation (nm) Emission (nm) 
WU2 BP 330 -  385 BA 420 
NIBA3 BP 470 - 495 BA 510 - 550 
WIG3 BP 530 - 550 BA 575 IF 
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2.5 Histology – Inflammation and Fibrosis 
2.5.1 Inflammation - Haematoxylin and Eosin (H&E) 
Staining 
Ventricular tissue sections were produced as described in section 2.4.2. 
The technique of H&E staining as described by LG Luna was performed 
with a Shandon Linear Stainer provided by Westmead Millennium Institute 
[141].  
 
Ventricular sections were initially immersed in Haematoxylin for a total of 
4 minutes, Scott’s Bluing solution for 1 minute, and 0.1% Eosin for 1 
minute. A 1 minute wash with tap room temperature water was performed 
following each step. Samples were then dehydrated with absolute ethanol 
for 30 seconds and placed in xylene clearing solution Following, the slides 
were coverslip mounted with a hydrophobic mounting agent, Ultramount 
No4 with colourfast (Fronine). Slides were allowed to set overnight.  
 
Following image acquisition as described in Section 2.5.3, images were 
assessed manually for inflammation by two independent observers. The 
technique described by Igarashi et al was used to grade inflammation on 
a scale of 1 to 5 Table 2.10 [142].  
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2.5.2 Fibrosis - Pico-Sirius Red staining 
Ventricular tissue sections produced as described in Section 2.4.2. 
Sections were fixed with 4% paraformaldehyde for 15 minutes and then 
washed 3 X in PBS for 5 minutes each. Following, sections were placed 
in Pico-Sirius red solution (0.1% Direct Red 80 (Sigma), 0.1% Fast Green 
FCF (Sigma), Saturated Picric Acid (Sigma)) for 1 hour in the dark on an 
orbital shaker. Sections were then washed twice carefully with MQH20 
followed by 3 washes in 100% ethanol for 1 minute each to assist in 
dehydration of the sections. They were then air dried for 1 hour and then 
immersed in xylene clearing solution for 5 seconds before cover slip 
mounting with a hydrophobic mounting agent, Ultramount No4 with 
colourfast (Fronine). Slides were left overnight to set. Sections were then 
analysed with custom made software designed (By Tony Barry from the 
Centre of Heart Research, Sydney, Australia) to objectively calculate the 
relative areas of red (collagen) and green stains (myocytes). 
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Table 2.10 Inflammation Scores 
    
Scores Inflammation 
1 No inflammation 
2 Occasional inflammation present 
3 Diffuse affecting <50% of the image 
4 Diffusely present and more than 50% of image 
5 Near complete presence of inflammation present 
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2.5.3 Image Acquisition and Processing 
An upright microscope (Leica DMBL) was used to visualise the samples 
then a 40X objective (Leica 40X/0.65 N plan /0.17/D 506099 Ph2) was 
used for acquisition of images from 4 random areas of each section under 
oil immersion. Sections from the apex, mid and base of each heart 
analysed were acquired to get an average amount of fibrosis. The PC 
based software, Spot Advanced version 4.1, was used to directly acquire 
digital images from a Spot RT KE camera fitted to the microscope.  
 
2.6 Immunoblotting  
2.6.1 Antibodies for Immunoblotting 
Primary antibodies and secondary used during experiments are listed in 
table 2.7. Secondary antibodies used during experiments are listed in 
table 2.11. Antibodies that required storage at -20°C were divided into 10-
15µL aliquots using microcentrifuge tubes to minimise freeze-thaw cycles. 
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Table 2.11: Secondary antibodies for immunoblotting 
Secondary Ab 
Specificity 
Label Host 
Species 
Source Dilution 
Mouse Fc HRP Goat Sigma 1 in 10000 
Rabbit Fc HRP Goat Sigma 1 in 10000 
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2.6.2 Protein Extraction 
Ventricular tissue 
Frozen collected ventricular tissue was placed into an ice cold round 
bottom microcentrifuge tube. Tissue used for protein extraction was flash 
frozen in nitrogen when collected. Tissue was divided into 50mg sections 
using a scalpel on metal plate over a surface of dry ice then placed in a 
new microcentrifuge tube and kept on dry ice. An ice cold steel ball 
(Qiagen) was inserted into the tube along with 500µL of ice cold lysis 
solution (RIPA buffer (Sigma-Aldrich), 1% (v/v) phosphatase inhibitor 
cocktail 2 (Sigma-Aldrich), and 4% (v/v) protease inhibitor cocktail (Sigma-
Aldrich). The tissue was subjected to disruption with bead milling for 3 
minutes using a TissueLyser (Qiagen) set to 30Hz. This was done twice 
to ensure the tissue was well homogenised. Suspensions were then 
centrifuged at 10,000rpm for 5 minutes at 4°C. The supernatant was 
decanted into a second microcentrifuge tube and kept on ice ready for 
protein estimation. 
 
2.6.3 Protein Estimation 
Protein estimation was performed using the Bradford method [143]. 
Standards and samples were assayed in triplicates. Bovine serum 
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albumin (1mg/mL) was added, in 1µL increments from 1µL to 8µL, to 
different wells of a 96 well plate, and used to generate a standard curve. 
Extracted protein samples were diluted 5 fold with MQH20 and 1µL added 
to wells. Protein assay dye reagent concentrate (Bio-Rad) was diluted 4 
fold and 200µL was added to each well. The absorbance used to measure 
was 595nm using a Victor2 Multilabel Counter (PerkinElmer life Sciences). 
The amount of protein was calculated by comparing its absorbance to the 
standard curve. This was then corrected for the dilution and averaged to 
determine the original protein concentration of an individual lysis 
supernatant. 
 
2.6.4 Immunoblotting 
Precast polyacrylamide 4-12% gradient Bis-Tris gels (NuPAGE; 
Invitrogen) were used. These were placed in a gel electrophoresis 
chamber (XCell SureLock Min-Cell; Invitrogen) containing running buffer 
(MOPS, NuPAGE; Invitrogen). For each sample, 20mg of protein was 
diluted in a microcentrifuge tube to a final volume of 20µL with 2µL of 
reducing agent (NuPAGE; Invitrogen), 5µL of LDS sample buffer 
(NuPAGE; Invitrogen), and MQH20. Samples were then subjected to 95°C 
heat for 10 minutes to denature proteins and then loaded into separate 
gel wells. A pre-stained protein ladder (PageRuler Plus; Thermo 
104 
 
Scientific) was used to assess protein separation and approximate protein 
sizes and was placed on wells adjacent to the study samples. A 200V 
constant current gradient was applied to the gel for 1 hour. Protein was 
transferred from the gels to a membrane using the IBLOT gel transfer 
system (Invitrogen), following electrophoretic separation. Gels were 
placed in a gel transfer stack (Invitrogen) and the IBLOT’s default 7 minute 
transfer protocol was used. Membranes were then blocked with a solution 
of 5% skim milk in TBST (0.05% Tween 20, Tris-Buffered Saline) for 2 
hours and subsequently incubated with primary antibody diluted in 
blocking solution. They were placed on an orbital shaker for gentle 
shaking overnight at 4°C.  
 
The following morning, 3 washes with TBST were carried out for 5 minutes 
each, and incubated with secondary antibody diluted in blocking solution 
for 1 hour. Again this was placed on an orbital shaker for gentle shaking. 
The membranes once again were washed with TBST 3 times for 5 
minutes each. SuperSignal Pico Chemiluminescent substrate (Thermo 
Fisher Scientific) blotting detection reagents was then added on to the 
membrane for 5 minutes, which had been mixed in a 1:1 ratio according 
to the manufacturer’s instructions. To enable detection of weak signals, 
SuperSignal west Femto (Thermo Scientific) was mixed with a ratio of 
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1:10 with the Pico substrate, and then added to the membrane for 5 
minutes. Membranes were transferred to an autoradiography cassette 
(Hypercassette; Amersham Biosciences). In a dark room, an X-ray film 
(Hyperfilm ECL; Amersham) was exposed to the Nitrocellulose 
membranes in the autoradiography cassette. The time required of 
exposure was dependant on the demands of the experiment. Films were 
then processed with an AGFA film processor according to the 
manufacturer’s protocol. 
 
2.7 Quantification of Tissue mRNA  
2.7.1 Messenger RNA Extraction and Purification  
Extraction and purification of mRNA was performed using an RNAeasy 
Mini Kit (Qiagen) according to the manufacturer’s protocol. Ventricular 
tissue was firstly cut into 50mg pieces and then transferred frozen to a 
round bottom microcentrifuge tube placed in dry ice. Following, 350µL of 
buffer RTL (Qiagen) along with a stainless steel bead (Qiagen), were 
placed within the microcentrifuge tube. The tissue was then subjected to 
homogenisation with bead milling for 3 minutes using a TissueLyser 
(Qiagen) set to 30Hz. This was then repeated again. 
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The lysate was centrifuged at 20,000 x g for 3 minutes at 21°C. All 
subsequent centrifugation steps were performed at 8,000 x g at 21°C as 
per the manufacturer’s instructions. The supernatant was carefully 
aspirated and placed in a fresh microcentrifuge tube. A 350µL volume of 
70% ethanol was added to the supernatant and mixed with pipetting. The 
resulting solution was transferred to an RNAeasy spin column in 2 
successive 350µL aliquots which were centrifuged for 15 seconds each. 
The column was washed using 700µL of buffer RW1 with centrifugation 
for 15 seconds. The column was then washed using 500µL of buffer RPE, 
with centrifugation for 15 seconds. This step was repeated but this time 
centrifugation was for 2 minutes for the second wash. After placing a new 
collection tube, the RNAeasy spin column was then centrifuged for 1 
minute to eliminate any possible carryover of buffer RPE. A new collection 
tube was again placed and 30µL volume of RNase-free water was added 
to the column and used to elute the RNA with centrifugation for 1 minute. 
RNA samples were placed on ice. Nanodrop was used to assess RNA 
concentration and purity as described in Section 2.1.4.6, however with the 
assumption that 40µg of mRNA had an absorbance of 1.0 at 260nm and 
pure mRNA had a 260/280 absorbance ratio of 1.8. 
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2.7.2 Complementary DNA Synthesis from mRNA 
Messenger RNA was converted to cDNA with reverse transcription using 
the Superscript First Strand Synthesis system (Invitrogen) according to 
the manufacturer’s instructions. 
 
A volume of mRNA containing 1µg of mRNA was diluted to 15µL using 
0.5µL of 10mM dNTP mix, 0.5µL of oligo(dT) primer, and DEPC-treated 
water. The mixture was incubated at 70°C for 5 minutes and then placed 
on ice for 1 minute. A reaction mix, consisting of 5µL of 5X RT buffer, 2µL 
of DEPC-treated water, 2µL of 0.1M DTT, 1µL of RNaseOUT, and 1µL of 
Superscript was made up. The reaction mix was added to the RNA/primer 
mixture and the resultant mixture was incubated at 37°C for 5 minutes, 
then 45°C for 60 minutes. The sample was then placed on ice ready and 
cDNA concentration assessed as described in section 2.1.5.  
 
2.7.3 Real Time Quantitative PCR for cDNA 
Real time PCR for cDNA was carried out using Corbett Rotorgene 3000 
with Platinum SYBER Green qPCR Master Mix (Invitrogen). SYBER 
Green is a cyanine dye that fluoresces when bound to double-standard 
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DNA and thereby allows the accumulation of a PCR product to be 
monitored over time.  
 
Oligonucleotides were designed and bought from GeneWorks.  The 
forward and reverse primer sequences for all genes used are in Table 
2.12. The components of PlatinumR SYBER Green qPCR SuperMix-UDG 
include PlatinumR Taq DNA Polymerase and SYBER Green I dye. The 
PlatinumR SYBER Green qPCR Super-Mix-UDG combines the automatic 
“hot-start” technology of PlatinumR Taq DNA Polymerase with integrated 
uracil-DNA glycosylase (UDG) carryover prevention technology and 
SYBER Green I fluorescent dye to deliver excellent sensitivity in the 
quantitation of target sequences. Standards were made by pooling 
3µL/sample into a micro-centrifuge Eppendorf tube to get a total of 33µL 
diluted to a total of 110µL of MQH2O. The standards S1-S7 were made by 
diluting 1:5 up to 7 times. The cDNA to be measured were diluted by 
diluting this further 1:5 up to 7 times. The cDNA to be measured were also 
diluted 1:5 with MQH2O. 
 
Average melting temperature for all primers was 60oC. A melt curve 
analysis was performed at the end of each run to confirm that specific 
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products were generated and that the fluorescence was not as a result of 
primer-dimer formation. The Rotor Gene 3000 qPCR software version 
4.0.1 (Corbett research) was used to analyse the results. Average of the 
cycle threshold values for all genes were normalised to the housekeeping 
gene (18s). The Delta-Delta cycle threshold data analysis method was 
used to calculate the fold change for each gene. 
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Table 2.12 Forward and Reverse Primer Sequences 
Oligo name Sequence (5’-3’) 
Rat ANP  
 
Forward CAA CAC AGA TCT GAT GGA TTT CA 
Reverse CCT CAT CTT CTA CCG GCA TC 
Rat βMHC  
 
Forward ATC CCT GGA TCA GGA CAA GA 
Reverse AGC TTC AGG TCA CCC TCC A 
Rat Connexin43 Forward AGC CTG AAC TCT CAT TTT TCC TT 
Reverse CCA TGT CTG GGC ACC TCT 
Rat Connexin45 Forward GGG AAA GCA ACA AAC AAA GT 
Reverse AAA GGC ATC ATA GCA GAC ATT 
Eucaryotic 18s rRNA 
probe 
Catalogue No. 4319413 E (Invitrogen) 
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Table 2.13 Real time PCR reaction contents 
Real-time PCR cocktail Volume per reaction (µL) 
PlatinumR SYBER Green Master 
Mix 
5 
Forward primer (10µM) 0.4 
Reverse primer (10µM) 0.4 
dH2O 0.2 
Diluted cDNA template 4 
Total volume 10 
 
 
 
 
 
 
 
 
112 
 
2.8 Duo-link 
The Duo-link In-Situ Kit (O-link – sigma Aldrich) was used with the primary 
antibodies previously described (Table 2.7) to show protein to protein 
interaction (Duo-Link Starter Kit Mouse/Rabbit). The method was 
performed according to the manufacturer’s instructions and as previously 
described by Soderberg et al. [144]. Ventricular tissue was cut and the 
sections were fixed, permeabilised and stained with primary antibody 
overnight at 4oC as previously described in Section 2.4.3. All washes 
were carried out on an orbital shaker with gentle agitation. The following 
day, the slides were washed twice with 1x Wash Buffer A for 5 minutes 
each. In the meantime, the two PLA probes were diluted 1:5 in Antibody 
Diluent (Anti-mouse and anti-rabbit). The PLA probe solution was applied 
to the slides and incubated in a pre-heated humidity chamber for 1 hour 
at 37oC. Slides were then again washed twice with 1x wash Buffer A. For 
the ligation step, Ligation stock was diluted 1:5 with high purity water, 
Ligase added to the ligation solution at 1:40 dilution and then placed onto 
slides for incubation in a pre-heated humidity chamber for 30 minutes at 
37oC. Slides were then washed twice with 1x Wash Buffer for 2 minutes 
each. For the amplification step the amplification stock was diluted 1:5 in 
high purity water to make the amplification solution.  Polymerase was 
then added to the solution at 1:80 dilution and applied to the slides and 
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incubated in a pre-heated humidity chamber for 100 minutes at 37oC. 
Slides were transferred to a dark room and samples were washed twice 
with 1x Wash Buffer B for 10 minutes each followed by a single wash of 
0.01x Wash Buffer B for 1 minute. Slides were dried over half an hour 
and cover-slipped with a minimal volume of Duolink In Situ Mounting 
Medium with DAPI. Slides were stored at -20oC overnight before 
microscopy was performed. 
 
2.9 Co-immunoprecipitation  
This experiment was performed with the assistance of Dr Renuka Rao. 
Ventricular heart tissue from Cx45 overexpressed rat was flash frozen in 
liquid Nitrogen and stored at -80oC. The tissue was the pulverized, 
homogenized and lysed in a buffer solution containing 1.5% NP-40, 1% 
Triton X-100, 0.1% SDS, 0.1% BSA and protease inhibitors. For the pull-
down, either monoclonal anti-Cx43 or monoclonal anti-Cx45 was 
incubated with protein G sepharose for 1 hour on a shaker at 4oC. Beads 
were washed with lysis buffer 3 X at 4oC. The lysate containing an 
equivalent of 1mg protein each was then incubated with the antibody 
bound beads in the presence of the Protease inhibitor cocktail (Sigma 
cat. #P8340) for 1 hour at 4oC to immunoprecipitate Cx43 and Cx45 
associated proteins, respectively. Mouse IgG1 (Sigma cat. # 1538) was 
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used as a negative control. The immunoprecipitates were spun down in 
a microcentrifuge at 16,000 x g for 15 min at 4oC, washed 3 x in lysis 
buffer with BSA, and suspended in sample loading buffer with β-
mercaptoethanol, heat inactivated at 95oC for 10 minutes and subjected 
to immunoblot analysis as described above. Rabbit Polyclonal anti-Cx45 
(kind gift from Dr M. Koval) and Rabbit Polyclonal anti-Cx43 (Chemicon) 
were used for immunoblotting. 
 
2.10 In Vivo Studies 
All animal experiments were approved by the Western Sydney Area 
Health Service Animals Ethics Committee. Female Sprague Dawley rats 
weighing approximately 200gm were used for all experiments and were 
sourced from the Australian Resources Centre (ARC, Canning Vale, 
West Australia). Rats were housed under conditions of constant ambient 
temperature (22oC), humidity and a 12hour light/dark cycle. Rats were 
fed a commercial pellet (Allied Foods, Sydney, Australia) and had access 
to food and water. They were housed in cages (550 x 370 x 170mm), with 
open wire tops and wood shavings for bedding. There was a maximum 
of three rats per cage. When protocol was complete, all animals were 
sacrificed by using CO2 chamber. 
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2.10.1 Anaesthesia, Intubation, Ventilation, and Positioning 
Anaesthesia was initiated in a custom made Perspex chamber with a mix 
of oxygen and 5% isoflurane (Aerrane; Baxter Healthcare) supplied via 
flexible PVC tubing from a small animal anaesthetic machine (The Stinger; 
Advanced Anaesthesia Specialists). The flow rate into the box was set at 
4mL tidal volumes. Once unconscious, rats were positioned, dorsal 
surface downwards, on a custom made intubation board that facilitated 
neck extension. Under direct laryngoscopy the tongue was pulled out with 
straight serrated forceps (Fine Science Tools) and passing a rigid 
hippocampal tool (Fine Science Tools) into the pharynx to support the 
anterior neck tissues. Once the vocal cords were visualised, the tubing of 
an 18 gauge intravenous cannula (Becton, Dickinson and Company) was 
passed under direct vision using a Seldinger technique. Following, rats 
were transferred to a bread board (Ikea) with their dorsal surface 
downwards. The cannula was attached with flexible PVC tubing to a small 
animal ventilator (Harvard Apparatus) set to deliver 2.5 mL tidal volumes 
at a rate of 70 breaths per minute. The ventilator received a mix of oxygen 
and 2% isoflurane from the small animal anaesthetic machine. Prior to 
carrying out EP studies or thoracic surgery; the upper and lower limbs 
were held fixed, extended at the shoulders and hips, by rubber bands 
looped around hooks screwed into the bread board. For tail vein injections 
the rat was placed on the ventral surface on the bread board or turned to 
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the ventral surface following the thoracic surgery to facilitate the 
visualisation of the tail vein easily.  
 
If however, only tail vein injections were to be carried out the rat would not 
need to be intubated but instead following induction of anaesthesia in the 
Perspex chamber the rat was transferred ventral surface onto the bread 
board and the nose was placed in a nose cone. This was attached with 
flexible PVC tubing to the small animal anaesthetic machine and a mix of 
4% isofluorane and oxygen was delivered. 
 
2.10.2 Surface Electrocardiography 
Four Unipolar needle electrodes (AD Instruments) were placed 
subcutaneously at the infra-clavicular and iliac fossa regions bilaterally. 
One ground lead was also placed subcutaneously in the abdominal 
region. Two lead electrocardiograms were generated combining 
potentials from left / right lower and right / left upper electrodes pairs. Bio-
potentials, sampled at 2 kHz, were amplified with an Octal Bio Amp (AD 
Instruments) and digitised using a Powerlab 16/30 (AD Instruments) data 
acquisition system. Using the Windows based version of Labchart Pro 7 
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(AD Instruments) running on a Dell laptop, data was recorded via a USB. 
No software filtering was used. All data were analysed offline in detail. 
 
2.10.3 Trans-oesophageal Cardiac Stimulation 
A 5 French octapolar catheter (Biosense Webster) connected to the Octal 
Bio Amp was passed via the oral cavity into the oesophagus and 
positioned at the point where recordings from the middle 2 electrodes had 
the largest ventricular electrograms amplitudes. Recordings were made 
from the middle 2 electrodes only and stimulation was delivered through 
the distal 2 electrodes only. The ventricle was captured using a constant 
60 volt stimulus of 1 millisecond duration via an isolated pulse stimulator 
(Model 2100; A-M Systems). To drive the stimulator via its trigger input, 
custom designed software installed on a second windows based laptop 
(Hewlitt-Packard) was used. 
 
The EP protocol involved an attempt to induce ventricular tachycardia or 
ventricular Fibrillation through programmed stimulation. The latter was 
achieved by pacing with a drive train of 8 stimuli at a coupling interval of 
180 milliseconds followed by extra-stimuli. The coupling interval between 
the drive train and the extra-stimulus started at 150 milliseconds and was 
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progressively reduced in 10 milliseconds step downs to ventricular 
refractoriness. A total of 4 extra-stimuli were applied, with shortening of 
the coupling interval for every extra stimuli. Further if no ventricular 
tachycardia was induced then burst ventricular pacing with a 90 
milliseconds cycle length for 30 seconds was carried out, after a 3 minute 
rest period a further burst of pacing at cycle length 60 milliseconds was 
also carried out to induce VT/VF. 
 
Ventricular tachyarrhythmia was defined as ventricular tachycardia when 
monomorphic/polymorphic wide complex tachycardia and lasted greater 
than 3 seconds and ventricular fibrillation was defined rapid irregular wide 
complex beats that last greater than 3 seconds.  
 
2.10.4 Tail Vein Injection of Vector 
Following anaesthesia, the rat was placed on the bread board with the 
ventral surface facing downwards.  A tourniquet was applied at the 
proximal end of the rat tail using a rubber band. The tail was warmed in 
water at 37oC for 30 seconds. This dilated the veins and made them easier 
to visualise and cannulate. A 25 gauge needle was used to cannulate the 
vein at its most distal end, once blood flow was demonstrated through the 
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syringe, the tourniquet is removed and the viral vector (1 x 1012 vector 
genomes diluted to 500 µL of 0.9% Saline) was injected slowly. Following 
vector injection a 500µL of 0.9% Saline was flushed through. The rat was 
then removed from the nose cone and left to recover in its box. 
 
2.10.5 Thoracic Surgery 
A total of 10µg of Buprenorphine hydrochloride (Temgesic; Schering-
Plough) and 1mg enrofloxacin (Baytril 50; Bayer Healthcare AG) were 
separately diluted in 1mL of PBS each and administered subcutaneously 
by injection. The hair of the anterior chest was moistened with 70% (v/v) 
ethanol (Fronine), shaved with electric clippers (Remington; Spectrum 
Brands), and removed. Skin disinfection was performed with 10% w/v 
Povidine-Iodine solution (Betadine; Sanofi-Aventis) or Cholhexidine 
applied for a minimum of 5 minutes prior to skin incision. Two hundred nL 
of Lignocaine 0.1% was administered subcutaneously prior to incision to 
allow it time to work prior to ligation of the coronary artery.    
 
A horizontal incision of the skin from the ventral midline to the left anterior 
axillary line was made at the level of the 4th intercostal space using a 
scalpel. To mobilise the surrounding skin, blunt dissection with straight 
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haemostats (Fine Science Tools) of the underlying superficial fascia for 
up to approximately 1cm on both sides of the incision was performed. The 
muscles of the left chest wall superficial to the ribs were also separated 
by blunt dissection with straight haemostats (Fine Science Tools). The 
thoracic cavity was punctured via the 4th intercostal space using curved 
haemostats (Fine Science Tools). The punctured intercostal muscles 
were blunt dissected with the same curved haemostats and a Castroviejo 
retractor (Roboz) was inserted to hold open the dissected intercostal 
space. The left atrium was visualized and just below it, a hole was made 
in the pericardial sac with curved forceps (Fine Science Tools). This was 
then carefully dissected off all the way to the distal ventricular apex. The 
LAD coronary artery was identified at the level of the left atrial appendage 
and a 6-0 75cm suture was placed around the artery approximately 1-
2mm below the appendage. The suture ends were passed through a 
polyethylene tube to form a “snare” like loop with the free ends. The snare 
loop was then pulled for 10 seconds to assess for area of cyanosis and 
then released with return to normal colour thereby demonstrating 
adequate occlusion of the LAD. When approximately 40-50% of the 
anterior visualised wall was seen to be cyanosed, the occlusion was then 
re-applied permanently. If adjustments were required, the suture was 
removed and the last step was repeated to get an equal amount of 
cyanosis for all rats. Following the LAD occlusion, the retractor was 
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removed and the rib space closed with a two stitches of 3.0 coated vicryl 
suture (Ethicon). The skin incision was then closed with a horizontal 
mattress technique using a 3.0 coated vicryl suture (Ethicon). The rat was 
then placed in the cage to recover. Drinking water for rats was 
supplemented with 0.01% enrofloxacin (Baytril 25; Bayer Healthcare AG). 
 
2.10.6 Telemetry Implantation 
Two weeks following transduction, a subset of animals were 
anaesthetised, intubated and ventilated as described above. Telemetric 
devices (ADI instruments MLE 1010) were implanted into 5 rats injected 
with rAAV.GFP and 5 rats injected with rAAV.Cx45 as previously 
described by Brockway et al [145]. A midline abdominal incision was made 
from the xiphisternum 3cm in size, the fascia was carefully dissected and 
the abdominal cavity exposed. The body of the telemetric device was 
inserted into the abdomen above the bladder of the rat and sutured to the 
abdominal musculature. One electrode was then sutured to the 
xiphisternum. The other electrode was then passed underneath the skin 
layer (with blunt dissection) and sutured to the second right intercostal 
space. The abdominal musculature and skin were then sutured and the 
rat recovered. Analgesia was achieved by administering buprenorphine 
(0.5mg/Kg SC) prior to the rat recovering from anaesthesia and at later 
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time intervals as needed. Rats were placed in cages with two battery 
chargers connected to the wireless receivers (ADI instruments TR101). 
Rats were regularly observed every 12 hours for the first 48 hours and if 
any sign of distress further buprenorphine was administered.  
 
Telemetry was recorded continuously for 2 weeks prior to the final study 
endpoint. 
 
2.10.7 Ventricular Tissue Extraction, Preparation, and 
Storage 
Adult rats were euthanized with CO2 in a custom made Perspex chamber 
box for 10 minutes and then weighed. Rat were then laid dorsal surface 
down and the chest wall cut open with scissors to the right of the midline. 
The heart was detached from the mediastinum just above the base and 
rinsed with PBS and weighed. The heart was dissected transversely 
leaving the atria behind. For histology and immunohistochemistry studies, 
the hearts were placed in a vinyl specimen mould (Cryomold; Sakura) 
filled with Tissue-Tek OCT compound (Sakura). The mould was then 
frozen with liquid nitrogen and transferred to a -80°C freezer for storage. 
For protein and mRNA studies, hearts were placed in microcentrifuge 
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tubes, frozen in liquid nitrogen and transferred to a -80°C freezer for 
storage.  
 
2.11 Data Analysis and Statistics 
NQuery Advisor (Statistical Solutions) was used to estimate the required 
sample sizes.  
 
Quantitative data were expressed as mean ± standard deviation (SD) (or 
standard error of the mean (SEM) which will noted in the text – otherwise 
it would SD). Continuous variables (such as QRS width, PR interval) were 
analysed using Student T tests or Mann-Whitney U test. Statistical 
analysis for 2x2 tables (such as in ventricular tachyarrhythmia inducibility) 
were performed using Fischer’s exact test (if samples in a cell were ≤ 5) 
or using two sample Pearson’s Chi-square (X2) test (2 x 2 table) on the 
SPSS (Version 17). Significance was set at P ≤ 0.05. Statistics were 
carried out with the assistance of Ms Karen Byth (Westmead hospital 
statistician). 
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CHAPTER 3 
 
THE EFFECTS OF CONNEXIN45 
OVEREXPRESSION ON CARDIAC 
PHYSIOLOGY 
 
 
 
 
3.1 Introduction 
 
Cardiovascular mortality is the leading cause of death in the industrialized 
world. Sudden cardiac death occurs most often after acute MI and 
ventricular tachyarrhythmias are responsible for the majority of cases. 
Implantable defibrillators and pharmacotherapy have been the mainstay 
treatment for such tachyarrhythmias but mortality remains high. Yamada, 
Rogers et al. and other authors have reported that intercellular electrical 
uncoupling mediated by decreased conductance of gap junctions is 
associated with ventricular tachyarrhythmias in the diseased heart [2, 4]. 
 
Gap junctions facilitate the inter-cellular flow of ions necessary for the 
propagation of electrical impulses within the myocardium. This in turn 
allows for coordinated mechanical activity throughout the heart. Gap 
junctions are formed by the union of two hemi-channels (connexins) each 
contributed by two adjacent cells. Each hemi-channel contains six 
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connexin proteins surrounding an aqueous pore and can be formed from 
a single connexin isotype (homomeric channels) or a mixture of isotypes 
(heteromeric channels) [21, 25-28]. The biophysical properties 
(conductance and permeability) of a gap junction are determined by the 
mix of connexin isotypes that constitute it.  
 
The connexin isotypes 43, 40 and 45 have been identified within the 
mammalian heart. Connexin43 is the most prevalent, being expressed 
throughout the heart [146], while the less abundant Cx40 is predominantly 
located within the atrium. Connexin45, the least prevalent and least 
studied, is mainly found in the ventricular conduction system and AV 
node.  
 
Peters et al. studied myocardial infarcts in a canine model and noted that 
myocardial gap junctions have a significant role to play in 
arrhythmogenesis, being one of the principal determinants of cardiac 
conduction velocity [23, 147, 148]. In particular, healed infarcts had 
smaller and fewer gap junctions in the fibrotic myocardium adjacent to 
infarcts, and was associated with a reduction in the proportion of side-to-
side vs. end-to-end intercellular connections. Immunohistochemistry 
studies revealed that the lateral part of the central common pathway 
consisted of myocytes with reduced intercalated disc content of Cx43. An 
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increase in lateralised membranous Cx43 expression in myocytes was 
noted but its functionality was not investigated [23]. With early infarction, 
on the other hand (before fibrotic healing); the Cx43 gap junctions in 
myocytes abutting the infarct showed disorganization similar to that 
described in healed human infarcts, suggesting that this disturbance is an 
early pathophysiological cellular response, and not simply due to later 
fibrotic distortion. It is understood that this disorganisation is what 
facilitates re-entry circuits and the propensity to ventricular arrhythmia.  
 
In the setting of heart failure, a condition associated with SCD, an 
increase in ventricular Cx45 expression and reduction in Cx43 
expression has been identified [77, 87, 149]. The present study was 
performed to explore the role of Cx45 in cardiac physiology and 
arrhythmogenesis. Using acute somatic gene transfer, Cx45 was 
overexpressed in normal adult rat hearts. We found that widespread 
expression of Cx45 was associated with conduction slowing and an 
increased propensity for inducible ventricular tachyarrhythmia. 
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3.2 Materials and Methods 
 
Study Protocol (Fig 3.1) 
Two hundred gram adult Sprague Dawley female rats were used in this 
study protocol. Three study groups were used; all rats received 1x1012 
vector genomes (diluted in 0.9% Saline to a quantity of 500 μL) of either 
rAAV.GFP (n=15), rAAV.Cx43 (n=15) or rAAV.Cx45 (n=22) injected via 
the tail vein. Electrophysiology studies were performed immediately prior 
to vector injection and 28 days later.  
 
This study was approved by the Animal Research Ethics Committee of 
Westmead Hospital. The study protocol conformed to the guidelines set 
for animal research by the National Health and Medical Research Council, 
Australia 
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Figure 3.1 Study Protocol Diagram 
A total of 3 groups were studied. The rAAV.GFP acted as the control 
group. The other 2 groups were rAAV.Cx45 and rAAV.Cx43. All rats 
underwent baseline EPS followed by transduction. EPS was then 
repeated at day 28 followed by removal of ventricular tissue. The 
ventricles were then probed for Cx45, Cx43 protein and mRNA levels, 
and inflammation and fibrosis with histological analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WB: Western Blot, IF: Immunofluorescence, EPS: Electrophysiology studies 
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3.2.1 Recombinant Adeno-associated Viral Vector 
Production 
Vector stocks encoding GFP, Cx43, and Cx45 were produced using the 
calcium precipitation method as described in Section 2.3. In summary, 
the cDNA for rat Cx45 and Cx43 was PCR amplified from a rat cardiac 
cDNA library, subjected to automated sequencing and sub-cloned into 
the recombinant adeno-associated virus vector 2 (rAAV2) backbone. As 
a control vector for the overexpression studies, the cDNA encoding GFP 
was also sub-cloned into the same vector backbone. Recombinant AAV 
vectors pseudo typed with capsid serotype 9 were produced using a 
helper-virus free system by calcium-phosphate co-precipitation 
transfection of the three vector plasmids into HEK293 cells as per Xiao et 
al [150-152]. Following plating of 120 petri dishes (10cm diameter) with 
HEK293 cells, 3 plasmids (vector plasmid, helper plasmid, and 
adenovirus helper plasmid) were transfected into HEK293 cells using the 
calcium phosphate precipitation method. Vector-containing cells was 
collected 48 hours after transfection, pelleted and subjected to three 
freeze/thaw cycles to release the vector. Cellular debris was pelleted and 
the supernatant treated with Benzonase and precipitated with saturated 
ammonium sulphate. Vector was purified through a CsCl gradient and 
dialysed against PBS. Vector titre was determined by qPCR on vector 
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stocks as described by Huang et al and using primers manufactured by 
Sigma Aldrich [140, 153]. Sequences for the rAAV forward primer 
AAV1277F (5’-CCGTTGTCAGGCAACGTG), reverse primer AAV1361R 
(AGCTGACAGGTGGTGGCAAT), and probe (5’ – 
[6FAM]TGCTGACGCAACCCCCACTGGT[TAM]) . 
 
3.2.2 Neonatal Rat Ventricular Myocyte Studies 
Neonatal rat ventricular myocytes were prepared as described in Section 
2.2.3.2. In summary NRVMs were isolated from 2-3 day old rat Sprague 
Dawley rat pups by enzymatic digestion as previously described [154]. 
Cells were cultured on 24 well plates. Neonatal RVMs were transduced 
with rAAV.Cx45 in the order of 1X1011 vector genomes per well. Forty 
eight hours later they were fixed and immuno-stained.  
 
3.2.3 In Vivo Studies 
In vivo studies were carried out as described in section 2.10. All rats were 
anesthetised, intubated and ventilated with a mixture of oxygen and 2% 
isoflurane for EPS and telemetry device implantation. 
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3.2.3.1 Surface Electrocardiography 
Electrophysiological studies were performed as described in Section 
2.10.3. In brief, four unipolar needle electrodes (AD Instruments) were 
placed subcutaneously at the infra-clavicular and iliac fossa regions 
bilaterally. One ground lead was also placed subcutaneously in the 
abdominal region. Two lead electrocardiograms were generated 
combining potentials from left / right lower and right / left upper electrodes 
pairs. Bio-potentials, sampled at 2 kHz, were amplified with an Octal Bio 
Amp (AD Instruments) and digitised using a Powerlab 16/30 (AD 
Instruments) data acquisition system. Data was recorded, via USB, using 
the Windows based version of Labchart Pro 7 (AD Instruments) running 
on a Dell laptop. No software filtering was used. All data was analysed 
offline. The PR and QRS intervals were calculated using the Lab chart 
software and by randomly sampling 10 continuous beats.  
 
3.2.3.2 Trans-oesophageal Cardiac Stimulation 
As described in Section 2.10.3, a 5 French octapolar catheter (Biosense 
Webster) connected to the Octal Bio Amp was passed via the oral cavity 
into the oesophagus and positioned at the point where recordings from 
the middle 2 electrodes had the largest ventricular electrogram 
amplitudes. Recordings were made from the middle 2 electrodes only, 
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while stimulation was delivered through the distal 2 electrodes only. The 
ventricle was captured using a constant 60 volt square shaped stimulus 
of 1 millisecond duration via an isolated pulse stimulator (Model 2100; A-
M Systems). Custom designed software installed on a second windows 
based laptop (Hewlitt-Packard) was used to drive the stimulator via its 
trigger input. 
 
Programmed ventricular stimulation was used to induce ventricular 
tachycardia. Hearts were paced with a drive train of 8 stimuli at a coupling 
interval of 180 millisecond followed by up to four extra-stimuli starting at 
150 millisecond and progressively reduced in 10 millisecond decrements 
to ventricular refractoriness. If programed ventricular stimulation failed to 
induce VT, then ventricular burst pacing was performed once at a cycle 
length of 90 milliseconds for 30 seconds and repeated once, if required, 3 
minutes later at a cycle length of 60 milliseconds.  
 
3.2.3.3 Implantable Telemetry 
As described in Section 2.10.6, two weeks following transduction, a 
subset of animals were anaesthetised, intubated and ventilated as 
described above. Telemetric devices (ADI instruments MLE 1010) were 
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implanted into 5 rats injected with rAAV.GFP and 5 rats injected with 
rAAV.Cx45 as previously described [145]. Briefly, a midline abdominal 
incision was made from the xiphisternum 3cm in size and the abdominal 
cavity exposed. The body of the telemetric device was inserted into the 
abdomen above the bladder of the rat and sutured to the abdominal 
musculature. One electrode was then sutured to the xiphisternum and the 
other to the second right intercostal space. The abdominal musculature 
and skin were then sutured and the rat recovered. Analgesia was 
achieved by administering buprenorphine (0.5mg/Kg SC) prior to the rat 
recovering from anaesthesia and at later time intervals as needed. Rats 
were placed in cages with two battery chargers connected to the wireless 
receivers (ADI instruments TR101). Telemetry was recorded continuously 
for 2 weeks prior to the final study end point. 
 
3.2.3.4 Tail Vein Vector Injection 
Tail vein vector injections were performed immediately after baseline EPS 
as described in Section 2.10.4. In summary, a 25 gauge needle was used 
to cannulate the tail vein at its most distal end and viral vector injected 
over 30 seconds. The tail vein was flushed with 500μL normal saline. 
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3.2.3.5 Tissue Preparation 
As described in Section 2.10.7, at the end of the study period, rats were 
euthanized with CO2 and weighed. Hearts were removed, rinsed with PBS 
and subsequently weighed. For histology and immunohistochemistry 
studies, hearts transduced with rAAV.Cx43 or rAAV.Cx45 were 
immediately embedded in Tissue-Tek OCT compound (Sakura).  For rats 
transduced with rAAV.GFP, hearts were fixed in 4% PFA overnight at 4oC 
prior to embedding in Tissue-Tek OCT. All embedded tissue was frozen 
in liquid nitrogen and transferred to -80°C storage. For protein and mRNA 
studies, hearts were placed into microcentrifuge tubes, frozen in liquid 
nitrogen and transferred to -80°C storage. Heart tissue was subsequently 
sectioned into 6μm slices and mounted onto glass slides for 
immunostaining, inflammation and fibrosis studies. 
 
3.2.4 Morphometric Studies 
All rats and their hearts were weighed at the end of the protocol. 
 
3.2.5 Immunostaining 
As previously described in Section 2.4, the ventricle was excised and 
stored at day 28 and after the EP studies were performed. Ventricular 
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sections were fixed with 4% (w/v) paraformaldehyde, subject to 
permeabilisation with 0.1% (v/v) Triton X-100 (Sigma-Aldrich) in PBS for 
15 minutes and blocked with Dako Protein Block, serum-Free. Samples 
were then incubated with primary antibody (mouse monoclonal anti-Cx45 
1:200 Millipore and rabbit monoclonal anti-Cx43 1:800 Millipore) diluted in 
blocking solution overnight at 4°C. Secondary antibody (Alexa488-
conjugated anti-mouse, 1:1000, Invitrogen; or Alexa594-conjugated anti-
mouse, 1:2000, Invitrogen; or Alexa594-conjugated anti-rabbit, 1:2000, 
Invitrogen), diluted with 0.1% (v/v) cold fish skin gelatine in PBST, was 
applied to the slides for 1 hour at room temperature in the dark. Samples 
were cover slipped (Deckgläser; Menzel-Gläser) mounted with Prolong 
Gold anti-fade reagent with DAPI (Life Technologies) and allowed to set 
in the dark, overnight and 4°C. Imaging was performed using either an 
inverted wide field fluorescent microscope (Leica DMIL) with a 40X – 100X 
objective (Leica 40X/0.50 Ph2 /1.1 506273 HI plan 1) or a confocal laser 
scanning microscope (Olympus FV 1000) using a 40X – 60X objective 
(Olympus 40X/1.30/0.20 (WD) Oil UPLFLN). 
 
For co-localisation studies described in detail in Section 2.4.4, we 
combined primary antibodies as well secondary antibodies following the 
same process as above but secondary antibodies used were Alexa488-
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conjugated anti-mouse, 1:1000 and Alexa594-conjugated anti-rabbit, 
1:2000, Invitrogen. This allowed different fluorescence to be able to note 
the different antibodies at the same time. Of note under fluorescence 
when the two antibodies were combined and seen at the same time, the 
fluorescence was yellow. 
 
3.2.6 Inflammation - Haematoxylin and Eosin Staining 
The technique of H&E staining was performed with a Shandon Linear 
Stainer described in Section 2.5.1. Heart sections were immersed in 
Haematoxylin for four minutes, Scott’s Bluing solution for one minute, and 
0.1% Eosin for one minute. Samples were dehydrated with absolute 
ethanol for 30 seconds and placed in xylene clearing solution. Images 
were then assessed manually for the extent of inflammation and graded 
based on a scale by Igarashi et al. [142] (1 - absent, 2 - occasionally 
present, 3 - ≤ 50% affected, 4 – 50% to 90% affected, 5 - ≥ 90% presence). 
      
3.2.7 Pico-Sirius Red Staining for Fibrosis 
As described in Section 2.5.2, heart tissue sections were fixed with 4% 
paraformaldehyde followed by 3 washes in PBS for 5 minutes. Sections 
were placed in Pico-Sirius red solution (0.1% Direct Red 80 (Sigma), 0.1% 
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Fast Green FCF (Sigma), Saturated Picric Acid (Sigma)) for 1 hour then 
washed in 100% ethanol for 1 minute each to dehydrate the sections. 
Samples were air dried then immersed in xylene clearing solution before 
cover slip mounting. Sections were processed with custom made software 
designed to objectively calculate the relative areas of red (collagen) to the 
area of the tissue section as described in Section 2.5.3 (Fig 3.2). 
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Figure 3.2: Image Processing of Pico-Sirius Red Tissue Staining 
 
Representative images from a GFP ventricle section showing Pico-Sirius 
Red staining on the left (collagen coloured red, remaining tissue coloured 
green) and a software processed image on the right (collagen identified 
as red, remaining tissue as blue). The formula (red pixels x 100) / (red 
pixels + blue pixels) was used to calculate the percentage fibrosis within 
processed images 
 
 
 
 
 
 
 
 
3,956 red pixels 
94,990 blue pixels 
4.00% fibrosis 
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3.2.8 Immunoblotting 
Primary antibodies used during experiments were described above and in 
Section 2.6.4. Tissue used for protein extraction was flash frozen in 
nitrogen when collected. Fifty mg tissue along with 500µl of ice cold lysis 
solution (RIPA buffer (Sigma-Aldrich), 1% (v/v) phosphatase inhibitor 
cocktail 2 (Sigma-Aldrich), and 4% (v/v) protease inhibitor cocktail (Sigma-
Aldrich) was subjected to disruption with bead milling using a TissueLyser 
(Qiagen) set to 30Hz. Samples were pelleted and supernatant recovered. 
Protein estimation was performed using the Bradford method using a Bio-
Rad protein assay kit.  The absorbance used to measure was 595nm 
using a Victor2 Multilabel Counter (PerkinElmer life Sciences). Protein was 
loaded into precast polyacrylamide 4-12% gradient Bis-Tris gels 
(NuPAGE; Invitrogen) and SDS-PAGE electrophoresis was performed in 
1X NuPAGE MOPS (Invitrogen) buffer in reducing conditions as per the 
manufacturer’s instructions. Protein membrane was transferred from the 
gels to a membrane using the IBLOT gel transfer system (Invitrogen), 
following electrophoretic separation. Gels were placed in a gel transfer 
stack (Invitrogen) and the IBLOT’s default 7 minute transfer protocol was 
used. Membranes were then blocked with a solution of 5% skim milk in 
TBST (0.05% Tween 20, Tris-Buffered Saline) for 2 hour and 
subsequently incubated with primary antibody diluted in blocking solution 
overnight at 4°C.  
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The following morning following washes, samples were incubated with 
secondary antibody (HRP-linked rabbit anti-mouse, 1:10000, Sigma; or 
HRP-linked goat anti-rabbit, 1:10000, Sigma) diluted in blocking solution 
for 1 hour. SuperSignal Pico Chemiluminescent substrate (Thermo Fisher 
Scientific) blotting detection reagents was then added on to the according 
to the manufacturer’s instructions. At times when extra luminescence was 
required then in addition to the Pico substrate, SuperSignal west Femto 
(Thermo Scientific) was mixed with a ratio of 1:10 dilution and added to 
the membrane for 5 minutes. Membranes were transferred to an 
autoradiography cassette (Hypercassette; Amersham Biosciences). In a 
dark room, chemiluminescence film (Hyperfilm ECL; Amersham) was 
exposed to the protein membranes in the autoradiography cassette. Films 
were then processed with an AGFA film processor according to the 
manufacturer’s protocol.  
 
3.2.9 Duo-Link 
The Duo-link In-Situ Kit (O-link – Sigma Aldrich) was to detect protein to 
protein interaction as described in Section 2.8. The method was 
performed according to the manufacturer’s instructions and as previously 
described by Soderberg et al [144]. Primary antibody was incubated 
overnight at 4oC. The slides were washed twice with 1x Wash Buffer A 
141 
 
for 5 minutes. The two PLA probes were diluted 1:5 in Antibody Diluent, 
applied to the slides and incubated in a pre-heated humidity chamber for 
1hour at 37oC. Slides were then again washed twice with 1x wash Buffer 
A. For the ligation step, Ligation stock was diluted 1:5 with high purity 
water, Ligase added to the ligation solution at 1:40 dilution and then 
placed onto slides for incubation in a pre-heated humidity chamber for 30 
minutes at 37oc. Slides were then washed twice with 1x Wash Buffer for 
2 minutes each. For the amplification step the amplification stock was 
diluted 1:5 in water to make the amplification solution.  Polymerase was 
then added to the solution at 1:80 dilution and  applied to the slides and 
incubated in a pre-heated humidity chamber for 100 minutes at 37oc. 
Slides were transferred to a dark room and samples were washed twice 
with 1x Wash Buffer B for 10minutes each followed by a single wash of 
0.01x Wash Buffer B for 1 minute. Slides were dried and cover-slipped 
with a minimal volume of Duolink in Situ Mounting Medium with DAPI. 
Slides were stored at -20oC overnight before confocal microscopy was 
performed. 
 
3.2.10 Co-immunoprecipitation  
As previously described in Section 2.9 ventricular tissue was initially flash 
frozen and stored at -80oC. The tissue was pulverized, homogenized and 
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lysed in a buffer solution containing 1.5% NP-40, 1% Triton X-100, 0.1% 
BSA and protease inhibitors. Either monoclonal anti-Cx43 or monoclonal 
anti-Cx45 antibody was incubated with protein G sepharose for 1 hour on 
a shaker. The lysate was incubated with antibody bound beads plus 
protease inhibitor cocktail for 1 hour at 4oC to immunoprecipitate Cx45 
and Cx43 associated proteins respectively. A non-specific IgG was used 
as a negative control. Following that the immunoprecipitate was spun 
down in a micro centrifuge at 16,000 x g for 15 min at 4oC. The precipitate 
was then washed 3 x in lysis buffer with BSA, and suspended in lysis 
buffer without BSA plus sample buffer with β-mercaptoethanol for 
immunoblot analysis. Rabbit Polyclonal (anti)-Cx45 and Rabbit 
Polyclonal (anti)-Cx43 were used for immunoblotting.  
 
3.2.11 Statistics 
Continuous variables were analysed using student T tests or Mann-
Whitney U test. Ventricular tachyarrhythmia inducibility was assessed 
using the fisher exact or X2 tests. All statistics were conducted at the ≤ 
0.05 significance level. Data are presented as mean +/- SD. 
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3.3 Results 
 
3.3.1 NRVM Studies 
To assess the functionality of the rAAV.Cx45 vector, in vitro studies were 
performed. Neonatal RVMs treated with rAAV.Cx45 demonstrated 
widespread transduction with the expected localisation at junctional 
membranes (Figure 3.3). Controls with no vector transduction were 
carried out alongside and did not reveal any signal. Figure 3.4 
demonstrates western blot images of Cx45 in NRVMs.  
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Figure 3.3:  Immunostaining of NRVM 
Fluorescence   microscopy   was   performed   on Cx45 labelled rat ventricular myocytes following transduction 
with a rAAV.Cx45. These cells are devoid of endogenous Cx45. The immunoreactive signal is clearly seen 
localizing at the junctional membrane between adjacent cells confirming the expression of Cx45 from this vector 
construct. No signal was seen in control cells (right panel). 
 
 
 
 
 
 
 
 
Cx45 
100x 
Control 
100x 
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Figure 3.4 Western Blot image of Connexin45 in NRVMs 
Western blot image of Cx45 protein expression in NRVM’s. This 
revealed increased signal in rAAV.Cx45 transduced NRVM’s and 
no signal in the control (n=3 in each group).  
 
 
 
 
 
 
 
 
 
 
                                
C
o
n
tr
o
l
C
x
4
5
0 .0
0 .5
1 .0
1 .5
G ro u p s
P
r
o
te
in
 D
e
n
s
it
o
m
e
tr
y
C o n tro l
C x45
 
 
Tubulin 
Cx45 
Densitometry    0  0.8 
146 
 
3.3.2 Protein/mRNA Expression Studies 
Tail vein injection of rAAV.GFP resulted in widespread transduction of 
cardiac myocardium as shown in Figure 3.5. Both rAAV.Cx43 and 
rAAV.Cx45 gene transfer also resulted in a widely transduced 
myocardium (Figure 3.5). Overexpression of Cx45 protein and mRNA 
was confirmed with Western blotting and qPCR, respectively (Figure 3.6, 
Table 3.1).  
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Figure 3.5: Fluorescent Microscopy Images Showing Expression of GFP, Cx43 and Cx45 in Transduced 
Rat Myocardium. 
Spontaneous fluorescence of GPF and fluorescent immunostaining of ventricular myocardium with Cx43 (red) 
and Cx45 (green). Images reveal a widespread transduction and localisation of connexins in the intercalated 
discs. 
 
 
 
 
 
 
 
 
 
Cx45 Cx43 GFP 
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Figure 3.6 Western Blot images Showing Cx45 and Cx43 
Expression in Transduced Rat Myocardium. 
Top image “A)” reveals significant Cx45 protein detected in Cx45 
overexpressed myocardium. Bottom image “B)” reveals as expected 
Cx43 is detected in all groups but overexpressed in the Cx43 group. 
A) Cx45 Protein levels (n=3 in each group) 
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B) Cx43 Protein levels 9 (n=3 in each group) 
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Table 3.1: Mean Cx45 and Cx43 mRNA expression results in 
transduced rat myocardium. 
A) Compares GFP to Cx43-overexpressed group and reveals a 
significant increase in Cx43 mRNA expression in the Cx43-
overexpressed group. 
B) Compares GFP to Cx45-overexpressed group and reveals a 
significant increase in Cx45 mRNA expression and a significant 
reduction in Cx43 expression in Cx45 overexpressed group. 
C) Compares the Cx43 to Cx45 overexpressed groups. It reveals a 
significant increase of Cx43 mRNA expression in the Cx43 
overexpressed group and a significant increase in Cx45 mRNA 
expression in the Cx45 overexpressed group.  
 
A) 
 rAAV.GFP 
n=8 
rAAV.Cx43  
n=7 
P-Value 
Cx45 0.27±0.086 0.31±0.025 NS 
Cx43 0.65±0.23 0.94±0.15 0.02 
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B) 
 rAAV.GFP 
n=8 
rAAV.Cx45 
n=7 
P-Value 
Cx45 0.27±0.086 0.62±0.316 0.007 
Cx43 0.65±0.23 0.24±0.22 0.02 
 
C) 
 rAAV.Cx43 
n=7 
rAAV.Cx45 
n=7 
P-Value 
Cx45 0.31±0.025 0.62±0.316 0.02 
Cx43 0.94±0.15 0.24±0.22 0.004 
 
 
All values represented as mean ± SD 
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3.3.3 Electrophysiology Studies 
Fifty two Sprague Dawley rats were studied and all reached maturation. 
The GFP and Cx43 groups had no significant difference between 
baseline and final ECG parameters as shown in Table 3.2. The Cx45 
group on the other hand, displayed evidence of conduction slowing with 
prolongation of both the PR and QRS intervals when final and baseline 
results were compared. When the final PR and QRS intervals of the Cx45 
group were compared to those of Cx43 and GFP treated rats there was 
also a significant prolongation see Table 3.2. 
 
Inducible ventricular tachyarrhythmia Figure 3.8 (a) was not observed in 
any rat at baseline. Twenty eight days after transduction, 13 rats in the 
Cx45 treated group had inducible ventricular tachyarrhythmia versus 2 in 
the Cx43 and none in the GFP treated group Figure 3.7. Furthermore 5 
rats in the Cx45 group had high degree atrioventricular nodal block figure 
3.6 (b) versus none in the control GFP and Cx43 groups; this did not 
however reach statistical significance.  
 
Telemetry did not show any spontaneous ventricular tachyarrhythmia in 
any group. 
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Table 3.2: ECG Parameters and Arrhythmias 
Table below summarises the results for the electrophysiology parameters 
studied between the groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 Treatment  
groups 
GFP 
n=15 
Cx43 
n=15 
Cx45 
n=22 
P-Value 
GFP 
vs 
Cx45 
GFP 
vs 
Cx43 
Cx45 
vs 
Cx43 
PR 
Interval 
(ms) 
Baseline 44±4.2 50.0±8.1 45.8±6.0 NS NS NS 
Post  
Treatment 
 
47.8±7.3 
 
49.8±6.7 
 
59.0±12.0 
 
0.005 
 
NS 
 
0.038 
Δ 3.68±4.52 0.54±4.9 14±12 0.04 NS 0.001 
QRS 
Duration 
(ms) 
Baseline 14.7±1.5 14.0±1.7 14.8±1.9 NS NS NS 
Post  
Treatment 
 
15.4±1.5 
 
14.0±2.4 
 
16.2±1.8 
0.014 NS 0.007 
Δ 0.69±1.1 0.04±1.5 1.4±1.8 0.001 NS 0.012 
High Block rate 0 0 5 (23%) 0.13 NS 0.13 
 
In vivo comparisons of the electrophysiological effects of Cx45 
overexpression (rAAV.Cx45), and Cx43 (rAAV.Cx43) overexpression 
 
PR 
Interval 
QRS Wave 
P=NS P=NS P<0.001 
P=NS P=NS P=0.009 
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compared to control rAAV.GFP. EP measurements include: mean PR 
interval and QRS durations for each group as measured at Day 0 
(Baseline) and Day 28 (Post Treatment). Δ = mean difference (post-
treatment – baseline). Baseline measurements of both QRS duration and 
PR interval were similar between the groups. Cx45 overexpression 
resulted in significant prolongation of PR interval and QRS duration post-
treatment compared to baseline Cx45 overexpression and against post-
treatment of Cx43 overexpression and post-treatment control. This effect 
was not observed in the Cx43 post-treatment compared to baseline Cx43 
overexpression and post-treatment control.  
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Figure 3.7 Incidence of Inducible of VT/VF 
Figure below shows a bar chart of the percentage of VT/VF noted in each 
of the groups. There was a significant increase in ventricular 
tachyarrhythmia noted between the rAAV.Cx45 and rAAV.GFP and 
rAAV.Cx43 groups. No significant difference between rAAV.GFP and 
rAAV.Cx43 was observed. 
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Figure 3.8: Rhythm Strips 
A) Evidence of drive train with two extra beats resulting in ventricular 
tachycardia.  
B) Complete heart block seen in a Cx45 overexpressed rat heart; there 
was dissociation of P wave and QRS complexes. 
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3.3.4 Connexin43/Connexin45 Protein Interaction Studies 
To assess for heteromeric gap junction formation as a mechanism for 
conduction slowing, co-immunostaining was carried out on Cx45 
transduced hearts. By confocal microscopy (Figure 3.9) this showed a 
heterogeneous expression of Cx45 with no alteration in the expected 
Cx43 expression level and subcellular localisation. Co-localisation of the 
immuno-reactive signal from the two connexins was observed. To directly 
assess for protein-protein interaction Duo-link studies and co-
immunoprecipitation were performed (Figure 3.10 and 3.11 respectively). 
These two methods confirmed interaction and further supported 
Cx45/Cx43 co-localisation.  
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Figure 3.9 Co-Immunostaining of Connexins in Rat Myocardium 
Co-immunostaining for Cx45 (red) and Cx43 (green) in Cx45 
overexpressed rat myocardium. Yellow signal identifies areas of possible 
co-localisation of Cx45 and Cx43. Nuclei labelled blue with DAPI. 
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Figure 3.10: Duo-Link 
Duo-Link image, the red signal (Duo-Link) identifies areas of co-localisation of Cx43 and Cx45. Nuclei are 
stained blue.  
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Figure 3.11 Co-immunoprecipitation 
The figure below shows co-immunoprecipitation of Cx43 and Cx45 from 
rat myocardium. Initially Cx45 or Cx43 were immunoprecipitated using 
monoclonal anti-Cx45 or anti-Cx43 antibodies as in Figure 3.6. The 
proteins in the immunoprecipitates were resolved by SDS-polyacrylamide 
gel electrophoresis and subjected to immunoblotting with rabbit 
polyclonal anti-Cx43 or anti Cx45 antibodies to reveal Cx43 in Cx45 
associated proteins and Cx45 in Cx43 antibodies (square boxes). Neither 
Cx43 nor Cx45 were observed in the negative control.  
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3.3.5 Heart Failure/Fibrosis Studies 
To further understand the mechanism behind the increased 
arrhythmogenesis for Cx45 overexpressed rats, we sought to exclude 
confounding processes such as heart failure, fibrosis and inflammation. 
There was no difference in heart to body weight ratios, heart failure gene 
expression (ANP and βMHC), intramyocardial fibrosis and inflammation 
between any of the groups (Figures 3.12, 3.13 and Table 3.3 
respectively). 
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Figure 3.12: Haematoxylin and Eosin Stains of Ventricular Tissue. 
Representative left ventricular tissue sections stained with H&E from each of the study group. Inflammation score 
from a total of 60 images (from 5 separate rat hearts) within each group was provided (mean ± SD). No significant 
difference was observed between means of GFP, Cx43, and Cx45 groups when compared.  
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Figure 3.13: Pico-Sirius Red Stains of Ventricular Tissue 
Representative left ventricular tissue sections stained with Pico-Sirius Red from each of the study groups. 
Percentage fibrosis from a total of 60 images (from 5 separate rat hearts) within each group was provided (mean 
± SD). No significant difference was observed between means of the GFP, Cx43 and Cx45 groups.  
 
 
 
 
 
 
 
GFP 4.15% ± 1.9 Cx43 4.30% ± 3.1 Cx45 4.07% ± 1.9 10x 10x 10x 
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Table 3.3: Heart Failure Parameters 
 
a) Table below shows the mean values of the heart to body ratio 
in all study groups (mean ± SD). There was no significant 
difference observed between all groups. 
 
GFP 
n=15 
Cx43 
n=15 
Cx45 
n=22 
P-Value 
3.83x10-3±1.9x10-4 3.85x10-3±2.3x10e-4 3.88x10-3±2.2x10-4 NS 
 
b) Table below shows the mean values for the heart failure mRNA 
gene expression in all study groups as mean ± SD. There was 
no significant difference observed between all groups. 
 GFP 
(n=7) 
Cx43 
(n=7) 
Cx45 
(n=7) 
P-Value 
ANP 0.48±0.63 0.25±0.34 0.36±0.12 NS 
βMHC 1.0±0.9 1.5±0.9 0.85±0.8 NS 
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3.4 Discussion 
The main findings of this study were that Cx45 over expression was 
associated with slowing of myocardial electrical propagation and an 
increased risk for arrhythmogenesis in the intact heart. Connexin43 
overexpression did not have the same effect. This supports previous 
studies that have suggested that Cx45 may be implicated in the cause 
of SCD.  
 
Our results support the hypothesis that there was an interaction between 
Cx45 and Cx43 likely secondary to heteromeric channel formation with 
the ensuing conduction slowing contributing to arrhythmogenesis. 
Connexin45 treated hearts were also noted to have a significant reduction 
in Cx43 as compared to control implying that Cx45 overexpression may 
affect Cx43 expression. It was likely that Cx45 overexpression alone 
resulted in arrhythmogenesis. Alternatively, a combination of both 
increased Cx45 and reduced Cx43 may increase the propensity to 
arrhythmogenesis. This result was consistent with studies of human heart 
failure showing an increased Cx45 expression together with reduced 
Cx43 expression [86, 155]. Heart failure, fibrosis and inflammation were 
excluded as causes of arrhythmia in this model. 
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3.4.1 Connexin45  
Ventricular tachyarrhythmia is the main cause for SCD. Gap junction 
remodelling has been investigated as a molecular mechanism for 
ventricular arrhythmia. Of the known cardiac connexins, knowledge of 
Cx45 and its functional role in the heart is the most limited. Most 
investigations have been performed on continuous cell lines such as 
SkHep1 or HeLa cells [31, 78-80]. In terms of the role of gap junctions 
composed of Cx45, Valiunas et al. have reported that gap junctions 
composed of Cx45 have a relatively small unitary conductance 
(~26pS) when compared to gap junctions composed of Cx40 or Cx43 
[83]. This property of Cx45 gap junctions likely underpins the 
prevalence of this connexin in the AV and sinoatrial nodes. These sites 
physiologically demand slow but safe electrical conduction.  
 
3.4.2 Connexin43/Connexin45 
Studies have suggested that reduced Cx43 expression may result in 
diminished coupling, conduction slowing and thereby contribute to re-
entrant tachyarrhythmia.  However data from Cx43 knockout mice 
showed that there needs to be a greater than 50% reduction in 
expression to effect significant conduction delay or arrhythmia [88, 156]. 
It seems, therefore, that the more modest reduction in Cx43 observed in 
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heart disease is unlikely to be the sole cause of the abnormal rhythm 
generation.  Others such as Peters et al. have suggested altered cellular 
patters of Cx43 expression allow formation of functional lines of 
conduction block and therefore enhance re-entry arrhythmia [23].  
 
Given the up-regulation of Cx45, it is conceivable that ventricular gap 
junction connexins in diseased hearts are made up of oligomers of Cx43 
and Cx45. A recent study by Bao et al. had found that Cx45 represents 
0.3% of total connexin protein and co-localizes with Cx43 in native 
ventricular gap junctions [91]. This was mainly noted in the apex and 
septum of the myocardium. This study, however, reported that 
overexpressed or down-regulated hearts were not found to have any 
notable effect in the electrical conduction system. This was in contrast to 
our study which demonstrated prolongation of AV nodal and QRS width 
compared to baseline. Of note, an earlier study by the same group 
showed that Cx45 overexpression resulted in increased susceptibility to 
ventricular tachyarrhythmia [3]. Differences to our study may relate to 
differences in the method of overexpression, the amount of 
overexpression and the animal models employed in the studies.  
 
The functional effects of heteromeric Cx43/Cx45 channel formation on 
gap junctional intercellular coupling have been assessed in heterologous 
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expression systems and in primary myocytes [90] [80, 81]. The resulting 
heteromeric gap junctions yielded disparate functions to their homomeric 
counterparts raising the possibility that heteromeric channel formation 
may be one mechanism by which intercellular communication can be 
altered to effect conduction slowing and predispose to arrhythmia.  
Notably,  Cx45 is overexpressed in human heart failure, a condition also 
known to predispose to VT/VF and SCD [149]. In our study we 
hypothesised that the formation of heteromeric Cx43/Cx45 gap junction 
channels with lower unitary conductance led to the ECG manifestations 
of prolonged PR interval and widened QRS width. We noted a more 
marked slowing for the PR interval than the QRS and this is likely due to 
Cx45 being more pronounced in the AV node than the bundle branches 
and possible increased expression in the AV node following transduction. 
Furthermore in our study we had shown co-localisation of Cx45 and Cx43 
with immunostaining and direct protein-protein interaction with Duo-Link 
and co-immunoprecipitation methods. These findings support the 
hypothesis that heteromeric Cx43/Cx45 channels do exist and are 
increased in prevalence with Cx45 overexpression leading to slower 
conduction and inducible ventricular tachyarrhythmia. 
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3.4.3 Transgenic Overexpression vs. Somatic Gene Transfer 
In a transgenic, cardiac-restricted, Cx45 overexpressing mouse model 
there was an increased incidence of spontaneous and inducible 
ventricular tachyarrhythmia [90]. Moreover in Cx45 knockout models of 
mice, they died from heart failure in utero at embryonic day 10. The 
embryonic hearts were found to be dilated. However even in the absence 
of Cx45, heart contractions were initiated but there was conduction block 
through the atrioventricular canal, and the contractions in the outflow tract 
were not co-ordinated with those in the ventricle. This latter finding implies 
a functional role for Cx45 in ventricular conduction.  
 
The use of transgenic mice to study connexin biology and arrhythmia is 
limited by changes in the expression of unintended molecules and the 
high-level of structural abnormalities encountered [62]. These limitations 
could explain the genesis of arrhythmia independent of the intended 
molecular alteration. While it is agreed that use of conditional transgenics 
may overcome these limitations, the somatic gene transfer approach 
may be considered superior in this context for the following the 
reasons.  Firstly, acute genetic changes will be induced in the adult heart 
essentially mimicking those likely to occur in the context of acute and 
acquired myocardial disease. Secondly, heterogeneity of gene transfer 
also mimics the heterogeneous pattern of connexin expression in the 
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diseased heart and is likely to result in higher levels of arrhythmia burden 
than the low levels seen by Betsuyaku et al [90].  In our studies using 
somatic gene transfer we achieved a high level of transduction with high 
levels of conduction slowing and inducible ventricular arrhythmia.  
 
3.4.4 Confounders and Limitations 
We have looked in this study at possible confounding factors that 
predispose to ventricular arrhythmogenesis. Heart failure patients with 
reduced ejection fraction have increased ventricular arrhythmias [157]. 
We examined the heart to body weight ratio and heart failure gene 
activation. The results were the same between the studied and control 
groups.  
 
A limitation of this study was that we did not look at sodium channel 
function. Studies had shown that the sodium channel can co-localise with 
gap junctions at the intercalated disc [158, 159]. The interaction with Cx45 
is not known and therefore this could potentially be a contributing factor 
to conduction slowing and increased arrhythmogenesis.  
A further limitation was that the effects of Cx45 overexpression on the 
post-translational states of Cx43 were not assessed. This in itself may 
lead to protein to protein interactions that were not assessed and 
contribute to the slowing of conduction. Moreover the localisation of  
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Cx43 in the intercalated discs had been shown to be an important 
factor in arrhythmogenesis and this had not been assessed in this 
study either.  
 
3.5 Conclusion 
Somatic gene transfer of Cx45 with resulting overexpression in the 
intact rat heart resulted in slowing of conduction (as evidenced by PR 
and QRS interval prolongation and widening respectively) and an 
increased susceptibility to ventricular arrhythmia. This was 
associated with a direct interaction between Cx43 and Cx45 proteins 
and independent of the presence of heart failure or fibrosis.  
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CHAPTER 4 
 
SILENCING CONNEXIN45 
OVEREXPRESSION AMELIORATES 
EXCESS VENTRICULAR 
TACHYARRHYTHMIA: TOWARDS 
GENE THERAPY OF VENTRICULAR 
ARRHYTHMIAS 
 
4.1 Introduction and Aims 
The previous chapter revealed that overexpression of Cx45 in rat 
myocardium led to ventricular tachyarrhythmia. Gene transfer technology 
and molecular cardiology advances make the prospect of using genetic 
manipulation to favourably modify normal physiological and 
pathophysiological processes in the heart increasingly plausible.[160]  
 
Short regulatory RNA’s such as short hairpin RNA (shRNA) and 
microRNA are a class of double stranded RNA molecules that are notable 
for interfering with the expression of specific genes with complementary 
nucleotide sequences. Their use to specifically silence genes has been 
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widely appealing as a new method of therapy [161]. Proof of concept 
studies involving short regulatory RNAs have previously demonstrated 
therapeutic efficacy in targeting organs such as the eye and nervous 
system have been undertaken [162-165]. Phase I studies have been 
performed utilising these short regulatory RNAs to switch off cancer-
related genes and stabilize diseases as devastating as cancer with liver 
metastases [166]. Cardiac applications of this technology have also 
emerged and led to exciting developments such as viral vector based 
delivery of shRNAs for the treatment of heart failure [161, 167].  
The therapeutic application of shRNAs has advantages over 
pharmacological agents and antibodies. The main advantage being that 
shRNA can potentially target all molecules including those not amenable 
to pharmacotherapy [161]. In addition, they are relatively simple to 
synthesize compared to small molecules or antibodies. The main 
disadvantage on the other hand, is that shRNAs can only provide 
antagonistic effects on their target molecules [161]. 
 
In the previous chapter it was demonstrated that Cx45, when 
overexpressed in-vivo, resulted in an increased susceptibility to 
ventricular tachyarrhythmia. It led to slowing of conduction as evidenced 
by lengthening of ECG intervals, specifically the PR interval and QRS 
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duration. This finding provided support for our hypothesis that Cx45 
inhibits gap junction function and slows conduction leading to ventricular 
tachyarrhythmia. In this chapter we explored the corollary of the 
hypothesis and test the effects of reversing Cx45 overexpression by 
shRNA mediated silencing of the transgene.   
 
In this study we confirmed that reversal of Cx45 overexpression leads to 
reversal of arrhythmia susceptibility and explored the effects of Cx43 
overexpression simultaneously with Cx45 overexpression. We 
hypothesized that an increase in the amount of Cx43 relative to Cx45 
would also lead to a reduction in ventricular arrhythmia.  
 
4.2 Methods 
Three groups of rats were each treated with two vectors as follows (1:1 
ratio); (1) rAAV.Cx45 and rAAV.shNS (non-silencing control vector), (2) 
rAAV.Cx45 and rAAV.sh45 (silencing vector) and (3) rAAV.Cx45 and 
rAAV.Cx43. 
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Figure 4.1 Study Protocol Diagram 
A total of 3 groups were studied. The rAAV.Cx45/rAAV.shNS acted as the 
control group. The other 2 groups were rAAV.Cx45/rAAV.sh45 and 
rAAV.Cx45/rAAV.Cx43. All rats underwent baseline EPS followed by 
vector injection. EPS was repeated at day 28 followed by removal of 
ventricular tissue. The ventricles were then probed for Cx45, Cx43 protein 
and mRNA levels, and inflammation and fibrosis with histological analysis.  
 
 
 
 
 
 
 
 
 
 
4.2.1 Vector Packaging and Titration 
 
Baseline 
EPS
Day 28 
EPS
WB and IF 
rAAV-vector gene transfer 
Histology 
analysis
mRNA 
PCR
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Vector stocks encoding GFP, Cx43, Cx45, non-silencing RNA, silencing 
RNA targeting Cx45 were produced using the calcium precipitation 
method as described in Section 2.3. The resulting vectors were 
designated rAAV.GFP, rAAV.Cx43, rAAV.Cx45, rAAV.shNS and 
rAAV.sh45, respectively. Vector stock titre was assessed by qPCR as 
described in Section 2.3.4.  
 
4.2.2 Ventricular Myocardium Transduction 
Ventricular myocardium transduction was performed as described in 
Section 2.10.4. In brief, rats were anesthetized with 2% isoflurane, 
intubated and baseline electrophysiology studies were carried out. 
Following this, viral vectors were injected via the tail vein. Repeat EPS 
was performed at day 28 followed by excision of the ventricles at sacrifice 
for subsequent histological and molecular analysis of tissues. 
 
4.2.3 Electrophysiological Studies 
Electrophysiological studies were performed as described in sections 
2.10.3. In brief, recordings were carried out using subcutaneous plunge 
needle electrodes during simultaneous stimulation via a trans-
oesophageal pacing probe. Stimulation was performed with programmed 
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stimulation and burst pacing. Programmed stimulation involved an 8 beat 
drive train with a coupling interval of 180milliseconds followed by up to 4 
extra beats. Burst pacing involved electrical stimulation using a coupling 
interval of 90milliseconds for 30seconds followed by 60milliseconds for a 
further 30seconds. 
 
4.2.4 Morphometric Studies 
All rats and their hearts were weighed at the end of the protocol. 
 
4.2.5 Immunoblotting 
The ventricles were excised and stored following day 28 of the protocol 
as described in Section 2.10.7. Protein was extracted and quantified by 
method of immunoblotting as previously described in the Section 2.6. In 
brief, samples were subjected to electrophoretic separation in 4-12% BIs-
Tris gradient gels, followed by membrane transfer using the iBlot 
(Invitrogen) gel transfer system. Subsequently, the membranes were 
washed and incubated with Cx45 or Cx43 primary antibodies followed by 
secondary antibody incubation and then chemiluminescence system was 
used to produce immunoblot images.  
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4.2.6 Immunofluorescence 
As described in Section 2.4, the ventricles were excised and stored at day 
28 and after the EP studies were performed. Ventricle tissue was then 
sectioned using the cryostat and subjected to immunostaining. In brief, 
sections were fixed with 4% (w/v) paraformaldehyde, permeabilised with 
0.05% (v/v) Tritom X-100, blocked with Goat serum from (Invitrogen). 
Slides were incubated with primary antibodies of either Cx45 or Cx43, 
followed by secondary antibody incubation and mounted with Prolong 
Gold antifade reagent containing DAPI nuclear stain. Fluorescent images 
were acquired using the Leica DMIL wide field microscope or Olympus FV 
100 confocal laser scanning microscope.  
 
4.2.6 Haematoxylin and Eosin Staining 
Following sectioning of ventricular myocardium H&E staining was 
performed as described in Section 2.5. Images were then acquired as 
described in Section 2.5.3 and assessed for inflammation. The scoring 
system was as follows: 1 – absent, 2- occasionally present, 3 - ≤ 50% 
affected, 4 – 50-90% affected and 5 - ≥90% affected.  
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4.2.8 Pico-Sirius Red Staining 
Following sectioning of ventricle myocardium, Pico-Sirius red staining of 
the sections was performed as described in Section 2.5.2. Images were 
then acquired as described in Section 2.5.3 and processed with custom 
software designed to objectively identify the total pixel area occupied by 
collagen (red) and the total pixel area occupied by the remaining tissue 
(green). Collagen density of each myocardial section was calculated as 
the ratio of collagen relative to the area of the section as demonstrated in 
Figure 3.2.  
 
4.2.9 Real Time Quantitative PCR  
See Sections 2.3.4 and 2.7.3 for full methods. Briefly, sequences for the 
forward primer, reverse primer and probes were used as described in the 
methods section. A master mix was made up with 1µl of probe, 0.8µl of 
each forward and reverse primers, 4.9µl of DNASEfree RNA (Sigmal 
Aldrich) a master mix 12.5µl (sigma – Aldrich), and 5µl of DNA per PCR 
reaction. For a negative template control, 5µL of H20 was used.  
Reactions were carried out in triplicates and ampliﬁcations were 
performed with 1 cycle of 95°C for 10 minute, 35 cycles of 95°C for 15 
seconds, and 60°C for 2 minutes using a Rotor-Gene 6000 PCR cycler 
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(Corbett) or Rotor-Gene 3000 PCR cycler (Corbett). Concurrent standard 
curves were generated. The number of vector DNA molecules in each 
sample reaction was calculated by comparing threshold cycle values of 
samples to the standard curve. To determine the ﬁnal viral vector titre, the 
number of vector DNA molecules of each sample reaction was corrected 
for dilution and then averaged.  
 
4.2.10 Statistical Analysis 
As described in Section 2.11, quantitative data were expressed as mean 
± standard error of the mean. Statistical analyses between control and 
treatment groups were performed using Fischer’s exact test (if samples in 
a cell were ≤ 5) or using two sample X2 test (2 x 2 table) on the SPSS 
(Version 17). Significance was set at P ≤ 0.05. 
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4.3 Results 
4.3.1 Electrophysiology Studies 
The effects of genetic therapies tested on electrophysiological function in 
vivo are summarised in Table 4.1. Overexpression of Cx45 resulted in 
significant QRS prolongation in the control group rAAV.Cx45/rAAV.shNS 
(p=0.046). In comparison to the control group, co-treatment with a Cx45 
silencing vector rAAV.Cx45/rAAV.sh45 significantly reversed this effect to 
equivalent levels as measured during baseline. Connexin43 
overexpression in the Cx45 overexpressed group resulted in no significant 
reduction in QRS duration as compared to the control group. In contrast, 
the PR interval was not influenced by any genetic treatments tested.  
 
Short hairpin RNA mediated knockdown of Cx45 in the 
rAAV.Cx45/rAAV.sh45 group resulted in a significant reduction of 
inducible VT/VF compared to the non-silencing rAAV.Cx45/rAAV.shNS 
group. The rAAV.Cx45/rAAV.Cx43 group did not show a significant 
reduction in susceptibility to VT/VF compared to the 
rAAV.Cx45/rAAV.shNS group (Table 4.2). 
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Table 4.1 Electrophysiological Results 
EPS parameters are shown for each group.  
 rAAV.Cx45 + co-
treatment 
rAAV.shNS 
(n=17) 
rAAV.sh45 
(n=18) 
rAAV.Cx43 
(n=10) 
p – value 
rAAV.shNS 
vs 
rAAV.sh45 
rAAV.shNS 
vs 
rAAV.Cx43 
PR Interval 
(ms) 
Baseline 45.5+/-5.97 46.9+/-4.03 46.9+/-3.19 NS NS 
Post Treatment 51.4+/-9.17 48.2+/-6.53 47.0+/-5.97 NS NS 
Δ 4.47+/-4.83 2.69+/-5.49 0.09+/-6.68 NS NS 
QRS Duration 
(ms) 
Baseline 16.2+/-2.17 16.6+/-1.42 15.7+/-2.72 NS NS 
Post Treatment 17.8 +/- 1.99 16.6+/-2.21 17+/-3.07 0.05    NS 
Δ  1.61+/-1.69ms 0.00+/-2.29 1.32+/-3.04 0.015  NS 
 
In vivo comparison of electrophysiological effects of Cx45 knockdown (rAAV.sh45), and Cx43 overexpression 
(rAAV.Cx43) following Cx45 overexpression (rAAV.Cx45) in rat hearts. Comparison made against Cx45 
overexpressing hearts that have been co-treated with a non-silencing vector (rAAV.shNS). Electrophysiological 
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measurements include: mean PR interval and QRS durations for each group as measured at Day 0 (Baseline) 
and Day 28 (Post Treatment). Δ = mean difference (post-treatment – baseline). PR interval was not influenced by 
treatment and did not change over time. Cx45 overexpression resulted in significant prolongation of QRS duration. 
This effect was reversed following Cx45 knockdown, but remained unchanged following Cx43 overexpression. All 
values are mean ± SD. 
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Figure 4.2 Incidence of Inducible of VT/VF 
In vivo comparison of VT/VF propensity in rats following Cx45 knockdown 
(rAAV.sh45) and Cx43 overexpression (rAAV.Cx43) following Cx45 
overexpression (rAAV.Cx45). Ventricular tachyarrhythmia was 
significantly reduced during Cx45 knockdown but not during Cx43 
overexpression as compared to control rAAV.Cx45/rAAV.shNS. 
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4.3.2 Immunofluorescence 
Immunofluorescence revealed less Cx45 immunoreactive signal in 
rAAV.Cx45/rAAV.sh45 group compared to the non-silencing group 
(Figure 4.3). There was no appreciable increase in Cx43 expression in the 
rAAV.Cx45/rAAV.Cx43 group compared to the control given the high level 
of background Cx43 expression. Furthermore, a high degree of co-
localisation between Cx45 and Cx43 was observed in the 
rAAV.Cx45/rAAV.Cx43 group using confocal microscopy (Figure 4.4).  
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Figure 4.3 Expression of Cx45 in Rat Myocardium (confocal microscopy) 
Connexin45 is represented by green signal. Nuclei were stained blue. Connexin45 is noted in the intercalated 
discs. As can be noted there was reduced Cx45 signal in rAAV.sh45 treated group compared to the control 
rAAV.shNS group.  
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Figure 4.4 Co-Immunostaining of Connexins in Rat Myocardium 
Co-immunostaining for Cx45 represented by green signal and Cx43 represented by red signal in Cx45 
overexpressed rat myocardium with non-silencing vector. Yellow signal identified areas of possible co-
localisation of Cx45 and Cx43. Nuclei were stained blue with DAPI.  
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4.3.3 Immunoblotting 
Immunoblotting of tissue lysates revealed no appreciable difference in 
level of Cx43 expression within the ventricles of rats transduced with 
rAAV.Cx45/rAAV.Cx43 Figure 4.5. This may be due to the significant 
amount of background Cx43 expression in rat myocardium. However, 
Cx45 was reduced in the rAAV.Cx45/rAAV.sh45 knockdown group 
compared to the other two groups as seen in Figure 4.5. 
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Figure 4.5 Western Blot for Connexin43 and Connexin45 in 
Transduced Rat Myocardium 
Cx45 and Cx43 protein levels are shown by Western blot.  The Image 
on the left was representative and revealed significant Cx45 expression 
reduction in AAV.Cx45/AAV.shRNA compared to the other groups (n= 
3, P<0.01). Bottom image “B)” revealed similar Cx43 detected in all 
myocardium (n=3). 
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4.3.4 Expression of Connexin43 and 45 mRNA in 
Transduced Rat Myocardium 
There was no significant difference in the expression of Cx43 between 
the groups. There was a significant 51% reduction in the expression of 
Cx45 in the rAAV.Cx45/rAAV.sh45 vs. rAAV.Cx45/rAAV.shNS group 
(Table 4.2). 
 
4.3.5 Fibrosis and Inflammation 
Inflammation scores were made of the ventricular tissue stained with H&E. 
These were found to be similar between the groups (Table 4.3). Further-
more the levels of fibrosis between the groups was also similar (Figure 
4.6). 
 
4.3.6 Heart Failure Parameters 
The ratio of heart to body weight as a parameter of heart failure was not 
different between the groups (Figure 4.7). 
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Table 4.2: Connexin45 and Connexin43 mRNA Expression in 
Transduced Rat Myocardium 
a) Shows Cx45 RNA expression between the rAAV.Cx45/rAAV.shNS 
(n=8) and rAAV.Cx45/rAAV.sh45 (n=9) groups. There was a 
significant reduction in Cx45 RNA expression in the 
rAAV.Cx45/rAAV.sh45 group compared to control.  
 
rAAV.Cx45/rAAV.shNS rAAV.Cx45/rAAV.sh45 p-value 
2.57±1.40 1.25±0.62 0.046 
 
b) Shows the Cx43 RNA expression in the three study groups. 
Although increased, the Cx43 mRNA level was not significantly 
higher in the rAAV.Cx45/rAAV.Cx43 (n=6) compared to the other   
two groups, rAAV.Cx45/rAAV.shNS (n=8) and 
rAAV.Cx45/rAAV.sh45 (n=9). 
rAAV.Cx45/rAAV.shNS rAAV.Cx45/rAAV.sh45 rAAV.Cx45/rAAV.Cx43 p-value 
0.63±0.29 0.54±0.18 0.86±0.26 NS 
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Table 4.3 Inflammation Score 
Table below shows the average inflammation score between the groups. 
(n=30 in each group from 5 separate rat hearts, p=NS) 
                                    
 
rAAV.Cx45/rAAV.shNS rAAV.Cx45/rAAV.sh45 rAAV.Cx45/rAAV.Cx43 p-value 
1.07±0.26 1.1±0.32 1.06±0.26 NS 
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Figure 4.6 Percentage Scar 
Graph shows a representation of the average scar percentage in each 
group. n=30 in each group (from 5 separate rat hearts); p = NS 
 
 
 
 
 
 
 
 
 
 
 
rAAV.Cx45/rAAV.shNS rAAV.Cx45/rAAV.sh45 rAAV.Cx45/rAAV.Cx43 p-value 
4.25±1.33 3.89±1.73 4.07±2.05 NS 
 
 
rAAV.Cx45/rAAV.Cx43 rAAV.Cx45/rAAV.shNS rAAV.Cx45/rAAV.sh45 
Study Group 
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Figure 4.7 Heart to Body Weight Ratio 
Table below shows the results between the 3 groups with regards to the 
heart to body weight ratio. 
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4.4 Discussion 
To the best of my knowledge, this is the first study to confirm that Cx45 
knockdown in vivo can be achieved by shRNA via a rAAV vector. Delivery 
of the Cx45 silencing vector to the myocardium not only reduced Cx45 
mRNA and protein expression but also decreased ventricular Cx45 
dependent conduction slowing, dispersion, and susceptibility to 
arrhythmias associated with Cx45 overexpression.  
 
The role of Cx45 in cardiac myocytes and its association with heart failure 
and ventricular tachyarrhythmia is an important area of study.  As 
previously discussed, studies have shown an increase in Cx45 expression 
in patients with heart failure; an illness with known increased risk of 
ventricular tachyarrhythmia. In Chapter 3, I was able to confirm this effect 
in vivo by demonstrating that when Cx45 was overexpressed in the normal 
heart, this led to significant impairment of conduction and increased 
propensity to ventricular tachyarrhythmias.  
 
Silencing mRNA with short regulatory RNAs such as shRNAs have 
received increased attention as an exciting and novel method for treating 
disease by down regulation of specific genes [168, 169]. The use of this 
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molecular strategy for therapy has already been explored in human trials 
[168, 170]. With regard to the cardiac application of shRNA, Suckau et al. 
have designed a shRNA targeting phospholambam (PLB) in 
cardiomyocytes in both adenoviral and rAAV vectors [167]. This study 
showed that viral vector mediated shRNA expression and knockdown of 
PLB was capable of restoring diastolic and systolic function in Sprague 
Dawley rats with heart failure [167].  
 
In gene therapy studies the viral vector rAAV supported stable transgenic 
protein expression for more than 1 year [100, 101]. This attests to the 
capacity for rAAV to confer long-term gene expression and its strength as 
a clinical vector for applications such as heart failure and as an 
antiarrhythmic. Long-term gene expression is not possible with adenoviral 
vector systems in immunocompetent hosts due to the immune response 
provoked by adenoviral proteins. The Suckau et al. study demonstrated 
the stability of rAAV-mediated shRNA expression for up to four weeks as 
evidenced by reduced PLB expression at 4 weeks [167]. Therefore its use 
in rats with induced heart failure would be ideal and was explored in the 
next chapter of this thesis.  
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In our studies Cx45 protein expression was decreased significantly after 
knockdown with shRNA. Although this reduction was not to the same 
extent as seen in the steady-state mRNA expression level, this may be 
due to the non-linear dynamics between mRNA and protein expression 
and the relatively short half-life of connexin proteins. The achieved level 
of protein reduction was sufficient to effect a significant reduction in 
propensity to ventricular tachyarrhythmia. There was also a reversal of the 
widening of the QRS following knockdown of Cx45. The PR interval on 
the other hand was not influenced by modulation of Cx45 expression even 
in conjunction with Cx43 overexpression. This may be due to less efficient 
transduction of the AV node or demand for higher level Cx45 knockdown 
before a phenotype becomes evident in this specialised structure. 
 
Connexin43 expression is reduced in heart failure [76, 77]. In Chapter 3 it 
was shown that Cx45 co-localised with Cx43 when overexpressed in the 
normal rat heart. This was also confirmed in the current study. This latter 
finding supports the hypothesis that alteration of the gap junction by 
heteromeric channel formation results in slowing of conduction and 
increases propensity to ventricular tachyarrhythmia. In Chapter 3 it was 
also shown that Cx43 overexpression in the normal rat heart does not alter 
the myocardial electrophysiology. In the current Chapter we found that 
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Cx43 overexpression in rats with overexpressed Cx45 
(rAAV.Cx43/rAAV.Cx45) did not result in any alteration of the ECG or a 
reduction in the propensity to arrhythmia, that is, overexpression of Cx43 
did not overcome the pro-arrhythmic effects of Cx45 in this model. It is 
likely that the level of Cx45 overexpression and the inhibitory effects 
conferred were too great to be overcome by simple overexpression of 
Cx43 in a one to one stoichiometry. A way to address this would have 
been to reduce the amount of Cx45 relative to Cx43 in diminishing ratios. 
Even though an increase Cx43 mRNA and protein was evident this did 
not achieve statistical significance. One explanation is that Cx45 may 
have reduced Cx43 expression, as seen in Chapter 3, and co-expression 
of Cx43 and Cx45 only served to restore expression levels of Cx43. A 
method to test this would be to transduce the heart with an increased 
amount of Cx43 vector.  
 
As shown in Chapter 3, the development of heart failure, fibrosis or 
inflammation were not factors in the effects of Cx45 knockdown on ECG 
parameters or a reduction in the propensity ventricular tachyarrhythmia in 
the study system.  
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Limitations: 
A dose dependent effect of vector transduction was not assessed. It is 
possible that with more knockdown of Cx45 there would be a further 
reversal of electrical parameters, such as PR interval. Moreover, a dose-
dependent effect of Cx43 overexpression may have overcome the 
inhibitory effects of Cx45 on gap junction function. 
 
4.5 Conclusion 
Connexin45 knockdown in vivo by shRNA via a rAAV vector reduced 
Cx45 mRNA and protein expression as well as reversing phenotypic 
changes. On the other hand, Cx43 overexpression in conjunction with 
Cx45 overexpression did not reduce the propensity to ventricular 
tachyarrhythmia.   
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CHAPTER 5 
 
GENE THERAPY FOR POST 
MYOCARDIAL INFARCTION 
VENTRICULAR TACHARRHYTHMIA 
 
5.1 Introduction and Aims 
5.1.1 Background 
Cardiovascular mortality is the leading cause of death in the industrialized 
world. Sudden cardiac death occurs most often following acute myocardial 
infarction [13, 171]. Ventricular tachyarrhythmias are the cause in the 
majority of cases [172].  
 
We have previously demonstrated that when Cx45 was overexpressed by 
somatic gene transfer it resulted in conduction slowing as evidenced by 
widening of both the QRS and PR intervals. This further translated to 
increased ventricular tachyarrhythmia in the rat model. Protein-protein 
interaction studies showed an interaction between both Cx45 and Cx43 
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and likely that heteromeric gap junction formation was a mechanism in the 
slowing of conduction and the propensity to ventricular tachyarrhythmia.  
 
Furthermore Cx43 mRNA expression was found to be reduced in Cx45 
overexpressed rat myocardium but no significant decrease was noted on 
Cx43 protein expression in the same group. This was explored further in 
experiments in Chapter 4 where Cx43 was overexpressed in addition to 
Cx45 in rat myocardium. This resulted in no appreciable reduction in 
ventricular tachyarrhythmia thereby demonstrating that Cx45 itself must 
have a role in the propensity to ventricular tachyarrhythmia.  
 
In the following study we tested two approaches to post-MI arrhythmia 
reduction: one with Cx43 overexpression, and other with Cx45 
knockdown. 
 
Method 1: Connexin43 Overexpression 
Connexin43 remodelling has been noted following MI. In particular a 
recurrent finding is a reduction in Cx43 expression in the infarct border–
zone [24, 69]. This contributes to alteration in gap junctions and may result 
in a myocardial re-entrant electrical circuit due to areas of slow conduction 
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and contributing to ventricular tachyarrhythmia. Greener et al. published 
data showing Cx43 gene transfer to the healed scar border resulted in 
overexpression of functional connexins and reduced VT inducibility [64]. 
Hence, we aimed to also transduce Cx43 in a rodent MI model and note 
the changes in the cardiac electrophysiology and propensity to ventricular 
arrhythmia. Differences between Greener’s and our study include the 
different animal models used and the viral vector system employed. We 
chose rAAV as a vector system as this has the least immunogenicity and 
would be an ideal vector system to be used in human clinical studies. 
Moreover we also chose to administer the Cx43 systemically as would be 
the ideal method in clinical practice not requiring invasive surgery.   
 
Method 2: Connexin45 Knockdown 
In-vivo models have been used to elucidate the role of Cx45 in electrical 
conduction and ventricular arrhythmia. Results however have been 
difficult to interpret given the inherent limitations with the transgenic 
models used. These animal models in general may suffer from congenital 
malformations. Human studies have also shown increased Cx45 in the 
ischemic and hypertrophic hearts that are associated with increased 
ventricular arrhythmia [86, 87]. In this Chapter we studied a rat model of 
MI that mimics acute MI in humans and resulted in an increased 
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propensity to ventricular tachyarrhythmia. We then assessed the effects 
for shRNA-mediated knockdown of Cx45 on inducibility of VT in this 
model.  
 
Short hairpin RNA technology has been gaining wide interest as a new 
method of therapy given its ability to specifically silence genes [161]. Short 
hairpin RNAs have gone through phase I trials where it was used to switch 
off cancer genes and show stabilization of the disease process. An 
example of this was the “first in human” study by Tabernero et al. These 
characteristics and early research findings suggested short hairpin RNA 
would be an appropriate technique for Cx45 knockdown in the current 
study [166]. 
 
In this study we hypothesized that either increasing Cx43 expression or 
reducing Cx45 in the rat MI model would result in a reduced propensity to 
ventricular tachyarrhythmia.  
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5.2 Methods 
A total of 4 study groups were assessed (Figure 5.1). The groups were 
as follows: Cx45 knockdown group (rAAV.sh45) with its control of non-
silencing shRNA vector (rAAV.shNS), and Cx43 overexpression group 
(rAAV.Cx43) with its control of GFP vector (rAAV.GFP).  
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Figure 5.1: Study Protocol Diagram 
A total of 4 groups were studied. The rAAV.GFP acted as the control 
group for rAAV.Cx43, while rAAV.shNS acted as control for rAAV.sh45. 
All rats underwent baseline EPS followed by MI formation followed by 
vector injection. Electrophysiology studies were then repeated at 5 weeks 
followed by removal of ventricular tissue. The ventricles were then probed 
for Cx45, Cx43 protein and Cx43 mRNA levels, inflammation and fibrosis 
with histological analysis. 
 
 
 
 
 
 
 
 
 
 
 
Baseline EPS 
Week 5 EPS 
WB and IF 
MI + rAAV-vector gene transfer 
Histology analysis mRNA PCR 
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5.2.1 Production of shRNA Vector against Connexin45 
Recombinant adeno-associated vector plasmids encoding shRNA to 
Cx45 and a scrambled non-silencing sequence were constructed by sub-
cloning a 200bp Kpn 1 fragment containing the H1 promoter followed by 
the shRNA from the respective lentiviral vectors PPT. H1.868 and PPT. 
H1. NS (unpublished reagents produced by Dr Eddy Kizana) into the 
rAAV.GFP vector. This was done with assistance of Dr Renuka Rao. 
 
Sequencing confirmed that the shRNA expression cassette had been sub 
cloned into the KpnI site. Plasmids representing the shRNA in forward as 
well as reverse orientation for both Cx45 and non-silencing sequence 
were selected to establish knockdown of Cx45 in vitro. 
 
To confirm knockdown of Cx45 in vitro, HEK293 cells were co-transfected 
with rAAV.Cx45 and either rAAV.sh45 or rAAV.shNS plasmids at molar 
ratios of 1:5 and 1:10. Forty-eight hours after transfection, Cx45 
expression at the transcriptional and translational level was determined 
by real-time qPCR and western blot analyses as previously described in 
Sections 2.7 and 2.6, respectively. 
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5.2.2 Vector Packaging and Titration 
Vector stocks encoding rAAV.GFP, rAAV.Cx43, rAAV.shNS and 
rAAV.sh45 were all produced using the calcium phosphate precipitation 
method as described in Section 2.3. Titre was then assigned to vector 
stocks by qPCR as described in Section 2.3.4. 
 
5.2.3 Myocardial Infarction and Vector Injection in the Rat 
Rat surgery was performed as described in Section 2.10.5. Briefly 
following anaesthesia, ventilation and baseline EP studies, rats were 
placed dorsal surface downwards. A total of 10µg of Buprenorphine 
hydrochloride (Temgesic; Schering-Plough) and 1mg enrofloxacin (Baytril 
50; Bayer Healthcare AG) were separately diluted in 1ml of PBS each and 
administered subcutaneously by injection. The hair of the anterior chest 
was moistened with 70% (v/v) ethanol (Fronine), shaved with electric 
clippers (Remington; Spectrum Brands), and removed. Skin disinfection 
was performed with 10% w/v Povidine-Iodine solution (Betadine; Sanofi-
Aventis) prior to skin incision.  
 
Lignocaine 0.1% was initially administered subcutaneously as an 
antiarrhythmic. Then using a scalpel, a horizontal incision of the skin from 
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the ventral midline to the left anterior axillary line was made at the level of 
the 4th intercostal space. Blunt dissection with straight haemostats (Fine 
Science Tools) of the underlying superficial fascia was performed to 
mobilise the surrounding skin. The muscles of the left chest wall 
superficial to the ribs were separated by blunt dissection with straight 
haemostats (Fine Science Tools). Using curved haemostats (Fine 
Science Tools), the thoracic cavity was punctured via the 4th intercostal 
space. The punctured intercostal muscles were blunt dissected with the 
same curved haemostats and a Castroviejo retractor (Roboz) was 
inserted to hold open the dissected intercostal space. The pericardial sac 
was carefully dissected off over the left ventricle with curved forceps (Fine 
Science Tools). The LAD coronary artery was identified at the level of the 
left atrial appendage and a 6-0 75cm suture is placed around the artery. 
The suture ends were passed through a polyethylene tube to form a 
“snare” like loop with the free ends. The snare loop was then pulled for 10 
seconds to assess for cyanosis and then released with return to normal 
colour thereby demonstrating adequate occlusion of the LAD. The 
occlusion was then re-applied permanently. Following this the retractor 
was removed and the rib space closed with a single stitch of 3.0 coated 
vicryl suture (Ethicon). The skin incision was then closed with a horizontal 
mattress technique using a 3.0 coated vicryl suture (Ethicon).  
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A tourniquet was then applied at the proximal end of the rat tail using a 
rubber band. The tail was warmed in warm water 37o Celsius for 
30seconds. A 25gauge needle was used to cannulate the vein at its most 
distal end, once blood flow was demonstrated, the tourniquet is removed 
and the viral vector was injected over 30 seconds. The tail vein was 
flushed with 500µL of saline. The rat was then extubated and left to 
recover in its cage. Drinking water for rats was supplemented with 0.01% 
enrofloxacin (Baytril 25; Bayer Healthcare AG). 
 
Five weeks after tail vein injection of viral vector, EP studies were 
repeated as described in Section 2.10.3. Rats were then euthanized by 
exposure to CO2 in a custom made Perspex chamber for 10 minutes and 
then weighed. The heart was detached from the mediastinum just above 
the base and rinsed with PBS and subsequently weighed. Studies were 
carried out at week 5 because in previous studies using post-MI VT model, 
VT was inducible in about two thirds of animals at this time point [173].  
For comparison of Cx45 levels in MI group, a sham group with only a skin 
incision and no further intervention on the chest was undertaken. 
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Figure 5.2: Myocardial Infarction Image 
The Left Anterior Descending coronary artery was initially located and 
snared as seen in Image A). Image B) shows side by side images of the 
same rat with pre and after area of ischemic blanching indicative of 
successful LAD occlusion. 
A) 
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B) 
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5.2.4 Electrophysiological Studies 
Electrophysiological studies were performed as described in Sections 
2.10.2 and 2.10.3. In brief, recordings were carried out using 
subcutaneous needles electrodes and stimulation was performed with a 
trans-oesophageal pacing probe. Stimulation was with programmed 
stimulation and extra beats as well as burst pacing. Programmed 
stimulation was with an 8 beat drive train with a coupling interval of 
180millisecond followed by up to 4 extra beats. Burst pacing used a 
coupling interval of 90millisecond for 30seconds followed by 
60milliseconds for a further 30seconds. 
 
5.2.5 Morphometric Studies 
All rats and the hearts were weighed at the end of the protocol. 
 
5.2.6 Immunoblotting 
The ventricles were excised and stored at the end of the protocol as 
described in Section 2.10.7. Protein was extracted and quantified as 
previously described in the Sections 2.6.2. Protein samples then 
underwent immunoblotting as described in Section 2.6. In brief, samples 
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were subjected to electrophoretic separation in 4-12% BIs-Tris gradient 
gels, followed by membrane transfer using the iBlot (Invitrogen) gel 
transfer system. Following that the membranes were washed and 
incubated with primary antibodies for Cx45 or Cx43 followed by secondary 
antibody incubation and then chemiluminescence system was used to 
produce immunoblot images.  
 
5.2.7 Immunofluorescence 
As previously described in Section 2.4, the ventricles were excised and 
stored the end of the study protocol. Ventricle tissue was then sectioned 
using the cryostat and subjected to immunostaining. In brief, sections 
were fixed with 4% (w/v) paraformaldehyde, permeabilised with 0.05% 
(v/v) Triton X-100, blocked with serum (Invitrogen). Slides were incubated 
with Cx43 primary antibodies, followed by secondary antibody incubation 
and cover slipped with Prolong Gold antifade reagent containing DAPI 
nuclear stain. Fluorescent images were acquired using the Leica DMIL 
wide field microscope or Olympus FV 100 confocal laser scanning 
microscope.  
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5.2.8 Pico-Sirius Red staining 
Following excision of ventricular tissue and sectioning Pico-Sirius red 
staining was performed on the sections as described in Section 2.5.2 
(Figure 5.3). Images were then acquired as described in Section 2.5.3 and 
processed as shown in Figure 3.2 with custom software designed to 
objectively identify the total pixel area occupied by collagen (red) and the 
total pixel area occupied by the remaining tissue (green). Collagen density 
of each myocardial section was calculated as the ratio of collagen relative 
to the area of the section. 
 
5.2.9 Statistics 
Continuous variables were analysed using student T tests or Mann-
Whitney U test. Ventricular tachyarrhythmia inducibility was assessed 
using the fisher exact or X2 tests. All statistics were conducted at the ≤ 
0.05 significance level. Data are presented as mean +/- SD. 
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Image 5.3: Pico-Sirius in Myocardial Infarction 
The image below reveals a Pico-Sirius image of a cross-sectional image 
of an infarct obtained by the APERIO microscope. The infarcted region is 
red. 
 
 
 
20x 
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5.3 Results 
5.3.1 In Vitro Results 
In vitro, co-transfection of HEK293 cells with rAAV.sh45 and rAAV.Cx45 
resulted in a nine-fold reduction in Cx45 protein expression compared 
with cells co-transfected with rAAV.shNS and rAAV.Cx45 (Figure 5.4).  
 
5.3.2 Increased Cx45 in Rat Heart following MI 
Following MI, ventricular tissue revealed an increase in Cx45 protein 
expression compared to those rats subjected to sham MI as shown in the 
western blot in figure 5.5. 
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Figure 5.4: In Vitro shRNA Mediated Knockdown of Connexin45 
A) Representative image of a Western blot demonstrating Cx45 
protein expression in HEK293 cells is shown. This image revealed 
reduced signal in rAAV.Cx45/rAAV.sh45 transfected HEK293 cells 
as compared to control rAAV.Cx45/rAAV.shNS transfected cells.  
B) Densitometry results are shown and represented as a bar graph. 
This was the average of 3 samples (P<0.05). 
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Figure 5.5: Increased Connexin45 expression in Rat Heart 
following Myocardial Infarction 
A) Image below is representative of Cx45 protein expression; there 
was evidence of Cx45 expression following myocardial infarction in 
our rat model and no signal in the sham rat model. 
B) Densitometry results are shown and represented as a bar graph. 
This was the average of 3 samples each (P<0.05). 
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5.3.3 In Vivo Transduction of Rat Hearts with rAAV.Cx43 
and rAAV.GFP 
Thirty one rats started the study and were randomly assigned to either 
the experimental rAAV.Cx43 (n=16) gene therapy group or the control 
rAAV.GFP (n=15) group (one rat in the rAAV.GFP group was excluded 
as it had died during the procedure). All the rAAV.Cx43 rats reached 
maturation while one rat in the rAAV.GFP had died at 2 weeks post 
transduction. Post-mortem was carried out. In particular there was no 
evidence of infective source, therefore the death was presumed to be 
due to ventricular tachyarrhythmia and was included as part of the 
inducible VT/VF analysis.  
 
5.3.4 In Vivo Transduction of Rat Hearts with rAAV.shCx45 
and rAAV.shNS 
Thirty nine rats started the study and were randomly assigned to either 
rAAV.shCx45 (n=22) gene therapy group or rAAV.shNS (n=17) control 
group. Rats that did not survive the procedure were excluded from the 
study. Two rats in the rAAV.shNS and two from the rAAVsh45 group were 
excluded as they had died during infarction. Three rats from the 
rAAV.shNS did not reach maturation: one died at 72hours, one at two 
220 
 
weeks and the other at three weeks post-transduction. Post-mortems 
were carried out on all three and as no other cause of death was found, 
it was presumed to be secondary to ventricular tachyarrhythmia and were 
included as inducible VT/VF in the analysis. All of the rats in the 
rAAV.sh45 group reached maturation.  
 
5.3.5 Electrophysiological Effects of In Vivo Transduction 
with rAAVCx43 or rAAV.GFP 
Baseline EP studies in both groups did not demonstrate any rats with 
inducible ventricular tachyarrhythmia. 
 
At 5 weeks following MI there was no significant difference noted in the 
baseline and final ECG parameters including PR interval and QRS width 
in the rats treated with rAAV.Cx43 and rAAV.GFP, refer to Table 5.1. 
 
At 5 weeks post MI and vector injection there was a significant reduction 
in inducible VT in rats treated with rAAV.Cx43 (Figure 5.6).  Five rats out 
of 16 injected with rAAV.Cx43 and 13 rats out of 15 injected with 
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rAAV.GFP had inducible ventricular arrhythmia as defined in section 
2.10.3.  
 
5.3.6 Connexin43 Expression 
Connexin43 mRNA expression was noted to be increased nearly two-fold 
in the rAAV.Cx43 gene therapy group but the difference did not reach 
statistical significance (2.00±0.73 (n=9) vs 1.18±1.05 (n=6), P=0.062) 
compared to control. This also translated into increased protein 
expression and immunofluorescence as noted by Western blot analysis 
and immunofluorescence in figure 5.7 A) and B) respectively. Of note, 
Cx45 gene expression was similar in the two groups (1.36±1.01 (n=9) vs 
1.00±0.53 (n=6), P =0.46). 
 
5.3.7 Animal Observation 
Rats were monitored on a daily basis with regard to activity level, appetite, 
respiration, posture and gait.  We found no difference between the groups. 
In addition, we also weighed the animals on Day 0 and at 5 weeks. There 
was no difference between the groups.  
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Table 5.1: ECG intervals in Rats with MI and rAAV.Cx43 or 
rAAV.GFP Transduction 
 Treatment 
Groups 
rAAV.Cx43 
n=16 
rAAV.GFP 
n=14 
P – Value 
PR 
Interval 
(ms) 
Baseline 45.0+/-8.47 44.3+/-4.80 NS 
Post 
Treatment 
46.3+/-5.72 44.2+/-9.94 NS 
 
Δ 1.3+/-8.0 0.34+/-1.3 NS 
QRS 
Duration 
(ms) 
Baseline 16.8+/-1.87 16.3+/-1.98 NS 
 
Post 
Treatment 
16.6+/- 1.99 16.2+/-1.90 NS 
Δ 0.1+/-1.3 0.3+/-1.8 NS 
  
In vivo comparison of electrophysiological effects of Cx43 overexpression 
(rAAV.Cx43) in post-MI rat hearts. Comparison made against GFP 
(rAAV.GFP) post-MI rat hearts. Electrophysiological measurements 
include: mean PR interval and QRS durations for each group as measured 
at Day 0 (Baseline) and Week 5 (Post Treatment). Δ = mean difference 
(post-treatment – baseline). PR interval and QRS duration was not 
influenced by treatment and did not change over time.  
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Figure 5.6: Post MI Inducible VT/VF in rAAV.Cx43 and rAAV.GFP 
Transduced Rats 
Graph below reveals a significant attenuation in VT/VF incidence when 
post-MI rats were treated with Cx43 (rAAV.Cx43) 
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Figure 5.7 Connexin43 and Connexin45 Expression Following MI 
and Transduction with rAAV.Cx43 and rAAV.GFP 
A) The image shown was representative of Cx43 and Cx45 protein 
expression in rat hearts following MI and transduction with 
rAAV.Cx43 and rAAV.GFP. Connexin43 expression was increased 
in the rAAV.Cx43 treated group (2 samples shown) and there was 
no observed difference in the Cx45 protein expression between the 
groups. 
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B) Immunostaining and fluorescent microscopy of infarct-scar border in post-MI rat myocardium with anti-Cx43 
(red) in both rAAV.Cx43 and rAAV.GFP treated rats. Increased fluorescence of Cx43 was noted in the 
rAAV.Cx43 group.  Nuclei stained blue. 
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5.3.8 Confounding Factors 
Confounding factors that could explain the change in propensity to 
ventricular tachyarrhythmia were looked for including the presence of 
myocardial fibrosis and heart failure. To assess for the latter heart to body 
weight ratio and heart failure gene expression (ANP and βMHC) were 
determined.  We found no significant difference in fibrosis, heart to body 
weight ratio or heart failure gene expression between the two groups 
(Table 5.2).  
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Table 5.2: Myocardial Fibrosis and Heart Failure 
 rAAV.Cx43 rAAV.GFP P-Value 
Heart to body 
weight Ratio 
3.8x10e-3±2.2x10e-4 
n=15 
4.0x10e-3±4.5x10e-4 
n=16 
NS 
ANP expression 1.47±1.40 
n=10 
1.17±1.20 
n=8 
NS 
βMHC expression 3.27±2.08 
n=10 
2.62±1.53 
n=8 
NS 
Fibrosis % scar 9.5±8.58 9.0±9.2 NS 
 
Table 5.2 demonstrated no significant changes between treated 
(rAAV.Cx43) and control (rAAV.GFP) post-MI rats in myocardial fibrosis 
and heart failure parameters. 
Fibrosis % scar was calculated from a total of 6 images from 5 separate 
rat myocardiums. 
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5.3.9 Results of In Vivo Transduction of Rat Hearts with 
rAAV.sh45 and rAAV.shNS  
Baseline EP studies were carried out on all the rats and there was no 
inducible VT/VF. 
 
Regarding ECG parameters there was no significant difference in the final 
ECG or change in ECG parameters including PR interval and QRS 
interval (Table 5.3). 
 
At 5 weeks post MI and vector injection there was a significant reduction 
in the rate of inducible VT/VF in rats treated with targeted Cx45 
knockdown.  Eight rats injected with rAAV.sh45 and 12 rats injected with 
rAAV.shNS had inducible ventricular arrhythmia as defined in section 
2.10.3 (Figure 5.8).  
 
There was an increased mortality noted in the rAAV.shNS treated group 
(n=3) as compared to the rAAV.sh45 treated group (n=0), this however 
was a small number and did not reach statistical significance 
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Table 5.3: Electrophysiological Results 
 Treatment 
groups 
rAAV.shNS 
n=22 
rAAV.Sh45 
n=14 
P – Value 
PR 
Interval 
(ms) 
Baseline 45.6+/-6.9 51.8+/-9.16 NS 
Post 
Treatment 
45.8+/-6.54 52.5+/-7.81 NS 
Δ 0.2+/-5.79 0.68+/-8.31 NS 
QRS 
Duration 
(ms) 
Baseline 16.4+/-1.50 17+/-2.45 NS 
Post 
Treatment 
15.9+/- 2.46 16.4+/-1.74 NS 
Δ -0.5+/-1.63 -0.55+/-2.98 NS 
 
In vivo comparison of electrophysiological effects of Cx45 knockdown 
(rAAV.sh45) in post-MI rat hearts. Comparison made against non-
silencing vector (rAAV.shNS) post-MI rat hearts. Electrophysiological 
measurements include: mean PR interval and QRS durations for each 
group as measured at Day 0 (Baseline) and Week 5 (Post Treatment). Δ 
= mean difference (post-treatment – baseline). PR interval and QRS 
duration was not influenced by treatment and did not change over time.  
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Figure 5.8: Post MI Inducible VT/VF in rAAV.shNS and rAAV.sh45 
Transduced Rats 
Graph below reveals a significant reduction in VT/VF propensity when 
post-MI rats were treated with Cx45 knockdown (rAAV.sh45) compared to 
non-silencing vector (rAAV.shNS) 
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5.3.9 Connexin45 Expression 
Connexin45 mRNA expression was halved in those treated with 
rAAV.shCx45 gene therapy with a trend to significance (1.15+/-1.35 in 
rAAV.shNS (n=7) vs. 0.456+/-0.549 in rAAV.sh45 (n=9); p=0.06). This, 
however, translated into a significantly reduced level of Cx45 protein 
expression on Western blotting (Figure 5.9). Connexin43 expression was 
similar in the two groups (0.578+/-0.256 in rAAV.shNS (n=7) vs. 0.447+/-
0.265 in rAAV.sh45 (n=9); p=NS).  
 
5.3.10 Animal Observation 
Rats were monitored on a daily basis for activity level, appetite, 
respiration, posture and gait. Animals were weighed prior to commencing 
the procedure and 5 weeks after gene therapy. There were no differences 
between the groups.  
 
5.3.11 Confounding Factors 
Confounding factors that could contribute to an increase in VT/VF were 
looked into including measures of heart failure such as heart to body 
weight ratio and heart failure gene expression. The presence of 
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myocardial fibrosis was also assessed. There was a significant reduction 
in ANP mRNA expression in the rAAV.sh45 treated group compared to 
the control group. There was however, no difference in the βMHC gene 
expression or the morphometric marker of heart failure.  There was no 
difference in the extent of myocardial fibrosis between the two groups 
(Table 5.4). 
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Figure 5.9: Western Blot 
A) Western blot representative image of Cx45 protein expression in 
infarcted rats transduced with either rAAV.sh45 or rAAV.shNS. This 
image reveals reduced signal in rAAV.sh45 transduced infarcts. 
Average of 3 densitometry results is shown. 
B) Western blot representative image of Connexin43 protein 
expression in infarcted rats transduced with either rAAV.sh45 or 
rAAV.shNS. This image reveals no difference in signal between 
both groups. Average of 3 densitometry results is shown. 
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Table 5.4: Confounding Factor Results 
 rAAV.shNS rAAV.Sh45 P – Value 
ANP expression 2.76+/-2.00 0.407+/-0.544 0.007 
βMHC expression 0.950+/-0.909 0.653+/-0.564 NS 
 
Heart to body weight 
ratio 
4.07x10-3+/- 4.26x10-4 3.76x10-3+/- 4.68x10-4 NS 
Fibrosis % scar 13.7+/-13.3 10.6+/-13.1 NS 
 
 
Table 5.4 demonstrated only a significant reduction in ANP mRNA 
expression in the Cx45 knockdown (rAAV.sh45) treated group compared 
to control (rAAV.shNS) group. Other heart failure and fibrosis parameters 
remain similar between the studied groups.  
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5.6 Discussion 
5.6.1 Connexin43 and Connexin45 
Connexin43 is the predominant connexin in the ventricular myocardium 
and is responsible for electrical propagation through the gap junctions. 
Cardiac connexins have been shown to interact and form heteromeric 
channels in vitro and studies have shown that co-expression of Cx45 in 
gap junctions with Cx43 have reduced gap junctional conductance and 
dye transfer [91, 174-176]. Connexin45 has been shown to be important 
in early cardiogenesis [84]. It has also been shown to be present in the 
conduction system indicating a role in the propagation of conduction from 
the AV node to the ventricular myocardium. In Chapter 3, we were able 
to confirm that Cx45 overexpression does co-localise with Cx43 resulting 
in phenotypic changes in keeping with slowing of conductance such as 
prolongation of PR and QRS intervals.  
 
Human studies of patients with heart failure that have an increased risk of 
ventricular tachyarrhythmia have also noted an increased Cx45 
expression. In other studies it had been shown that there was reduced 
Cx43 in the myocardium of ischaemic hearts [69]. It is therefore likely that 
this altered ratio of Cx45/Cx43 expression in the post-MI heart leads to 
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formation of heteromeric connexin channels. The latter have reduced 
unitary conductance and will slow electrical conduction. The ensuing slow 
conduction would confer an increased vulnerability to ventricular 
tachyarrhythmia via the mechanism of re-entry. We hypothesized that 
correction of the ratio of Cx45/Cx43 by either Cx45 knockdown or Cx43 
overexpression would have the net effect of reduction in propensity of 
inducible ventricular tachyarrhythmia.  
 
5.6.2 Connexin Gene Therapy and Post-MI Ventricular 
Tachyarrhythmia  
Connexin 43 
Our study supports the study by Greener et al. where they assessed the 
antiarrhythmic effects of injected adenoviral vectors expressing Cx43 in 
pigs with post-MI VT [64]. They demonstrated reduced VT at two weeks 
following gene transfer. Their study only used animals with inducible VT 
for therapy whereas in the current study all animals post-MI were enrolled. 
Our study revealed a relative increase in Cx43 mRNA and protein 
expression in the rAAV.Cx43 treated group strongly suggesting 
transduction with Cx43 vector system.  
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The absence of significant inflammatory and fibrotic changes and the 
absence of differences in markers of heart failure between the treated 
group and the control group indicated that the change in arrhythmia 
inducibility was not due to structural changes. Thus an adequate level of 
Cx43 had a protective mechanism against propensity to VT.  
 
Connexin 45 
Our study supported the hypothesis that knockdown of Cx45 in rat MI 
model may decrease the propensity of VT/VF. We observed a significant 
reduction of arrhythmia in the rAAV.sh45 treated group compared to 
control. This translated into halving Cx45 mRNA expression in this group 
and significant reduction in protein expression. We hypothesize that if 
further knockdown was achieved by increasing the vector dose injected 
this may have further improved the results. The incidence of VT/VF was 
reduced with an absolute incidence of ~ 34%.  
 
Connexin43 mRNA and protein expression was noted to be similar 
between the rAAV.sh45 and rAAV.shNS groups indicating that it was likely 
that the knockdown of the Cx45 resulted in the reduced propensity to 
arrhythmia and not Cx43 changes. 
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Interestingly when heart failure genes were assessed in this group 
(rAA.sh45) there was significant reduction in the ANP mRNA expression 
compared to the control group.  It is difficult to interpret this finding as the 
βMHC and the heart to body weight ratio were not significantly altered.  
Furthermore, the extent of myocardial fibrosis was not different between 
the two groups. Unfortunately echocardiography and MRI studies were 
not able to be done during this thesis and may have proved useful as tools 
to measure LV function.  
 
5.6.3 Adenovirus vs. Recombinant Adeno-associated Virus 
The study by Greener et al. used adenovirus as the gene transfer vector. 
The vector system has many inherent limitations and safety concerns that 
preclude its application as a gene therapy vector for ventricular 
arrhythmia. These include lack of capacity to confer long-term transgene 
expression and high immunogenicity in an immunocompetent host.  
Recombinant adeno-associated virus on the other hand lacks parental 
agent pathogenicity, vector related toxicity and has minimal 
immunogenicity. It also has the capacity for stable long-term transgene 
expression by virtue of episomal persistence [177]. It is therefore an ideal 
candidate for human experiments and its use in this study has shown that 
it is comparable in efficacy to the adenovirus vector used by Greener et 
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al. Recombinant AAV does have some limitation, the  main one being the 
ability for production of high-titre stocks of consistent purity and bioactivity. 
This limitation may now be overcome by the new approach of insect cell 
production described by Kotin et al. [178-180].  
 
5.6.4 Future Research 
Transduction efficiency was not assessed in these study groups. This 
could have been optimised. It is possible that a greater effect on post-MI 
VT/VF may have been observed by using larger doses of vector or 
screening rats for pre-existing antibodies and excluding rats with 
significant titres. Furthermore, the bioactivity of vector stock was not 
assessed and variability between batches may have affected vector 
performance and outcomes in our study system. It may prudent to test the 
vectors in vitro for efficient and consistent transduction between the vector 
batches prior to in vivo studies.  
 
A further area that needs to be explored is the extent of MI caused in this 
rat model. Greener et al. have previously described in their model for MI 
that the placement of catheter for infarct was imperative, with catheter 
placement too far reducing incidence of VT and too high the animals do 
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not survive [135]. With the area of blanching kept as subjectively constant 
as possible in this group we were able to achieve similar fibrosis levels 
between the groups making this an unlikely reason for the difference 
noted in VT/VF between the control groups. However further objective 
measurements in large animal MI models such as MRI assessment 
following MI would be helpful for future research.  
 
Ambulatory telemetry would have been useful to determine the extent of 
spontaneous arrhythmias and to confirm a cardiac cause in animals that 
had died suddenly. Telemetries were not implanted this group of rats 
given the concern of further morbidity and mortality on this group of rats 
but this maybe a worthwhile addition to future experiments in larger 
animals at the start of MI induction. 
 
Green fluorescence protein has been previously noted to alter 
conductance in Cx43 gap junctions and it is therefore theoretically 
possible that it would increase propensity to ventricular tachyarrhythmia 
[181]. This was not noted in other studies and also our incidence of 
inducible VT was similar to our non-transduced pilot MI group (~ 70%) 
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making this unlikely. Further study with other potential reporter genes 
such as LacZ may be useful.  
 
Another consideration was the method used to cause MI. We used 
completed infarct where in Greener et al. they used infarct reperfusion. 
This method had been studied in rat model by Ding et al. showing that 
ischemia reperfusion was an effective method of induction of VT with 70% 
of rats having inducible VT/VF [173]. Never-the-less in our hands 
complete ligation of the mid-LAD resulted in similar VT/VF rates as noted 
by the rAAV.GFP group.  Further studies with knockdown of Cx45 using 
the ischemia-reperfusion technique would be useful in the current clinical 
era.  
 
Combination rAAV.Cx43 and rAAV.shCx45 or head to head studies 
comparing Cx43 overexpression with knockdown of Cx45 would be 
helpful to perform in order to evaluate more options for reducing the 
propensity of arrhythmia. This would likely require a large number of 
animals to achieve adequate power to study arrhythmia inducibility and 
was beyond the scope of this thesis. 
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Despite the isolated change in ANP gene expression differences in other 
markers of heart failure were not evident such heart to body weight ratio, 
cardiac fibrosis or βMHC expression levels when comparing the 
rAAV.sh45 to the rAAV.shNS infarct groups. We were limited by 
equipment availability and therefore were unable to assess cardiac 
function accurately with other modalities such as echocardiography or 
MRI. It would have been interesting explore this further to assess whether 
or not Cx45 knock-down was actually improving cardiac function.   
 
5.7 Summary 
In summary, Cx43 transduction in the rat post-MI VT model did reduce 
propensity to ventricular tachyarrhythmia implicating Cx43 
overexpression as a protective mechanism in preventing VT/VF. 
Furthermore knockdown of Cx45 has shown significant reduction of 
ventricular tachyarrhythmia in this same model, implicating a pathogenic 
role for this molecule in post-MI VT.  
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CHAPTER 6 
 
SUMMARY AND GENERAL 
DISCUSSION 
 
 
Summary and General Discussion 
 
With an aging population and an attendant increase in the incidence of 
cardiac disease and SCD there is a need to understand the mechanisms 
underpinning ventricular arrhythmogenesis. At a molecular level 
connexins and gap junctions have long been understood to play a role in 
normal conduction and arrhythmias as outlined in Sections 1.4 and 1.5. 
Connexin43 has been the most heavily studied connexin in 
arrhythmogenesis. There is limited and conflicting data on the role of other 
connexins such as Cx45. In this thesis, the role of Cx45 in cardiac 
ventricular arrhythmias was studied and found to be relevant.  Moreover 
the gene transfer technology employed in this study lends itself to be 
developed as a highly novel and innovative treatment approach for life-
threatening cardiac arrhythmias. 
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6.1 Connexin45 and Heart Disease 
 
6.1.1 Summary 
Connexins, or gap junction proteins, are a family of structurally related 
transmembrane proteins that assemble to form vertebrate gap junctions. 
Connexin43 is the predominant connexin in adult human myocardium, 
while Cx45 the least prevalent. Connexin40 is mainly located in the atria. 
The study of Cx45 in this thesis has contributed to the understanding of 
the role of Cx45 in arrhythmia formation in the “diseased” heart and 
therefore, may help with the future development of treatments for reducing 
incidence of sudden cardiac death. 
 
6.1.2 Connexin45 Physiology 
Connexin45 has been cloned from mouse, human and rat cDNA. It 
consists of 396 amino acids in the human and rat genome and 395 in the 
mouse [81, 175]. Gap junctions composed of Cx45 are selective for 
cations and are voltage dependent with half maximal activation at +/- 
20mV[61, 81]. The molecular weight of Cx45 is between 45kD and 
48kD. Importantly homotypic homomeric Cx45 channels have a 
relatively small unitary conductance of approximately 26pS and 
therefore would have the potential to slow conduction when present 
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in gap junctions [83]. For heterotypic Cx43–Cx45 channels, the unitary 
conductance has been reported at approximately 50-60pS, corresponding 
to the Ohmic sum of the predicted conductances for each of the 
homomeric native connexons [182]. Connexin45 is noted to be 
moderately permeable to fluorescent dyes such as LY, DCF but not 
6CF [79]. With regards to post-translational modifications, there have 
been reports of 15 possible phosphorylation sites for PKC in human 
Cx45, and 17 in rodents[31].   
 
6.1.3 Connexin45 and Normal Myocardium 
Connexin45 has an indispensable role for the development and 
function of the embryonic heart. In foetal heart tissue, it has been 
found to be the first connexin to be expressed and therefore essential 
in myocardial maturation [84, 85]. It is the only cardiac connexin 
essential for cardiogenesis and embryonic survival. During 
myocardium development, Cx45 expression is reduced. In the adult 
myocardium, it is the predominant connexin in the atrial conduction 
system consisting of the sinus node and AV node [183]. In addition to 
the nodes, Cx45 is expressed in the His bundle, the bundle branches 
and at lower levels in proximal Purkinje fibres. Connexin45 has also 
been noted to be present in very low levels in the working myocardium 
of the ventricle as well as the atria [183]. In Chapter 3 of this thesis, 
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Cx45 was overexpressed in the normal heart. As predicted by the 
known physiology of Cx45 gap junctions and the role of this molecule 
in the SA and AV nodes, markers of slowed conduction were 
observed on the surface ECG, namely prolonged PR intervals and 
QRS width. Furthermore, there was an increased incidence of high 
degree AV block. 
 
6.1.4 Connexin45 in Diseased Myocardium 
Connexin45 expression increases under pathological conditions. This 
has been reported in the context of human heart failure, a condition 
known to predispose to ventricular tachyarrhythmia [149]. Down-
regulation of Cx45 did not produce any notable deficits in electrical 
conduction in adult mice hearts as studied by Bao et al. [91]. Connexin45 
has been found essential for the viability of the embryo but when mice 
were generated in which deletion of Cx45 was specifically induced in 
cardiomyocytes of adult mice, these mice remained viable [183]. 
Betsuyaku et al. on the other hand had shown that when genetically 
modified Cx45 over-expressing mice were produced, these were 
susceptible to ventricular tachyarrhythmia in vivo [3]. This model has its 
limitations given that germ-line gene modifications were made which 
would have the potential to result in altered expression of 
unintended/other molecules. When compared to the germ-line approach, 
247 
 
somatic gene transfer is more relevant for modelling the clinical 
pathophysiology of acute MI and subsequent alterations in gene 
expression pattern. Results presented in Chapter 3 of this thesis have 
shown that with somatic gene transfer there was an increased incidence 
of ventricular tachyarrhythmia. Heart failure was not a confounding factor 
as observed by no change in heart failure genes or weight gain. However 
a reduction in Cx43 expression was identified which could be an important 
confounding factor and may have led to the propensity for arrhythmia. 
Never-the-less when both Cx43 and Cx45 were transduced in the normal 
myocardium there remained a high incidence of arrhythmia in this group. 
This showed that Cx45’s role in promoting arrhythmogenesis is important, 
regardless of Cx43 expression in the myocardium.   
 
6.1.5 Connexin45 Knockdown Results in Reduction of 
Ventricular Tachyarrhythmia 
As shown in human studies Cx45 is up-regulated in human heart failure. 
When overexpressed by somatic or transgenic methods Cx45 results in 
an increased propensity to ventricular tachyarrhythmia. It is therefore 
conceivable that knocking down Cx45 in those models would reverse the 
slowing of conduction and thereby result in reduction of ventricular 
tachyarrhythmia. In Chapter 5, the rAAV.sh45 vector successfully reduced 
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Cx45 expression in Cx45 transduced HEK293 cells in vitro. This also 
occurred in vivo where Cx45 transduced rat myocardium showed 
reduction in Cx45 expression when treated with rAAV.sh45 vector 
compared to the control group (Chapter 4). Furthermore phenotypic 
changes such as the QRS duration and VT inducibility were reversed 
when rAAV.sh45 was introduced into Cx45 overexpressed rats. On the 
other hand, when Cx43 was transduced into Cx45 overexpressed rats (to 
overcome the down regulation noted in Chapter 3 following 
overexpression with Cx45) there were no phenotypic changes noted. This 
further implicates Cx45 as mechanistic factor involved in ventricular 
arrhythmia.  
 
It was hypothesised that knockdown of Cx45 could be used to reduce the 
predisposition to arrhythmia after MI. A model was chosen in which similar 
overexpression of Cx45 was expected. In section 5.3.2, I demonstrated 
that indeed Cx45 is increased in the Post-MI rat model. As expected 
transduction of rAAV.sh45 decreased this Cx45 expression compared to 
the control MI model. This translated to a reduction of in incidence of 
VT/VF. This finding adds weight to the hypothesis that excess Cx45 is a 
factor in the pathogenesis of ventricular arrhythmia after myocardial 
infarction.  
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6.1.6 Limitations 
The mechanism by which conduction slowing causes ventricular 
tachyarrhythmia in the setting of acute gene transfer in the rat myocardium 
requires further clarification. Our understanding of how Cx45 transduction 
gives rise to a re-entrant circuit is limited. It is likely the formation of 
heteromeric channels Cx43/Cx45 form resulting in conduction slowing 
thereby reducing the circuit length and thus re-entry may occur in smaller 
tissue volumes. Other factors in the myocardium likely to play a role in 
conduction slowing and not studied in this thesis are changes in 
expression of ion channels subserving excitation and action potential 
propagation such as the sodium and calcium channels. Abnormal Cx43 
localisation and post-translation modification have been found to be 
important factors in arrhythmia in the acute MI and post MI models. These 
events were not studied in this thesis. Another limitation of this thesis is 
that the rat myocardium and human myocardium are clearly different in 
respect to size, ion channel expression and even ECG characteristics. 
Therefore what maybe significant in the rat heart may not necessarily be 
so for human myocardium. Lastly, transduction was not cell specific and 
therefore non-myocytes transduced with Cx45 may also play a role in 
modulating impulse propagation and alter the propensity for ventricular 
tachyarrhythmia.  
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Limited Treatment Potential to Reduce Ventricular Tachyarrhythmia in 
Post-MI Model. 
The question arises as to why did knockdown of Cx45 or overexpression 
of Cx43 not reduced VT/VF in all animals. Several potential explanations 
can be deduced including inadequate gene transfer, altered Cx45, Cx43, 
or rAAV.sh45 processing after gene transfer, incorrect targeting of the 
gene transfer, or increased mass or complexity of the border-zone region 
in the failed rats. Another potential explanation is that for knockdown to 
occur successfully there needs to be sufficient number of viable 
myocardial cells within the scar region that are capable of successful gene 
transfer and expression. This thereby would reduce conduction slowing 
and the propensity to ventricular tachyarrhythmia. Another important 
consideration is that Cx45 knockdown alone is insufficient to reduce 
VT/VF, and that there are likely other process such as ion channel 
changes, Cx43 modulation as well as possible fibrotic changes and other 
processes not fully assessed that contribute to the propensity to 
ventricular tachyarrhythmia. Finally the presence of neutralising 
antibodies in a few of those animals may have rendered our viral vector 
ineffective in transmitting the transgene to the required target. 
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6.2 Connexin43 and Ventricular Tachyarrhythmia 
 
6.2.1 Connexin43 Physiology 
Connexin43 is the most prevalent connexin in the myocardium. The 
molecular weight of Cx43 is between 41 to 46 kDa depending on its 
phosphorylated state [63]. Connexin43 gap junctions are permeable 
to organic ions and molecules of less than 1K Da [63]. Homomeric-
homotypic Cx43 channels have a high conductance of 100-120ps, much 
greater than homomeric-homotypic Cx45 channels at 26pS. Connexin43 
has been extensively studied and shown to be permeable to many 
different dyes including LY, DCF, carboxyfluorescein, and N- biotinamide 
hydrochloride[184]. 
 
6.2.2 Connexin 43 Expression in Diseased Hearts 
Peters et al. have studied patients with both hypertrophied myocardium 
as well as ischemic hearts and noted a reduced content of Cx43 in gap 
junctions [69]. This was noted in particular at the border zone of infarcted 
and normal myocardium [24, 69]. This implied there was some alteration 
in the gap junction that would result in areas of slowing of conduction that 
support myocardial re-entry and ventricular tachyarrhythmia. Other 
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studies had also supported the above findings showing that Cx43 was 
also reduced in patients with other types of cardiomyopathies [77, 87]. To 
study the hypothesis that reduced Cx43 results in ventricular arrhythmia, 
conditional Cx43 knockout mice were studied. These experiments 
revealed significant conduction delay and arrhythmia but only when Cx43 
expression was reduced to 70-90% of baseline levels [88, 89].  
 
6.2.3 Connexin43 Overexpression and Ventricular 
Tachyarrhythmia 
Greener et al. [64] published a study using somatic gene transfer of Cx43 
to the healed myocardial scar border. In this study, pigs were subjected 
to MI and the infarct allowed to heal. Adenoviral vector mediated Cx43 
gene transfer resulted in Cx43 expression, reduced conduction slowing 
and reduced VT inducibility with programmed stimulation. There are many 
important differences between the study by Greener and the current 
thesis.  In the former pigs that had been previously known to have 
inducible VT were employed and there was targeted gene transfer to the 
expected infarct border zone. This would be difficult in humans as it would 
imply invasive thoracic surgery to get to the infarct zone and utilize 
directed gene transfer. A simpler and more generalizable method would 
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be to use systemic gene transfer as used in the current study or gene 
transfer via the commonly used, intracoronary route.  
 
The study by Greener et al. treated pigs with recurrent VT, which in clinical 
experience would be a more efficient use of scarce resources. However 
the use of rAAV vector system would be more applicable to clinical 
practice, given the stability of expression and reduced immunogenicity of 
the virus in humans compared to adenovirus vector system. Nevertheless 
the current study supports Greener’s findings that Cx43 overexpression 
can reduce inducible ventricular tachyarrhythmia. This was independent 
of worsening heart function as expected following MI. 
 
6.2.4 Benefits of Using Connexin43 
Connexin43 is the most prevalent connexin in the myocardium and its 
biology is well understood. It is generally thought that the heart is over-
engineered with Cx43 given that heterozygous knockout mice show no 
abnormal cardiac phenotype. It is, therefore possible to speculate that with 
further expression of Cx43 that this would be unlikely to result in any 
unwanted gap junction modulation that could result in adverse alterations 
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of conduction. The latter may not hold true for other connexins such as 
Cx45 or Cx40.  
 
6.2.5 Limitations 
Connexin43 overexpression may have a role in the future regarding 
therapy for VT and thereby SCD reduction in the post-MI patient 
population. More studies are needed to define the most efficacious 
approach for overexpression of Cx43 for gene therapy of post-MI VT. 
Variables that need to be addressed in these studies include: dose of 
vector to be injected, delivery method, and expression cassette design 
including choice of promoter, for example. Moreover, the mechanism of 
effect is not fully understood. Large animal models and high resolution, 
multipoint mapping of electrical activation could be used to assess the 
effects of gene therapy on conduction at the MI border-zone. In addition, 
MRI of the scar border could be used to assess if there is a reduction is 
scar tissue that could underpin the improved conduction.  
 
An additional consideration with Cx43 gene therapy for post MI VT is the 
time of vector injection. In the current study all rats were injected at time 
of MI. Studies in transgenic mice in whom Cx43 was engineered to remain 
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open during MI have shown that this would generally increase infarct size 
[185]. This was not observed in the current study and likely due to the 3-
4 day delay in gene expression following vector administration and that 
somatic Cx43 overexpression resulted in functionally normal gap 
junctions which are likely to close appropriately. Similarly, Greener et al. 
had used somatic gene transfer following infarction and this reduced VT. 
Further studies need to be carried out determine the optimal time for 
vector delivery. 
 
6.3 Gene Therapy using Regulatory Short RNAs to Modulate 
Connexin Gene Expression 
 
6.3.1 Regulatory Short RNAs 
Short or small RNAs are 20-40 nucleotide long noncoding RNA molecules 
present in most eukaryotic organisms that regulate gene expression in a 
sequence-specific manner either transcriptionally or post-transcriptionally 
[169]. These small RNAs are derived from double-stranded RNAs 
(dsRNAs) and can induce gene silencing through specific base-pairing 
with the target molecules. There are two well defined classes of small 
RNAs: microRNAs and short hairpin RNA (shRNA) [169]. Gary Ruvkam 
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and Victor Ambros, the pioneers in microRNA research, found that a small 
temporal non-coding RNA could regulate translation by base pairing to the 
3” untranslated region of a coding messenger RNA [186, 187]. Since then 
there has been a vast amount of research into microRNA. MicroRNA led 
to the birth of short hairpin RNA. Unlike microRNA, shRNA is designed to 
target a single transcript rather than hundreds of transcripts and is 
therefore more useful in single gene disorders. The benefits are vast, 
specifically in their ability to knockdown unwanted or disease causing 
genes. Short hairpin RNAs are perfectly complementary to their mRNA 
targets. Their target sites may disperse throughout the entire transcript 
giving it a wide use in illnesses. The shRNA differ to the microRNA and 
cause RNA degradation while microRNA causes translational 
suppression. They can also facilitate RNA degradation depending on 
extent of complementarity to the target sequence. Their use has already 
been investigated widely in cancer-genetics. Numerous clinical trials 
using microRNA have begun [170]. In addition to modulators for the 
treatment of variety of diseases, microRNAs can be used as potential 
biomarkers in clinical diagnostics.  
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6.3.2 Short-hairpin RNA use in Cardiac Gene Therapy 
Short Hairpin RNA therapeutics has already been widely utilized in pre-
clinical models of cardiac gene therapy [167, 168, 188]. Huang et al. 
described its use in ischemic heart disease [168]. They studied the 
knockdown of prolyl hydroxylase-2 (PHD2) protein in adult mice hearts. 
Infarcts were created with LAD ligation and vector directly injected into the 
myocardium. Compared to controls they demonstrated significant 
improvement in angiogenesis and contractility. Bioluminescence imaging 
detected plasmid-mediated transgene expression for 4 to 5 weeks. 
Echocardiography showed improved fractional shortening compared to 
the control group at week 4. Histological analysis showed increased 
presence of small capillaries and venules in the infarcted zones by CD31 
staining. Suckau et al. studied shRNA in a heart failure rat model [167]. In 
this study they injected vector intravenously. The rAAV vector-expressed 
shRNA silenced phospholamban (rAAV9-shPLB) in the heart. They 
reported cardiac PLB protein was reduced to 25% of baseline. 
Recombinant AAV9-shPLB therapy was noted to restore diastolic and 
systolic functional parameters to normal ranges. Cardiac dilatation was 
also reversed and a reduction of cardiac hypertrophy and fibrosis was 
noted. Importantly they showed that rAAV9 had a high affinity for 
myocardium and low affinity for liver and other organs. No evidence was 
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found of shRNA deregulation or hepatotoxicity by rAAV-mediated shRNA 
therapy [167].  Hence the use of rAAV9 shRNA to deliver targeted gene 
knockdown in cardiac therapy would be efficacious and safe given the 
findings in the above model when translated to clinical practice.  
 
6.4 Limitations of Gene therapy 
The nature of the vector-host interaction can be potentially limiting in gene 
therapy, particularly in humans. The vector particles are replication-
deficient but their use has not been fully investigated in humans and 
therefore they may give rise to side effects that we are currently unaware 
of. In addition given these are foreign particles the human immune system 
is likely to mount an immune response. Although the latter will depend on 
the type of vector employed. In the current study we chose to use rAAV 
because it has minimal immunogenicity. No inflammatory response was 
seen in rat hearts transduced with this vector in this study. There is, 
however, the problem of neutralising antibodies to rAAV capsid proteins. 
Some animals have pre-existing neutralising antibodies to a number of 
rAAV capsid serotypes [189]. Neutralising antibodies can be formed due 
to natural infections or as a result of vector exposure. The presence for 
neutralising antibodies would preclude vector injection of the same 
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serotype. If additional vector is required this could be delivered via a rAAV 
with a different capsid and therefore bypass any neutralising antibodies.  
 
For a small number of rats in the current study gene therapy appeared to 
have no effect. Several explanations exist. Firstly the vector may not have 
been injected into the venous system and therefore it did not reach the 
heart. Secondly the batch of viral particles used was ineffective and 
therefore no active particles were used. Thirdly, it is possible that the 
rodent was immune to our viral vector due the presence of antibodies. 
These and other limitations of gene therapy would need to be addressed 
before any human trials can be commenced.  
 
A further issue in gene therapy is that of transduction of unintended 
targets. The use of specific vectors and promoters helps to limit this but 
targeting is never perfect. In the current study, rAAV was used because 
of its tropism for heart muscle. Other tissues such as liver and lung will 
also be transduced but to a much lesser extent. The effect of unintended 
transduction was not assessed in the current study but will need to be 
considered when translating this technology to humans. 
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With regard to the use of small regulatory RNA molecules for gene 
therapy, one of the most important translational hurdles is the stability of 
shRNA once delivered in vivo. Endogenous microRNA is highly stable 
when secreted into the circulation as they resist nucleases by being 
enclosed into micro-vesicles or exosomes. One way to improve stability 
of regulatory RNAs is to express them from vectors. As seen in the current 
study rAAV2/9 was capable of expression at 5 weeks following vector 
injection. The effects of the shRNA targeting Cx45 were also evident at 
this time point with continued reduction on the Cx45 steady state levels. 
Other than viral vector based expression there are other methods to 
improve stability of regulatory RNA molecule. These include chemical 
modifications to the nucleic acids such as, phosphorothioate, 2′-O-methyl 
RNA, 2′-Fluoro-RNA and 2′O-methoxy-ethyl RNA, all of which provide 
greater nuclease resistance.  Another modification that also confers 
nuclease resistance results in molecules known as locked nucleic acid. 
Locked nucleic acids are widely used in synthesis for microRNA inhibiting 
drugs, sometimes referred to as antagomirs. This modification utilizes a 
bridge between the 2′O group and 4′ carbon atom also referred to as 2′O-
4′C-methylene linked ribonucleotides [190, 191]. 
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6.5 Future directions 
Further evaluation within a large animal model is required given the 
limitations with a small animal model. Somatic gene transfer should be 
performed globally as well as in the scar area alone to understand both 
focal and diffuse overexpression as well as knockdown of genes in the 
prevention of VT. A larger myocardium would allow for 3 dimensional 
electro-anatomical mapping of VT circuits and subsequent correlation with 
tissue and in turn allow a better understanding of the origin of VT and 
effects of gene therapy. A larger heart will also more closely mimic the 
human myocardium. More-over an optimal dose for Cx43 transduction is 
required, and further studies carrying out difference vector amounts would 
facilitate the understanding of the optimum dose. 
 
6.6 Connexins and Ventricular Arrhythmias – Final 
Comments 
The clinically relevant studies described within this thesis provide the first 
direct evidence for a role of Cx45 in the pathogenesis of post-MI VT. In 
addition to confirming previous findings with respect to the ability of Cx45 
to modify myocardial electrical stability, they also represent the first ever 
in-vivo non-transgenic genotype-phenotype correlation between Cx45 
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and VT. This thesis also provides incremental evidence for the role Cx43 
gene therapy in reduction of post-MI ventricular tachyarrhythmia.  
 
The studies performed in this thesis are an important first step in using 
somatic gene transfer techniques to treat post-MI VT in humans. The next 
step would be to recreate these studies in a large animal model of post-
MI ventricular tachyarrhythmia that recapitulates the same human 
condition. This would enable preclinical safety and efficacy studies to be 
undertaken prior to seeking regulatory approval for the translation of this 
technology to human application.  
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